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Abstract
The role of membrane transporters in the pharmacokinetics of psychotropic
drugs: in vitro studies with special focus on organic cation transporters
The treatment of common psychiatric disorders like major depression, schizophrenia and
bipolar disorder is characterized by low efficacy and variability in the case of depression
and bipolar disorder, and of undesirable side effects in the case of schizophrenia. One of
the explanations is that the drug may not be reaching its site of action, at concentrations
that are high enough to provoke a response. On the other hand, poor elimination of
the drug from the body may lead to high plasma concentrations, which may cause
undesirable side effects.
Variations in membrane transport at the blood-brain barrier might affect the concentra-
tion of psychotropic drugs at their site of action. In organs such as the liver and kidney,
variations in membrane transport may affect drug elimination.
Using a parallel artificial membrane assay, 31 commonly used psychotropic drugs were
screened for their ability to penetrate cell membranes by passive diffusion. Using custom
made TaqManr low-density gene expression arrays, the mRNA expression of 90 drug
transporters was analyzed in organs relevant for drug pharmacokinetics and in human
primary brain cells. HEK293 cells overexpressing organic cation transporters were used
to study the transporter-mediated cellular uptake of psychotropic drugs. Finally, the
immortalized human brain microvascular endothelial cell line, hCMEC/D3, was used as
a blood-brain barrier model to study influx transport.
In human primary brain microvascular endothelial cells (HBMECs), the expression of
organic cation transporters was substantially lower than in other organs like the liver
and the kidney. Nonetheless organic cation transporters were detected in HBMECs.
OCTN2 was the organic cation transporter with the highest expression, followed by
OCTN1, OCT1 and OCT3.
Amisulpride, sulpiride, sultopride and tiapride were identified as drugs with low mem-
brane permeability, which may require influx transport to reach their site of action in
the brain. Amisulpride and sulpiride were identified in vitro as substrates of the organic
caiton trasnporters of the SLC22 family and may depend on organic cation mediated
transport to cross the blood-brain barrier. The presence of a carrier-mediated trans-
port mechanism for the uptake of amisulpride and sulpiride was confirmed in the brain
endothelial cell line model hCMEC/D3.
x
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Furthermore, absorption and elimination of amisulpride and sulpiride may also depend
on organic cation transporters. OCT1 may contribute to the billiary elimination of
amisulpride and sulpiride. In addition, the transporters OCT2, MATE1 and MATE2-K
may contribute for the renal elimination of amisulpride and sulpiride in the proximal
tubule epithelium. Common genetic polymorphisms on the OCT1 gene were found to
affect the cellular uptake of amisulpride and sulpiride.
The majority of the psychotropic drugs, like amitriptyline, have high membrane perme-
ability and may not benefit from drug transporters to permeate cellular barriers in the
in vitro models used in this work. However, these drugs can still interact strongly with
membrane transporters, like OCT1. Clinical studies, providing in vivo evidence for the
interaction of high permeability drugs with membrane transporters, will be needed in the
future. Weak basic psychotropic drugs may inhibit the OCT1-mediated uptake of other
important drugs, like morphine. The psychotropic drugs amitriptyline, clomipramine,
imipramine and fluoxetine, and also irinotecan, ondansetron and verapamil, inhibited
the OCT1-mediated uptake of morphine at therapeutically relevant concentrations.
Furthermore, the effect of genetic polymorphisms in the OCT1 gene on the OCT1-
mediated uptake of the biogenic amine tyramine was studied. In addition, an MDCK II
cell line carrying a site for targeted chromosomal gene integration was developed. This
model should in the future enable the analysis of the effects of genetic polymorphisms
on drug transport by efflux transporters, which are present at the blood-brain barrier.
In conclusion, this study demonstrates that influx transporters may mediate the uptake
of psychotropic drugs with low membrane permeability like amisulpride and sulpiride,
and may influence their pharmacokinetics and distribution to the brain. This work, and
the tools which were developed here, can serve as a basis for further work on the role of
organic cation transporters at the blood-brain barrier, and to study in more detail the
role of organic cation transporters in the pharmacokinetics of amisulpride and sulpiride.
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Introduction
“A compound must get in, move about, hang around, and then get out.”
– Hodgson (2001) Nature Biotechnology
1.1 Efficacy of the treatment of major depression, schizo-
phrenia and bipolar disorder
Major depression, schizophrenia and bipolar disorder are among the most common psy-
chiatric diseases worldwide.
The efficacy of drug treatment of mild to moderate depression is very low, with patients
presenting only small changes from the baseline HRSD Scores (Hamilton Rating Scale
for Depression) in comparison to placebo. The treatment of severe depression is more
efficient, showing significant differences from the baseline after treatment, but response
to the same medication varies between clinical trials (Kirsch et al. (2008)).
The administration of several antipsychotics in the treatment of schizophrenia is asso-
ciated with a range of undesirable neurologic effects, and many patients suffering from
bipolar disorder have a poor treatment outcome. A third of the patients suffer chronic
symptoms and 13-24% of the patients develop rapid cycling disorder, and have four or
more episodes per year. The recognised risk of completed suicide is 15% in patients
suffering from bipolar disorder (Young et al. (2000)).
A possible reason for non-response to the therapy may be the drug not reaching its site
of action. On the other hand, poor elimination of the drug may lead to higher drug
concentrations in the blood and undesired drug side-effects.
1
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1.2 Drug absorption, distribution, metabolism and excre-
tion
1.2.1 General principles of pharmacokinetics
The term pharmacokinetics was first described by the German physician F.H. Dost
(Dost (1953)). It studies the time course of the absorption, distribution, metabolism and
excretion (ADME) of a drug or compound. These four processes affect the concentration
of a specific drug at its site of action and are depicted on figure 1.1.
After an oral dose, a compound is absorbed in the gastrointestinal tract before it reaches
the portal vein. In the intestine, it can already be subject to enzymatic metabolism.
From the portal vein, it will be delivered into the liver, where first pass metabolism and
billiary elimination may occur. If a compound is eliminated through the billiary route, it
may be re-absorbed in the intestine (a process known as entero-hepatic circulation). If a
compound is delivered intravenously, it will be first found in the venous circulation, and
therefore not be subject to first pass metabolism. Once a compound reaches the arterial
circulation it will be distributed throughout the body. When a drug is in the peripheral
circulation, the two most common routes of elimination are hepatic metabolism (liver),
and excretion into the urine by the kidney. The concentration at which a compound
reaches its site of action will depend on all these factors. If the target of a certain
compound is the brain, it also has to cross the blood-brain barrier (Figure 1.1) (Fan &
de Lannoy (2014)).
1.2.2 Absorption and distribution
In order for an orally administrated drug to be absorbed and reach the blood, it has
to cross the intestinal epithelium. Distribution takes place mainly through the systemic
circulation, and compounds present in the blood stream will be delivered to all relevant
tissues, at a rate which will depend on the organ/tissue blood flow. The brain, how-
ever, is separated from the systemic circulation by two main barriers, the blood-brain
barrier (BBB) and the blood-cerebrospinal fluid barrier (BCSFB). The BBB is made of
endothelial cells which build tight junctions and do not allow the paracelluar diffusion
of compounds. The BCSFB is formed by an epithelial cell layer which lines the choroid
plexus (Hammarlund-Udenaes et al. (2008)). Compounds may cross the BBB and the
BCSFB through simple diffusion or carrier mediated transport. The specificities of drug
transport at the BBB will be addressed in section 1.4.1.
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Figure 1.1: Absorption, distribution, metabolism and excretion of orally administered
compounds. A compound is first absorbed into the portal vein (1), it is exposed to first-
pass metabolism in the liver or intestine (1 and 2) and it is distributed by the peripheral
blood circulation throughout the body, including to the brain (3). It is eliminated in
the liver or kidney by metabolism or excretion (2 and 4). Based on Schwenk (1987)
and Fan & de Lannoy (2014)
1.2.3 Metabolism and excretion
The elimination of a drug from the body is due to either metabolism, excretion, or both
processes together. An important pharmacokinetic parameter, clearance, introduced by
F.H. Dost (Dost (1949)), describes the rate of elimination of a drug from the blood.
Clearance (CL) describes the volume of blood from which all the drug is removed,
per unit of time (i.e. mL min−1). It may be divided into metabolic clearance, renal
clearance (excretion), billiary clearance (excretion) and other (for example, exhalation
through breathing):
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CLtotal = CLmetabolic + CLrenal + CLbile + CLother (1.1)
For most of the molecules with a molecular weight under 500 Daltons, the metabolic and
renal elimination pathways are the most relevant which greatly simplifies this equation
by removing the parameters CLbile and CLother (Pandit & Soltis (2011)).
Metabolism is by far the most important of the clearance pathways, followed by re-
nal clearance (Figure 1.2) (Wienkers & Heath (2005)). Billiary clearance is the major
clearance mechanism for only a small number of drugs.
Metabolism Renal Bile 
Figure 1.2: Major routes of drug elimination. Adapted from Wienkers & Heath
(2005)
The organ where most of drug metabolism occurs is the liver, although other tissues
may also play a role. Drug metabolism is also known to occur in the intestine, kidney,
lung, plasma, blood cells and in the brain. Enzymatic metabolism has the goal of
turning compounds into more hydrophilic substances, in order to facilitate their excretion
through the kidney and the bile (Fan & de Lannoy (2014)).
The human body has two major routes for drug excretion: Kidney excretion and billiary
excretion. Renal excretion is by far the most important excretion mechanism in the
human body (Figure 1.2) and it is usually due to one or more distinct processes which
happen in the kidney: glomerual filtration, tubular secretion and reabsorption (Kwon
(2001)).
Glomerulal filtration is the process through which blood is filtered through the glomeru-
lus to form urine. Only small molecules which are not bound to plasma proteins are
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filtered in the glomerulus. The GFR (glomerual filtration rate), measures kidney func-
tion and is normally determined by measuring the renal clearance of substances which
have low binding to plasma membrane proteins (i.e. creatinine). The normal GFR for
humans is 120-130 mL/min (Stevens et al. (2006)). The rate of glomerual filtration
for a specific drug can be determined by multiplying the fraction the drug which is not
bound to plasma proteins, fu, by the GFR (i. e. a substance which is 90% bound to
plasma, will have a fu ×GFR = 0.1 ×125 mL/min, on a healthy adult kidney).
Tubular secretion is a carrier-mediated transport process, where membrane transporters
play a major role. Several organic anion transporters (OAT1, OAT3), organic cation
transporters (OCT2, MATE1 and MATE-2K) and efflux pumps (MDR-1, MRP4 and
MRP2) are involved in this process (Kusuhara & Sugiyama (2009)).
Compounds can also be reabsorbed from the urine into the blood. The fraction of
the compound which is reabsorbed (FR) from the urine into the blood depends on the
lipophilicity of the compound. The more lipophilic a compound is, the greater the extent
of the reabsorption. Influx transporters may also contribute to the reabsorption process,
and efflux transporters may prevent it (Feng et al. (2010)).
A simple way to illustrate how glomerulal filtration, tubular secretion and tubular re-
absorption influence the renal clearance of a drug is:
CLrenal = (fu ×GFR+ CLsecretion) × (1 − FR) (1.2)
After comparing the renal clearance of a substance with its fu ×GFR, one can charac-
terise the mechanism of renal clearance. If the renal clearance is lower than the filtration
rate (CLrenal < fu ×GFR), it normally means that a greater fraction (FR) of the drug
is reabsorbed, indicating a net reabsorption mechanism. If the renal clearance is similar
to the filtration rate (CLrenal ≈ fu × GFR), reabsorption and secretion mechanisms
will probably not play a role in renal excretion. If the renal clearance is higher than
the filtration rate (CLrenal > fu × GFR), more drug is excreted as it is filtered, indi-
cating a net secretion clearance mechanism which is likely mediated by carrier mediated
transport (Fan & de Lannoy (2014)).
1.3 Transport across cellular membranes
As soon as a drug enters the human body, it comes directly into contact with cellular
barriers. The way it crosses these cellular barriers will influence its pharmacokinetics
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(i.e. its absorption, distribution, metabolism and excretion - ADME). There are several
key cellular barriers which influence ADME processes (Table 1.1).
Table 1.1: Key celular barriers for drug absorption, distribution, metabolism and
excretion in the human body
Organ/Tissue Cellular barrier
Intestine Intestinal epithelium
Liver Sinusoidal and canicular membrane of hepatocytes
Kidney Proximal and distal tubular epithelium
Brain Microvascular endothelial cells
Choroid plexus epithelial cells
For a compound which is orally administered to reach the blood it has to first be absorbed
in the intestine, and to cross the intestinal epithelium (Figure 1.3). In order to be
metabolized in the liver, it has to cross the sinusouidal membrane of the hepatocytes
(blood) and to be eliminated through the bile, it has to exit the hepatocytes through
their canicular membrane (Figure 1.4 A). In the kidney, compounds may be secreted
and reabsorbed in the tubules, where they have to cross the interstitial (blood side),
and the luminal (urine side) cell membrane of tubular epithelial cells (Figure 1.4 B). At
the blood-brain barrier (Figure 1.4 C), drugs have to cross the luminal and basolateral
membranes of the microvascular endothelial cells which make up the blood vessels in the
brain.
A compound may permeate a cell membrane by four different processes, paracellular
diffusion, transcelullar diffusion, facilitated diffusion and active transport (Figure 1.3
and Schwenk (1987)). Paracellular diffusion is the process through which substances
permeate a cell layer through the spaces between cells. In the case of the intestinal
epithelium, depicted on figure 1.3, the presence of leaky tight junctions allows small
hydrophilic molecules (like water) and electrolytes to use the paracellular pathway to
cross cell membranes. Most pharmaceutical compounds are absorbed through the tran-
scellular route. An explanation is given by Nellans (1991): The tight junctions in the
intestine are large enough to allow compounds up to a size of 3500 Dalton to go through
but they only represent 0.1% of the epithelial surface available for drug absorption. Even
hydrophilic pharmaceutical compounds (LogD = −0.5) are lipophilic enough to benefit
from the 1000 × greater surface area available for the transcellular pathway (more on
LogD on section 1.3.1, figure 4.1.2).
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The transcellular pathway is the major absorption pathway for small molecule pharma-
ceuticals and is dominated by the ability of a compound to penetrate the cell membrane














Figure 1.3: Routes of permeation of a drug through a cell membrane illustrated by
an example of intestinal absorption. Note: Endocytocis is also an important process
of membrane permeation, which was left out of this work, as it mostly important for
larger molecules. Based on an illustration by Schwenk (1987).








































Figure 1.4: Schematic drawing of key cellular barriers important for drug absorption,
distribution, metabolism and excretion. Shown is the cellular organisation in the liver
(A), the localisation of renal drug elimination systems (B), and a scheme of the blood-
brain barrier showing the brain microvascular endothelial cells and their tight junctions
(C). Based on illustrations by Schwenk (1987) and Cecchelli et al. (2007).
1.3.1 Passive diffusion
Simple diffusion, also known as passive diffusion is the unspeciffic diffusion of compounds
through the cellular membrane and it is the main pathway responsible for the cellular
uptake of very lipophilic compounds. Over 100 years ago, Overton and Meyer, proposed
that the membrane permeability (related to the efficacy of anaesthetics) of a molecule
could be predicted from its partition between an aqueous phase and an organic phase
(Meyer (1899), Overton (1901) and Missner & Pohl (2009)). Overton also found that
neutral molecules cross the cell membrane faster than charged molecules, and that the
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diffusion occurred according to a concentration gradient. Weak bases and weak acids
may also cross the cell membrane by passive diffusion. In this case, the substances,
either give up (weak bases) or pick-up (weak acids) a proton before crossing the cell
membrane (Figure 1.5 and Missner & Pohl (2009)).
B	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   BH+	  
B	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A-­‐	   A-­‐	  
AH	  
Weak	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Figure 1.5: Passive diffusion of weak acids and weak bases. A represents a weak acid,
























Figure 1.6: Methods to determine the passive membrane permeability of compounds.
A) Partition coefficient between octanol and water (Meyer (1899) and Overton (1901)).
B) Cell permeability assay (usually Caco-2 cells, Artursson (1990)) C) PAMPA assay -
Parallel artificial membrane permeability assay (Kansy et al. (1998)).
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In pharmaceutical research, three methods can be used to assess the passive diffusion
of a compound. The simplest one is the determination of the LogP of a substance,
which is the partition coefficient between octanol and water. In the case of weak acids
and weak bases, LogD7.4 can be measured, which also accounts for the pKa, and the
dissociation of a drug at the physiological pH of 7.4 (Figure 1.6 A). This follows the
principles established by Meyer (1899) and Overton (1901) who used vegetable oil instead
of octanol (Franks & Lieb (1978)). The second method takes advantage of the ability
of certain cell lines, usually the Caco-2 cell line, to form monolayers, which allows the
measurement of membrane permeability across a cellular barrier (Artursson (1990))
(Figure 1.6 B). Because cell lines express membrane transporters, some artefacts may
occur when a substance is a substrate for a membrane transporter in Caco-2 cells. The
third model, the PAMPA - Parallel artificial membrane permeability assay (Figure 1.6
C), was developed in order to measure membrane permeability without having to go
through the tedious process of establishing cell monolayers (Kansy et al. (1998)). The
fact that no membrane transporters are present in the PAMPA membranes is also an
advantage of this method.
1.3.2 Carrier-mediated transport
Carrier-mediated transport of drugs was not known to Meyer (1899) and Overton (1901),
when the process of passive diffusion was proposed. Later, it was discovered that drugs
may also penetrate the cellular membranes in the kidney, liver and intestine, by carrier-
mediated transport.
Facilitated diffusion occurs in the direction of the concentration gradient and is an
energy independent process (Schwenk (1987)). In the case of clinically relevant drugs,
carrier mediated transport is the major form of facilitated diffusion (Giacomini et al.
(2010)). Active transport is another form of carrier-mediated transport, and is an energy
dependent process, where a compound is transported against a concentration gradient
(Figure 1.7).
There are several types of carrier proteins, which can transport from small ions up to
small peptides (Dobson & Kell (2008)). Carrier mediated transport can facilitate a com-
pound’s passage through a cell membrane (facilitated diffusion), or actively transport it
against a concentration gradient. Carrier-mediated transport in the direction of the con-
centration gradient, may take place through uniport, antiport, or symport mechanisms
(Figure 1.7 and (Dobson & Kell (2008)).
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Figure 1.7: Mechanisms of carrier-mediated transport. Uniport: passive transporter,
antiport: exchanger, symport: coupled transport.
Today it is accepted that both passive diffusion and carrier-mediated transport mecha-
nisms co-exist and contribute to the permeability of substances through a cell membrane
(Sugano et al. (2010)). Passive diffusion is not a saturable process. In contrast, carrier-
mediated transport is saturable, and follows Michaelis-Menten Kinetics (Figure 1.8).
As of this date, the TransportDB website lists 1022 membrane transporters for H. Sapi-
ens. With a genome size of 3150 Mb, this leads to a number of 0.32 membrane trans-
porter per Mb of genome (http://www.membranetransport.org, Ren et al. (2007), as of
November 2014). In 2007, the total number of known transporters was 758 (Dobson &
Kell (2008)). The transporters of the SLC family (total of 395, Hediger et al. (2013))
and of the ABC family (total of 48, Tarling et al. (2013)) have become very important
in the study of human health and disease, including drug therapy.
Figure 1.8: Coexistance of carrier-mediated transport and passive diffusion. dM/dt =
VMax×C
Km+C
+C×D. Carrier-mediated transport follows Michaelis-Menten kinetics. dM/dt
is the total mass transported per unit of time, which is equal to the sum of carrier-
mediated transport VMax×CKm+C and passive diffusion C ×D. C is the concentration of the
substance, KM and VM are the Michaelis-Menten constants, and D is the rate of simple
diffusion.
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1.4 Influence of membrane transporters on drug pharma-
cokinetics
As mentioned before, cellular membranes in the human body play a major role in drug
pharmacokinetics. Because membrane transporters can facilitate the permeation of
drugs through cell membranes, they are important for drug absorption, distribution
and elimination. Although the SLC and ABC families consist of large number of trans-
porters, only a restricted number of transporters within these families are known to play
a role in drug pharmacokinetics (Hillgren et al. (2013)). The international transporter
consortium (ITC) has released a list of membrane transporters which should be consid-
ered during drug development (Figure 1.9 and Table 1.2) . This list represents a broad
review of the literature and does not account for new developments in membrane trans-
porter research (i.e. the recent identification of OCT1 at the apical membrane (intestine
side) of human enterocytes (Han et al. (2013)), the accumulating data for the expres-
sion of OCT1 in the kidney (Tzvetkov et al. (2009)), or the expression of organic cation
transporters at the blood-brain barrier which will be addressed in the next section).
In the ITC list of transporters which should be regarded during drug development (Hill-
gren et al. (2013)), no pathways for the intestinal transport and thus absorption of
cationic drugs are depicted (Figure 1.9 A). In contrast, the kidney has several organic
anion transporters which are expressed on the basolateral membrane (blood) of its prox-
imal tubules (OAT1, OAT2, OAT3, OATP4C1), but only one on the luminal mem-
brane (urine) (OAT4). In the kidney proximal tubules, there is a major organic cation
transporter (OCT2) located on the basolateral membrane, and five (MATE1, MATE2,
MATE2-K, OCTN1 and OCTN2) on the luminal membrane (Figure 1.9 B).
As in the kidney, in the liver there is only one major organic cation transporter on
the basolateral/sinusoidal membrane (OCT1), and several organic anion transporters
(OAT2, OAT7, OATP1B1 and OATP1B3). On the cannicular membrane (bile), there is
only one major organic cation transporter (MATE1) and no organic anion transporters.
However, efflux transporters like MDR1, BCRP and MRP2, may also contribute to
billiary secretion of drugs.
At the blood-brain barrier, no organic cation transporters are depicted. In contrast, four
efflux transporters are shown to be present at the blood-brain barrier (BCRP, MRP4,
MRP5 and MDR1). These transporters are suggested to be expressed at the luminal
membrane of brain microvascular epithelial cells and to transport drugs back to the
blood.
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Figure 1.9: Membrane transporters which are important for drug absorption, distri-
bution and elimination, according to the international transporter consortium (ITC).
Organic cation transporters are shown in green, organic anion transporters are shown
in blue, drug efflux transporters are show in red, other transporters are shown in dark
red. Arrows indicate the direction of the transport. Note: The intestine epithelium
expresses one or more transporters of the OATP family. According to Hillgren et al.
(2013) with modifications.
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Table 1.2: Membrane transporters important for drug absorption, distribution and
elimination according to the international transporter consortium (ITC) (Hillgren et al.
(2013)).
Transporter Type of transporter Gene name Expression
OCT1 Organic cation transporter SLC22A1 Liver
OCT2 Organic cation transporter SLC22A2 Kidney
OCTN1 Organic cation transporter SLC22A4 Kidney
OCTN2 Organic cation transporter SLC22A5 Kidney
MATE1 Organic cation transporter SLC47A1 Liver, Kidney
MATE2 Organic cation transporter SLC47A2 Kidney
MATE2-K Organic cation transporter SLC47A2 Kidney
(Kidney isoform)
OAT1 Organic anion transporter SLC22A6 Kidney
OAT2 Organic anion transporter SLC22A7 Liver, Kidney
OAT3 Organic anion transporter SLC22A8 Kidney
OAT4 Organic anion transporter SLC22A11 Kidney
OAT7 Organic anion transporter SLC22A9 Liver
OATP1B1 Organic anion transporter SLCO1B1 Liver
OATP1B3 Organic anion transporter SLCO1B3 Liver
OATP2B1 Organic anion transporter SLCO2B1 Liver
OATP4C1 Organic anion transporter SLCO4C1 Kidney
BCRP Efflux transporter ABCG2 Liver, Intestine
Blood-brain barrier
MDR1 Efflux transporter ABCB1 Kidney, Blood-brain barrier
Kidney, Blood-brain barrier
MRP2 Efflux transporter ABCC2 Liver, Intestine
Kidney
MRP3 Efflux transporter ABCC3 Liver, Intestine
Kidney
MRP4 Efflux transporter ABCC4 Liver, Kidney
Blood-brain barrier
MRP5 Efflux transporter ABCC5 Blood-brain barrier
MRP6 Efflux transporter ABCC6 Liver
MCT1 Monocarboxylate transporter SLC16A1 Intestine
ENT1 Nucleoside transporter SLC29A1 Liver, Intestine
Kidney, Blood-brain barrier
ENT2 Nucleoside transporter SLC29A2 Liver, Intestine
Kidney, Blood-brain barrier
PEPT1 Peptide transporter SLC15A1 Liver, Intestine
Kidney
PEPT2 Peptide transporter SLC15A2 Liver, Intestine
Kidney
URAT1 Urate transporter SLC22A12 Kidney
ASBT Bile acid transporter SLC10A2 Intestine
NTCP Bile acid transporter SLC10A1 Liver
OST-α/β Bile acid transporter SLC51A / SLC51B Liver, Intestine
BSEP Bile salt efflux pump ABCB11 Liver
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1.4.1 Drug transport and drug transporters at the blood-brain barrier
For a psychotropic drug to exert its action, it has first to be delivered to the brain.
Psychotropic drugs usually act on neural receptors or on a transporter specific for the
pre-synaptic uptake of neurotransmitters. A number of factors contribute to the effective
concentration of a psychotropic drug at its site of action. These include influx and
efflux trough the blood-brain barrier (BBB), drug distribution within the brain and
binding to brain tissue (Hammarlund-Udenaes et al. (2008)). The limiting step in
reaching the brain is the crossing of the blood-brain barrier. The paracellular diffusion of
compounds through the BBB is restricted due to the presence of tight-junctions between
the endothelial cells, which make the brain capillaries. The transcelullar diffusion of
compounds is limited by the presence of efflux transporters. However, small molecules,
for example nutrients, are still transported into the brain by specific solute carriers
(Strazielle & Ghersi-Egea (2013))
As previously stated, figure 1.9 is based on a broad literature review and ignores several
recent research developments. It does not, for example, depict any organic cation trans-
porter at the blood-brain barrier. It has been recently suggested that organic cation
transporters like OCT1, OCT2, OCT3, OCTN2 and MATE1 are expressed at the hu-
man blood-brain barrier (Kido et al. (2001), Lin et al. (2010) and Geier et al. (2013a)).
MCT1 (depicted here only on the intestinal epithelia), as well as LAT-1, are also known
to be highly expressed at the blood-brain barrier (Geier et al. (2013a)) and LAT-1 has
recently been shown to be able to transport psychotropic drugs (Geier et al. (2013b)).
1.4.2 Factors affecting drug transporter activity: genetic polymor-
phisms and drug-drug interactions
Because drug transporters play a major role in drug absorption, distribution and elimi-
nation, factors which lead to a decrease in their activity may dramatically change drug
pharmacokinetics. These can be for example, genetic polymorphisms leading to a de-
crease, or absence of transporter activity (Kerb (2006)), or drug-drug interactions, which
may also lead to a decrese in transporter activity (König et al. (2013)).
Membrane transporters for which important genetic variants have been identified in-
clude MDR1 (ABCB1 ), BCRP (ABCB1 ), OCT1 and OCT2 (SLC22A1 and SLC22A2 ),
MATE1 (SLC47A1 ), MATE2 (SLC47A2 ) OAT1 (SLC22A6 ) and OATPs (SLCO) (Kerb
(2006), Ha Choi et al. (2009) and Stocker et al. (2013a)).
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A notable example is the genetic variability in the OATP1B1 transporter, highly ex-
pressed in human hepatocytes and responsible for the uptake of several statins (simvas-
tatin, pravastatin, atorvastatin, etc.) in the liver. If OATP1B1 is inactive, the elimina-
tion of statins in the liver will be reduced. Polymorphisms in this gene have been found
to result in remarkably increased plasma concentrations of statins, and were associated
with increased risk of startin-induced myopathy (for review, see Niemi et al. (2011)).
OCT1, the major liver transporter for organic cations, has been shown to be important
for the hepatic uptake of cationic drugs which are metabolized in the liver. Lack of
OCT1 activity will lead to increase drug plasma concentrations (for review, Brockmöller
& Tzvetkov (2013)). Within the efflux transporters, polymorphisms in MDR1 have been
shown to be associated with changes in drug pharmacokinetics (Kerb (2006)).
Inhibition of drug transporters by co-administered substances can also alter the phar-
macokinetics of the victim drug. For example, the inhibition of the hepatic OATPs
has a similar effect to genetic polymorphisms on drug pharmacokinetics, resulting in an
increase in the blood concentration of the victim drug. In the kidney, the inhibition of
OATs, and OCTs also leads to an increase in the plasma drug concentrations of drugs.
Cimetidine is a known inhibitor of the organic cation transport system in the kidney,
and co-administration of cimetedine has been shown to reduce the elimination of drugs
like metformin (Somogyi et al. (1987)). It has been demonstrated that renal drug-drug
interactions with cimetidine are likely due to the intracelllular inhibition of the MATE
transporters at the luminal membrane (urine), and not of OCT2 at the basolateral mem-
brane (blood) (Ito et al. (2012)). On the other hand, the inhibition of intestinal OATPs,
has the effect of lowering drug concentrations, as less drug is absorbed (König et al.
(2013)). The inhibition of MDR1 (an efflux transporter) at the blood-brain barrier has
been shown in mice to increase the concentration of drugs in the brain (Fellner et al.
(2002)).
1.5 OCT1 - A highly polymorphic membrane transporter
important for drug pharmacokinetics
1.5.1 Drug-binding to OCT1
OCT1 is a polyspecific organic cation transporter (Koepsell et al. (2007)) which has
affinity for structurally different substances. Inhibition of a membrane transporter by
a compound gives an idea of its affinity to the transporter, and is an indication that
the compound may also be a substrate. A positive charge and the increasing size of
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tetraalkyl-ammonium compounds (the bigger the alkyl chains, the larger the hydropho-
bicity) was shown to correlate to the inhibition of MPP+ uptake by organic cation
transporters (Ullrich (1997)). An interesting model has also been proposed by Moad-
del et al, which states that an ion pair interaction (protonation site), a H-bond donor
(hydrogen bonds) and a hydrophobic moiety are important for binding to OCT1 (Fig-
ure 1.10 and Moaddel et al. (2005)). This is present in substances like morphine,
O-desmethyl-tramadol, which have been identified as OCT1 substrates (Tzvetkov et al.
(2011), Tzvetkov et al. (2013)). On the other hand, Ahlin et al. (2008) proposes that
many hydrogen bonds are negatively correlated with OCT1 inhibition. The different
structural specificities identified by different authors for the binding to OCT1 reflects
the polyspecificity of OCT1, and the likely presence of multiple binding sites for different
substrates.
Figure 1.10: Pharmacophore describing drug binding to OCT1. Figure obtained
without changes from Moaddel et al. (2005).
1.5.2 Genetic variation on the OCT1 gene
The organic cation transporter 1, OCT1 (SLC22A1 ), is the most expressed transporter
in the human liver (Hilgendorf et al. (2007), Schaefer et al. (2012)) and is able to
transport organic cations which include clinically relevant drugs (Koepsell (2013)). The
OCT1 gene is highly polymorphic and in the caucasian population, 30% of the individu-
als carry a loss-of-function mutation on at least one of its alleles (Table 1.3). This means
that circa 9% of the caucasian population will have two copies of an inactive OCT1 allele,
and circa 40% will have only one functional allele, leading to reduced OCT1 activity.
Loss of function polymorphisms on the OCT1 gene have been shown to affect the phar-
macokinetics of drugs which are metabolized in the liver like tramadol, tropisetron and
morphine (Tzvetkov et al. (2011), Tzvetkov et al. (2012) and Tzvetkov et al. (2013)).
If drugs cannot enter the liver, they will not be a metabolized, and plasma concentra-
tions will increase. This may lead to unwanted drug adverse effects during therapy, or
treatment failure in case the drug needs to be activated in the liver via metabolism.
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Recently, the global variability in the OCT1 gene in 54 populations worldwide was
analysed. Interestingly, while caucasians have 9% loss of OCT1 activity, asians lacked
any of the known loss-of-function polymorphisms. In contrast, in a small population
of native american indians, 70% of the individuals were homozygous carriers of loss-of-
function mutations in OCT1, while 30% were heterozygous carriers of loss-of-function
mutations (Stalmann et al. (2014)). Pharmaceutical drugs have been around for a
very short time considering the time span of the evolution of the human species. Food,
and exposure to naturally occurring xenobiotics may be one of the explanations for the
worldwide variability observed in the OCT1 gene. In this context, it is very interesting
to study, not only drugs, but also natural substances which are liver metabolized and
may depend on OCT1 to enter the liver.
Table 1.3: The haplotype combinations of the five most frequent loss of function
polymorphisms and their frequencies in Caucasians. From Tzvetkov et al. (2013)
Haplotype Codon Allele freq
61 88 401 420 465 [%]
OCT1*1 Arg Cys Gly Met Gly Fully active 70.3
OCT1*2 Arg Cys Gly del Gly Deficient 14.8
29.7
OCT1*3 Cys Cys Gly Met Gly Deficient 10.1
OCT1*4 Arg Cys Ser Met Gly Deficient 2.4
OCT1*5 Arg Cys Gly del Arg Deficient 1.8
OCT1*6 Arg Arg Gly del Gly Deficient 0.6
1.6 Variability on the pharmacokinetics of psychotropic
drugs
The variability in the treatment with psychotropic drugs may be explained by variable
drug pharmacokinetics. In order for a psychotropic drug to reach its target, it has to be
absorbed, go through first pass metabolism, and be distributed to the brain. The rate of
elimination of a drug also influences its plasma concentrations and concentration at the
site of action. Genetic polymorphisms in drug metabolising enzymes have been shown
to affect the plasma concentrations of antidepressants (Kirchheiner et al. (2004) and
Rau et al. (2004)). However, the plasma concentration of psychotropic drugs poorly
correlates with their efficacy (Hendset et al. (2006)).
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One possible hypothesis is that variable distribution of drugs to the brain may also affect
treatment efficacy. The presence of efflux transporters in the brain and their influence
on the distributon of psychotropic drugs to the brain has been already demonstrated
(Abaut et al. (2009), Grauer & Uhr (2004) and Uhr et al. (2008)). Not much is
known about how changes in influx membrane transport at the blood-brain barrier
may influence the efficacy of psychotropic drugs. Indeed, little is known about which
influx transporters at the blood-brain barrier are important for the blood-brain barrier
permeation of psychotropic drugs.
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1.7 Aims of this work
The aim of this work is to evaluate the extent to which carrier-mediated influx transport
may modulate the pharmacokinetics and efficacy of psychotropic drugs, by influencing
their distribution and elimination. Specifically, it is hypothesised that organic cation
transporters present at the blood-brain barrier mediate the uptake of psychotropic drugs
into the brain. It is also hypothesized that carrier-mediated uptake through OCT1 may
mediate the hepatic uptake of psychotropic drugs which are liver metabolized. In this
case, polymorphisms in OCT1 would lead to lower hepatic uptake, and slower elimination
of these drugs. Thus, genetic polymorphisms in and drug-drug interactions with OCT1,
and other cation transporters may affect the distribution and elimination of psychotropic
drugs and influence therapy efficacy.
The specific aims of this project were to:
• Identify psychotropic drugs which may benefit from carrier-mediated transport to
cross cellular membranes
• Study the gene expression of membrane transporters at the blood-brain barrier
• Evaluate to what extent organic cation transporter mediated drug uptake con-
tributes to the transport of drugs through the blood-brain barrier
• Evaluate to what extent carrier-mediate transport through OCT1 contributes to
the hepatic uptake and further metabolism of psychotropic drugs
• Ivestigate how genetic polymorphisms and drug-drug interactions at membrane
transporters may influence the pharmacokinetics of psychotropic drugs





Table 2.1: Reagents used shown in alphabetical order (A-C)
Substance Manufacturer Use
14C-Tetraethylamonium (TEA+)(55mCi/mmol) Hartmann Analytic Uptake experiments
14C-Tyramine(55mCi/mmol) Hartmann Analytic Uptake experiments
3H Amantadine (439 mCi/mmol) Hartmann Analytic Uptake experiments
3H Clozapine (80mCi/mmol Hartmann Analytic Uptake experiments
3H-1-Methyl-4-phenylpyridinium(MPP+) (80 Ci/mmol) Hartmann Analytic Substrate uptake assays
3H-Amitriptyline (60 Ci/mmol) Hartmann Analytic Uptake experiments
3H-Citalopram (85Ci/mmol) Hartmann Analytic Uptake experiments
3H-Lamotrigine (5Ci/mmol) Hartmann Analytic Uptake experiments
3H-Morphine (80 Ci/mmol) Hartmann Analytic Substrate uptake assays
3H-Sulpiride (80,6 Ci/mmol) Hartmann Analytic Uptake experiments
Acetonitrile Merck Lysis Buffer and LC-MS/MS
Amisulpride Sigma-Aldrich Uptake experiments
Amitriptyline Sigma-Aldrich Uptake experiments
Atropine Sigma-Aldrich Uptake experiments
Bicinchoninic Acid solution (B9643) Sigma-Aldrich BCA assay
Bovine Serum Albumin (BSA) Sigma-Aldrich BCA assay
Citalopram Sigma-Aldrich Uptake experiments
Clomipramine Sigma-Aldrich Uptake experiments
Clozapine Sigma-Aldrich Uptake experiments
Codeine Sigma-Aldrich Uptake experiments
Cultrex rat collagen I R&D Systems Cell culture (hCMEC/d3)
Cupric sulfate pentahydrate Sigma-Aldrich BCA assay
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Table 2.2: Reagents used shown in alphabetical order (D-O)
Substance Manufacturer Use
DAB (3,3’- Diaminobenzidine) Sigma-Aldrich Immunostaining
Desipramine Sigma-Aldrich Uptake experiments
DMEM Life Technologies Cell culture
DMSO Sigma-Aldrich Freezing of mammalian cells
dNTPs Thermo Scientific Reverse transcritpion
Doxepine Sigma-Aldrich Uptake experiments
Duloxetine Sigma-Aldrich Uptake experiments
EndoGRO-MV (SMCE-004) Merck Cell culture (hCMEC/d3)
Eukitt Quick hardening mdium Sigma-Aldrich Immunostaining
Fetal Calf Serum (FCS) Life Technologies Cell culture
Fluoxetine Sigma-Aldrich Uptake experiments
Flupentixol Sigma-Aldrich Uptake experiments
Fluphenazine Sigma-Aldrich Uptake experiments
Formic Acid Sigma-Aldrich Running buffer LC-MS/MS, Lysis buffer
GFP plasmid (pIRES2-EGFP) Addgene Controlling transfection efficiency
H2O2 Carl Roth GmbH Immunostaining
Haloperidol Sigma-Aldrich Uptake experiments
HBMEC RNA Lots 7686, 6221, 5803 ScienCell Gene expression analysis
HBSS (with phenol red) Life Technologies Transport experiments
HBSS (without phenol red) Life Technologies Cell culture (hCMEC/d3)
Hematoxylin Sigma-Aldrich Immunostaining
HEPES Sigma-Aldrich Buffer for cell culture
Human basic fribroblast growth factor Sigma-Aldrich Cell culture (hCMEC/d3)
Imipramine Sigma-Aldrich Uptake experiments
Irinotecan Sigma-Aldrichn Uptake experiments
Lamotrigine Sigma-Aldrich Uptake experiments
Lipid pen Sigma-Aldrich Immunostaining
Lipofectamine 2000 Life Technologies Transfection reagent
Melperon Sigma-Aldrich Uptake experiments
Methanol Merck LC-MS/MS
Methylphenidate Sigma-Aldrich Uptake experiments
Milk powder Carl Roth GmbH Immunostaining
Milnacipram Sigma-Aldrich Uptake experiments
Mirtazapine Sigma-Aldrich Uptake experiments
MPP+ 1-Methyl-4-phenylpyridinium Sigma-Aldrich Uptake experiments
NaOH Sigma-Aldrich Cell lysis buffer, Mini-prep buffer 2
Nortriptyline Sigma-Aldrich Uptake experiments
Olanzapine Sigma-Aldrich Uptake experiments
Ondansetron Sigma-Aldrich Uptake experiments
OptiMEM Life Technologies Transfection MDCK II cells
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Table 2.3: Reagents used shown in alphabetical order (P-Z)
Substance Manufacturer Use
Paroxetine Sigma-Aldrich Uptake experiments
Penicillin-Streptomycin (10000 U/mL) Life Technologies Cell culture
Perazine Sigma-Aldrich Uptake experiments
Perphenazine Sigma-Aldrich Uptake experiments
pFRT/LacZeo Life Technologies Transfection MDCK II cells
poly-D-lysine (1-4 kDa) Sigma-Aldrich Cell culture
Potassium dihydrogen phosphate Sigma-Aldrich Lysis buffer
Promethazine Sigma-Aldrich Uptake experiments
Quetiapine Sigma-Aldrich Uptake experiments
Random hexanucleotide primers Roche Reverse transcritpion
Recombinant human placenta RNase inhibitor Affymetrix Reverse transcritpion
Risperidone Sigma-Aldrich Uptake experiments
RNA Ch.Plex.Epithelial cells ScienCell Gene expression analysis
RNA primary astrocytes ScienCell Gene expression analysis
SacI-HF restriction enzyme NEB Transfection MDCK II cells
SDS Sigma-Aldrich Cell lysis buffer, Mini-prep buffer 2
Sodium citrate Sigma-Aldrich Immunostaining
Sulpiride Sigma-Aldrich Uptake experiments
Sultopride Santa Cruz Biotechnology Uptake experiments
Sumatriptan Sigma-Aldrich Uptake experiments
Sumatriptan-d6 Santa Cruz Biotechnology Internal standard LC-MS/MS
SuperScript II reverse transcriptase Life Technologies Reverse transcritpion
TaqManr Universal PCR Master Mix 2x Life Technologies Gene expression analysis
Tiapride Sigma-Aldrich Uptake experiments
Total intestine RNA Ambion Gene expression analysis
Total kidney RNA Ambion Gene expression analysis
Total liver RNA Life Technologies Gene expression analysis
Tranylcypromine Sigma-Aldrich Uptake experiments
Triton Sigma-Aldrich Immunostaining
Tropisetron Sigma-Aldrich Uptake experiments
Trypan Blue Sigma-Aldrich Reagent for assessing cell viability
TrypLE Express Life Technologies Cell culture
Trypsin 0.25% EDTA Life Technologies Cell culture (hCMEC/d3)
Tyramine Sigma-Aldrich Uptake experiments
Vectastain ABC Kit (PK-6100) Linaris Immunostaining
Verapamil Sigma-Aldrich Uptake experiments
Xylene Sigma-Aldrich Immunostaining
Zeocin Life Technologies Cell culture




Goat polyclonal antibody for OCTN2 Santa Cruz Biotechnology Immunostaining - Primary antibody
(H-13) sc-19822
Mouse monoclonal anti-OCT1 (2C5) Novus Biologics Immunostaining - Primary antibody
Mouse Monoclonal antibody (BXP-21) BCRP Abcam Immunostaining - Primary antibody
Anti-ABCB1 antibody (HPA002199-100UL) Sigma-Aldrich Immunostaining - Primary antibody
Polyclonal rabbit anti-goat IgG Biotinylated Dako Immunostaining -Secondary antibody
Polyclonal rabbit anti-mouse IgG Biotinylated Dako Immunostaining -Secondary antibody




PAMPA 96-well plates BD Biosciences PAMPA assay
96-well Costar UV plates Corning PAMPA assay
96-Well RNAse free plates Sarstedt cDNA synthesis
Thermo-Fast 384er Plate (qPCR) Thermo Scientific Gene expression assay
Absolute qPCR Seal (Optically Clear) Thermo Scientific Gene expression assay
NunclonTM 12-well cell culture plates Nunc Cell culture
6 well plates Corning (Cat 3506) Corning Cell culture of hCMEC/D3 cells
Cell culture flasks 75mm Sarstedt Cell culture HEK293 and MDCK II cells
Cell culture flasks (Cat 430641) Corning Cell culture of hCMEC/D3 cells
Liquid Scintilation flasks Zinsser Analytics Liquid scintillation counting
AQUASAFE 500 Plus Zinsser Analytics Liquid scintillation counting
Petri dishes 100mm Sarstedt Cell culture HEK293 and MDCK II cells
(5 µm, 4 × 12.50 mm)
Brownlee SPP RP-Amide column Perkin Elmer LC-MS/MS
(4.6x100 mm, 2.7 µm)
SecurityGuard Standard precolumn Phenomenex LC-MS/MS
(C18, ODS, 4 mm x 2 mm, KJO-4282)
96-well plates sterile clear Sarstedt BCA assay
Phosphate Buffer Saline (PBS) Powder Sigma-Aldrich PAMPA assay
Transwell permeable supports 12-well format Corning MDCK II cell culture
QUIAGEN Plasmid Plus Midi Kit Quiagen Midi-prep:Isolation of plasmid DNA
Beta-Gal assay kit Life Technologies Assessing of Beta-galactosidase actitivy
QUIAGEN QIAquick Gel Extraction Kit Quiagen DNA gel extraction
QUIAGEN RNeasy plus mini kit Quiagen RNA extraction
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2.4 Cell lines
Table 2.6: Cell lines
Cell Line Obtained from:
HEK-OCT1 Institute for Clinical Pharmacology - UMG Göttingen
HEK-OCT2 Institute for Clinical Pharmacology - UMG Göttingen
HEK-OCT3 Prof. Koepsell and Dr. Gorboulev, University of Würzburg, Germany
HEK-OCTN1 Institute for Clinical Pharmacology - UMG Göttingen
HEK-OCTN2 Institute for Clinical Pharmacology - UMG Göttingen
HEK-pcDNA5 Institute for Clinical Pharmacology - UMG Göttingen
hCMEC/D3 PO Couraud, INSERM Paris
MDCK-II cell line canine European Collection of Cell Cultures (ECACC) Cat No. 00062107, Lot No. 13A022, 24 May 2013, P 28
HEK-MATE1 PortaCellTec biosciences, Göttingen, Germany
HEK-MATE2 PortaCellTec biosciences, Göttingen, Germany




TECAN Ultra Microplate Reader TECAN PAMPA assay, BCA assay, Beta-gal assay
Beckman LS5000TD Beckman Coulter Liquid scintillation counting
PerkinElmer/Sciex HPLC system Perkin Elmer LC-MS/MS
API4000 tandem mass spectrometer Applied Biosystems LC-MS/MS
7900HT Fast Real-Time PCR System Applied Biosystems Gene expression analysis
TaqManr Array Micro Fluidic Applied Biosystems Gene expression analysis
Card Thermal Cycling Block
Neubauer chamber Geier Chamber for cell counting
Microscope Zeiss Cell observation and counting
BX51 Microscope with DP-50 camera Olympus Imaging of immunostained slides
2 mm electroporation cuvette PeqLab Transformation of bacteria
Centrifuge 5810 R Eppendorf Centrifuge
Multifuge X3R Thermo Scientific Microfluic cards
Microfluidic card holders (75015679) Heraeus Centrifuge Buckets
Biofuge pico Heraeus Bench-top centrifuge
Spectrophotometer Eppendorf Quantification of RNA and DNA
EVOM meter with STX2 electrode World Precison Instruments Measurement of TEER
TaqManr Array Micro Fluidic Card Sealer Life Technologies Card sealer
BioPhotometer Eppendorf Quantification of nucleic acids
Nanodrop cuvette Implen Quantification of nucleic acids
PTC-200 Thermal Cycler Biorad Thermal cycler




ADMET Predictor 5.5 Simulations Plus Prediction of LogD, logP and pKa
SDS 2.4 Life Technologies Gene expression analysis
RQ-Manager 1.2.1 Life Technologies Gene expression analysis
SigmaPlot 12 Systat Software Inc. Determination of IC50, VMax, KM and data visualisation
IBM SPSS Statistics version 21.0 IBM Corporation Statistics
3
Methods
3.1 Parallel artificial membrane permeability assay
(PAMPA)
Parallel artificial membrane permeability assays (PAMPA) were performed using PAMPA
96-well plates (BD Biosciences) according to the manufacturer’s instructions. Briefly,
300 µL of PBS (pH 7.4) with increasing concentrations of the drug to be analyzed were
pipetted into the donor wells. Two hundred µL of PBS (pH 7.4) without drug were
pipetted into the acceptor wells. Each concentration was measured in duplicate.
The PAMPA plates were incubated at room temperature for 5 h. Equal volumes of 150
µL, from the donor and acceptor well, as well as from the initial drug solution (C0), was
transfered into a Corning UV plate (Figure 3.1). It is important to use these plates, as
they are made of a plastic which has no UV absorption. Drug concentrations from both
the donor and acceptor wells were determined by UV absorption in a TECAN Ultra Mi-
croplate Reader (TECAN, Crailsheim, Germany). The following wavelengths were used:
230 nm for amitriptyline, citalopram, clomipramine, doxepine, fluoxetine, haloperidol,
methylphenidate, nortriptyline and paroxetine; 260 nm for desipramine, fluphenazine,
imipramine, lamotrigine, melperon, milnacipram, perphenazine and tranylcypromine;
and 280 nm for amisulpride, clozapine, duloxetine, flupentixol, mirtazapine, olanzapine,
paliperidone, perazine, promethazine, quetiapine, risperidone, sulpiride, sultopride and
tiapride. Membrane permeability (Pe) was calculated as follows:
Pe =
− ln(1 − CA/(1 − (0.3 × CD + 0.2 × CA)/0.3 × C0)
(A× (1/VD + 1/VA) × t)
(3.1)
• C0 is the initial concentration in the donor well
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• CD and CA are the end concentrations in the donor and acceptor wells, respectively
• A represents the area of each well (0.3 cm2)
• VD is the volume of the acceptor well (0,2 mL)
• t is the time of incubation in seconds (18 000 seconds = 5 hours)
The assays were performed using three different concentrations for each drug and average




























































































































































































UV Plates 1 & 2 
Figure 3.1: Schematic representation of a PAMPA assay showing the PAMPA accep-
tor and donor plates, and the cross-pipetting scheme to the Costarr UV plates
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3.2 Gene expression analysis
The procedures described in this section were used to synthesise copy DNA (cDNA) and
to study the gene expression of membrane transporters in cell lines and tissues. RNA
was either obtained commercially, or isolated from hCMEC/D3 and HEK293 cells with
the RNeasy Plus Mini Kit (QUIAGEN) according to the manufacturer’s instructions.
RNA was quantified by photometry in an BioPhotometer (Eppendorf) with a Nanodrop
cuvette (Implen) using 3 µL of RNA solution. A 260nm/280nm ratio above 1.9 was
considered good for RNA.
3.2.1 Reverse transcription
To synthesize cDNA, 1 µg of RNA was diluted in 17,75 µL of RNAse free water. The
reaction was performed in a thermal cycler, by first incubating the cDNA at 42°C with
random hexanuclotide primers for 10 min. After cooling down at room temperature
for 5 to 10 min, the reverse transcription master mix was added, and incubated for an
additional 60 min at 72°C. At the end of the reaction, 70 µL of H2O was added to the
cDNA. This procedure is described in Table 3.1. The reverse transcription master mix
is described on Table 3.2.
Table 3.1: Protocol for reverse transcription
Reagent Volume added Time Temperature
Random hexanucleotide
primers
1 µL 10 min 72°C





11,25 µL 60 min 42°C
Table 3.2: Master mix for cDNA synthesis
Reagent Volume
SuperScriptr II reverse transcriptase 0,25 µL
RNAse inhibitors 0,5 µL
10 mM dNTPs 1 µL
0,1 M DTT 3,5 µL
5x RT Buffer 6 µL
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3.2.2 Gene expression analysis with TaqManr low density gene ex-
pression arrays
Gene expression analysis were carried out using customized TaqManr low density gene
expression arrays, in a 384-well format, designed to analyze the gene expression of 90
different transporter genes (Appendix A on Table A.1). The gold standard TaqManr
single assays were used to validate the gene expression arrays (assays used are also
listed on table A.1). The gene expression analysis using single assays was carried out
by mixing 3 µL of cDNA with 5.1 µL of H2O, 0.9 µL of the TaqMan
r gene expression
assay and 9 µL of TaqManr Universal PCR Master mix. The gene expression analysis
using microfluidic cards was carried out according to the manufacturers instructions.
Twenty µL of cDNA were mixed with 80 µL H2O and 100 µL TaqMan
r Universal
PCR Master Mix. The mixture was pipetted into two wells of the microfluidic card (100
µL per well, 4 samples per microfluidic card). The cards were centrifuged at 331×g for
1 min (Thermo Scientific Multifuge X3R, using the Heraeus microfluidic card holders).
The cards were sealed with the TaqManr array micro fluidic card sealer.
Both for the single assays, as well as for the microfluidic cards, the qPCR was performed
using a 7900HT Fast Real-Time PCR System equipped with the 384-well thermo cycling
block (single assays) or the TaqManr array micro fluidic card thermal cycling block using
the conditions listed on Table 3.3.







Data analysis and calculation of the Ct values was performed using SDS version 2.4
and RQ-manager version 1.2.1. Gene expression was normalized to the arithmetic mean
of the expression of 6 housekeeping genes (GADPH, ACTB, HPRT1, MVP, TBP, and
UBC) included in the TaqManr Array microfluidic cards (Table A.1). Gene expression
was calculated with the equation:
Relative gene expression = 2−(Ctgene of interest−Ctaverage house keeping genes) (3.2)
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3.3 DAB-Immunostaining of paraffin-embedded sections
on glass
The immunostaining of paraffin-embedded sections on glass was performed following a
protocol provided by Dr. Oliver Wirths (Wirths et al. (2002), with modifications). The
method is based on the oxidation of DAB (3,3’-diaminobenzidine) in the presence of
a peroxidase enzyme and hydrogen peroxide. The product of the oxidation is a brown
precipitate which stays at the site of enzymatic activity and is insoluble in alcohol. First,
the tissue slides are incubated with a primary antibody which binds to the protein
to detect. In a second step, a biotinilated secondary antibody binds to the primary
antibody. The detection is made with the VECTASTAINr ABC kit, which is comprised
of a peroxidase enzyme bound to avidin (avidin binds to the biotinilated secondary
antibody). The primary and secondary antibodies used for this procedure are listed on
Table 3.4. Imaging was performed with a Olympus BX51 Microscope. The full staining
method is described on Appendix.B.
Table 3.4: Antibodies for the detection of OCT1, BCRP and MDR-1 by DAB-
Immunostaining
Protein Primary antibody Secondary antibody Reference
BCRP Mouse monoclonal for Polyclonal rabbit Budak et al. (2005)
BCRP (BXP-21) anti-mouse IgG / Biotinylated
MDR-1 Rabbit polyclonal (HPA002199) Polyclonal swine Uhlen et al. (2010)
anti-ABCB1 antibody anti-rabbit IgG / Biotinylated
OCTN2 Goat polyclonal antibody Polyclonal rabbit Chang et al. (2011)
for OCTN2 (sc-19822) anti-goat IgG / Biotinylated
OCT1 Mouse monoclonal Polyclonal rabbit Saadatmand (2012)
anti-OCT1 (2C5) anti-mouse IgG / Biotinylated
3.4 Cell culture
3.4.1 HEK293 cells
All HEK293 cell lines were routinely cultured in DMEM medium supplemented with
10% FCS and 1% Penicillin/Streptomycin (100 U/mL) in 75 mm flasks. A dissociation
reagent was not used for routine sub-cultivation of HEK293 cell lines. Before plating cells
for uptake experiments, cells were treated with 3.5 mL of TrypLE™Express for 3 to 5
minutes. Adding 10 mL of cell culture medium stopped the action of TrypLE™Express.
After centrifugation at 300×g for 3 min, cells were re-suspended in fresh cell culture
medium, counted on a Neubauer chamber using trypan blue staining, and used for
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further experiments. To store HEK293 cells, cell stocks were frozen in FCS with 10%
DMSO.
3.4.2 hCMEC/D3 cells
hCMEC/D3 cells were routinetly cultured (Weksler et al. (2005), with modifications)
in EndoGRO™medium (including kit supplements) additionally supplemented with 1%
Penicillin/Streptomycin (100 U/mL) and 1 ng/mL of human basic fribroblast growth
factor (Table 2.2). After the addition of supplements, the cell culture medium was
stable for at least 1 month. Before subcultivation, or plating, cells were washed once
with sterile HBSS, and incubated with 0.25% trypsin for no more than 5 min (controlled
under the microscope, until cells round-up). Adding cell culture medium stopped the
action of trypsin. After centrifugation at 288 × g for 5 min, cells were re-suspended in
fresh cell culture medium, counted on a Neubauer chamber using trypan blue staining,
and used for further experiments. The hCMEC/D3 cell line was grown in Corningr
tissue culture treated 75mm flasks and 6-well plates, coated with rat collagen I. Before
use, the collagen was dissolved at concentration of 150 µg/mL in sterile water. Enough
collagen to cover the whole cell culture surface was added to the flask or well and the
cell culture surface was incubated at 37°C for one hour. The collagen was removed,
the surface was washed with sterile PBS and cell culture medium was added to the cell
culture surface (so that the collagen coating does not dry). To store the hCMEC/D3
cell line, cell stocks were frozen in 95% FCS and 5% DMSO. To use frozen vials, cells
were quickly thawed and placed in culture in EndoGRO™medium in a 25mm flask. A
medium exchange to remove the DMSO was performed after 4 to 5 hours when cells
have attached.
3.4.3 MDCK II cells
MDCK II cells, obtained from the European Collection of Cell Cultures (ECACC),
were routinely cultured in DMEM medium supplemented with 10% FCS and 1%Peni-
cillin/Streptomycin (100 U/mL) in 75mm flasks. MDCK II cells attach strongly to the
cell culture surfaces. Therefore, before sub cultivation or plating of the MDCK II cell
line, cells were treated with 3,5 mL of TrypLE™Express for 15 to 20 minutes. Adding
10 mL of cell culture medium stopped the action of TrypLE™Express. A cell scrapper
was used to further de-attach the cells from the cell culture surface. After centrifugation
at 300×g for 3 min, cells were re-suspended in fresh cell culture medium, counted on
a Neubauer chamber using trypan blue staining (to determine cell viability), and used
for further experiments. To store the MDCKII cell line, cell stocks were frozen in FCS
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with 10% DMSO. The MDCKII-LacZeo/FRT cell line was cultured in the same way as
the parent MDCKII cell line, and Zeocin was added to the cell culture medium at the
concentration of 250 µg/mL.
3.5 Uptake measurements in HEK293 cells
3.5.1 Uptake measurements in 12-well plates
Table 3.5: Summary of the methods used for cell lysis and quantification of drug
uptake in assays performed in 12-well plates
Dilution
(labeled: non-labeled)
Lysis Bufer Detection method
3H-sulpiride(80,6 Ci/mmol) 1:4000




400 µL of cell
lysate plus 9 mL of
AQUASAFE
500 Plus™
3H-morphine(80 Ci/mmol) Only labeled
14C-tyramine(55 mCi/mmol) Only labeled (5 - 20 µM)
1:3.6 (50 - 200 µM)
1:39.6 (500 - 1000 µM)
3H-MPP+(80 Ci/mmol) Only labeled (5 nM)
1:40000 (10 - 800 µM)
14C-TEA+(55 mCi/mmol) 1:50
3H-clozapine(80 Ci/mmol) Only labeled
3H-lamotrigine(5 Ci/mmol) Only labeled
3H-amantadine(439 mCi/mmol) Only labeled
3H-citalopram(85 Ci/mmol) Only labeled
3H-amitriptyline(60 Ci/mmol) Only labeled (<100 nM)
1:100 (0.1 and 1 µM)
Amisulpride Not Applicable 500 µL of
80% acetonitrile, 20%water









To measure the uptake of sulpiride, amisulpride, tiapride and sultopride in 12-well plates,
0.6 million HEK293 cells were cultured in a single well pre-coated with poly-D-lysine
(1-4 kDa). Cells were cultured for two days to reach complete confluence. All uptake
measurements were performed at pH 7.4. The cells were washed with 1 ml 37°C Hank’s
Buffered Salt Solution (HBSS). The reaction was started by adding 400 µL 37°C HBSS
containing the drug at different concentrations. The reaction was stopped after exactly
2 min by adding 2 ml ice-cold HBSS. The cells were washed twice with 2 ml ice-cold
HBSS and lysed with 500 µL of the lysis buffer (Table 3.5). Liquid scintillation counting
was used to quantify 3H and 14C label substances, according to table 3.5. Amisulpride,
tiapride and sultopride were quantified by LC-MS/MS according to table 3.5. The intra-
cellular drug concentrations were normalized to the total protein amount, as determined
using the bicinchoninic acid (BCA) assay. HEK293 cells expressing the MATE-1 and
Chapter 3. Methods 34
MATE-2K transporters were incubated with HBSS supplemented with 40 mM NH4Cl
for 30 min at 37°C before the start of uptake measurements.
3.5.2 Uptake measurements of amisulpride in Petri dishes
Nine million cells were plated in Petri dishes, which were pre-coated with poly-D-lysine.
Cells were incubated for 48 h until confluent. Before starting the uptake, cells were
washed with 10 ml 37°C HBSS. The uptake was initiated by adding 5 ml 37°C HBSS
supplemented with amisulpride and the reaction was stopped after 2 min by adding 20
ml ice-cold HBSS. Cells were washed twice with 20 ml ice-cold HBSS and transferred
to a 2 ml tube. At this point, an aliquot was stored for protein quantification. The
remaining cells were lysed in 1 ml of Lysis buffer (80% acetonitrile and 20% 30 mM
potassium dihydrogen phosphate buffer (pH 6,5)). The intracellular concentration of
amisulpride was determined as described in Dos Santos Pereira et al. (2014). The
intracellular amount of amisulpride was normalized to the total protein content of the
sample as determined by the bicinchoninic acid (BCA) assay.
3.6 Uptake measurements in hCMEC/D3 cells
One million hCMEC/D3 cells were plated in a single well of a 6-well plate coated with rat
collagen I, and cultured for two days to reach complete confluence. Before the uptake
assay, cells were washed with 2 ml 37°C Hank’s Buffered Salt Solution (HBSS). The
reaction was started by adding 1 mL 37°C HBSS containing sulpiride or amisulpride at
the concentrations of 1 µM , 5 µMand 25 µM . Sulpiride was used in a mixture of 3H-
labeled and non-radiolabeled in a molar ratio of 1:400. The reaction was stopped after 2
min by adding 5 ml ice-cold HBSS. For quantifying the intracellular amount of sulpiride,
cells were lysed with 1mL of a 0.1N NaOH solution containing 0.1% SDS. Eight hundred
(800) µL of the cell lysates were mixed with 15 ml liquid scintillator (AQUASAFE 500
Plus™). The total amount of sulpiride was quantified by liquid scintillation counting.
For quantifying the intracellular amount of amisulpride, sultopride and tiapride, cells
were lysed with 1 mL of a lysis solution (80% acetonitrile, 20% water) containing 10
ng/mL of sumatriptan-d6, which was used as internal standard. The cell lysate was used
for the quantification of intracellular drug accumulation by LC-MS/MS. The uptake
measurements at 4°C were performed after pre-incubating the cells for 15 min on ice
and the uptake reaction was carried out with ice-cold HBSS buffer. The intracellular
drug concentrations were normalized to the total protein amount, as determined using
the bicinchoninic acid (BCA) assay.
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3.7 LC-MS/MS quantification of tiapride, sultopride and
amisulpride
Tiapride, sultopride and amisulpride were quantified by LC-MS/MS by adapting pre-
viously described methods (Fisher et al. (2013), Moon et al. (2004)). Ten µL of the
sample were injected into a PerkinElmer/Sciex HPLC system coupled with an API4000
tandem mass spectrometer (Applied Biosystems, Darmstadt, Germany). Separation
was carried out in a Brownlee SPP RP-Amide column (4.6x100 mm, 2.7 µm particle
size; Perkin Elmer, Waltham, MA, USA) with a Phenomenex SecurityGuard Standard
precolumn (C18, ODS, 4mmx2mm, KJO-4282, Phenomenex, Aschaffenburg, Germany).
Isocratic elution was performed with a mobile phase of 0,1% formic acid, 6,9% acetoni-
trile, and 1,1% methanol at a flow rate of 0.3 mL/min. Detection was performed with
the mass transitions and retention times listed on table 3.6.
Table 3.6: Mass transitions and retention times used for LC-MS/MS detection of
amisulpride, sultopride and tiapride




3.8 Quantification of total cellular protein by the bicin-
choninic acid (BCA) assay
The bicinchoninic acid was first described by Smith et al. (1985). After cell lysis with a
0.1 N NaOH solution containing 0.1% SDS, 10 µL of the cell lysate were incubated with
200 µL of a commercial bicinchoninic acid solution (Sigma-Aldrich), supplemented with
4 µL of a 4% cupric sulfate pentahydrate solution (2 mg of CuSO4 × 5H2O in 50 mL
of H2O). The cell lysate was incubated with the BCA solution for 25 min at 37°C and
absorbance at 570 nm was measured in a TECAN plate reader using 96-well sterile clear
plates (Sarsted). The total protein amount was determined through a standard curve
containing 1-10 µg of bovine serum albumin (from a 1µg/µL BSA solution in water).
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3.9 Stable integration of the pFRT/LacZeo plasmid on the
MDCK II cell line
This section describes the procedures used to transfect and select MDCK II cell lines
stably expressing the pFRT/LacZeo plasmid. The pFRT/LacZeo plasmid was obtained
from Life Technologies and is shown schematically on Figure 3.2.
Figure 3.2: The pFRT/LacZeo plasmid. SV40 is the early promotor; ATG is the
initiation codon. LacZ-Zeocin™ is the β-Galactosidase - Zeocin™fusion gene. SV40 pA
is the polyadenylation signal; Ampicilin is the ampicilin resistance gene; pUC origin is
the plasmid origin of replication
3.9.1 Plasmid midi-prep: Isolation of plasmid DNA by solid extraction
with a commercial kit
The isolation of plasmid DNA by solid extraction is the preferred method to obtain
higher amounts of high purity plasmid DNA. This method is used to prepare plas-
mid DNA for a transfection of mammalian cells. The commercial kit used was the
QUIAGENr Plasmid Plus Midi Kit according to the manufacturer’s instructions. Briefly,
bacteria were grown in a pre-culture of 5 mL of LB medium containing antibiotics (ampi-
cillin 100 µg/mL) for 5 hours. After this period, 5 mL of the pre-culture were transferred
into a 500 mL autoclaved glass bottle containing 20 mL of LB medium with ampicillin
(100 µg/mL). The 25 mL bacterial culture was grown overnight. The bacterial suspen-
sion was harvested by centrifugation at 4000 rpm for 15 min. Buffers P1, P2, S3, ETR,
PE and EB were obtained from the QUIAGENr Plasmid Plus Midi Kit. The cells were
re-suspended in 2 mL of buffer P1.
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Then, 2 mL of buffer P2 were added, and the tubes gently mixed by invertion, and
incubated for 3 min at room temperature. During the incubation time, QIAfilter car-
tridges are placed in 50 mL tubes. After 3 min, 2 mL of buffer S3 were added to the
lysate and mixed by inverting 4-6 times. The lysate was transferred to the QIAfilter
cartridges and incubated at room temperature for 10 min. During the incubation time,
QUIAGEN Plasmid Plus spin columns with tube extenders were placed into the QIAvac
24 Plus (vacuum). With the aid of the supplied plunger, the lysate was passed through
the filter into the 15 mL tube and the filter cartridges were disposed of. Then, 2 mL
of the BB buffer were added to the cleared lysated (in the 50 mL tube) and mixed by
inverting 4-6 times. The lysate was added to the QUIAGEN Plasmid Plus spin column
(with the tube extender) and vacuum was applied until all the liquid has been drawn
into the column.
The column (where the DNA was now bound) was washed with 0.7 mL of ETR buffer
followed by 0.7 mL of PE buffer. Vacuum was applied until all the buffer had passed
trough the column. To remove the residual buffer in the column, the QUIAGEN Plasmid
Plus spin column was centrifuged for 1min at 10000×g in a bench top centrifuge (Biofuge
pico). Finally, to elute the DNA, 200 µL of Buffer EB was added to the column,
incubated for 1 min, and centrifuged for 1 min into a collection tube. DNA was quantified
by photometry in an BioPhotometer (Eppendorf) with a Nanodrop cuvette (Implen)
using 3 µL of DNA. A 260nm/280nm ratio above 1.6 was considered good for DNA.
3.9.2 Plasmid linearization and gel extraction
Before transfecting MDCK II cells, the plasmid DNA obtained from a midi-prep (Section
3.9.1) was linearised with the SacI enzyme. The restriction reaction was performed for
3h (1h, with additional 2h) at 37°C with the components listed on (Table 3.7). After
linearisation, the plasmid was run on an 0.8% agarose gel, and isolated with the QIAquick
Gel Extraction Kit.
Table 3.7: Linearization of Plasmid DNA
Reagent Volume (µL)
SacI-HF 5
10x Enzyme buffer 5
Plasmid DNA 40
SacI-HF (after 1h) 2
incubate for 2h
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3.9.3 Transfection and Selection of MDCK II clones
MDCK II cells were seeded at 0.4 million cells/well in a 6-well plate and cultured for
48 hours (MDCK II cells are considered difficult to transfect cells. For a successful
transfection, it is important that the cells are less than 80% confluent). On the day of
transfection, 14 µg of the linearised plasmid DNA was diluted in 150 µL of OptiMEM
medium in a 1,5 mL tube (supplemented with 100 U/mL of penicillin and streptomycin
(1%) and without serum). In another tube, 9 µL of Lipofectamine 2000 was added to 141
µL of OptiMEM medium. The 150 µL of medium containing Lipofectamine 2000 was
added to the tube containing the plasmid DNA and incubated for 5 min (Lipofectaminer
2000 reagent protocol, No. MAN007824 Rev. 1.0, Life Technologies) at room temper-
ature. The Lipofectamine-DNA complexes were formed at this point. Then, the cell
culture medium covering the MDCK II cells in the 6-well plates was removed, and 300
µL of OptiMEM medium containing the Lipofectamine-DNA complexes, are added to
the each well. Next, 700 µL of OptiMEM medium are added to each well, to a final
volume of 1000 µL per well. It is important to make the DNA complexes in a smaller
volume of medium, and then diluting them to a bigger volume (therefore, 300 µL +
700 µL). A plasmid containing the gene encoding for GFP (green fluorescence protein)
should be transfected in another well at the same time as the plasmid to be integrated.
A GFP-overexpressing plasmid was transfected in an independent well under the same
conditions in order to control for transfection efficiency. After 24h, cells are controlled
for GFP expression and are harvested from the 6-well plate (with the help of TrypLE
r Express and a cell scrapper) and transferred into a Petri dish (10 cm diameter) with
fresh DMEM medium (10% FCS, 1% PenStrep) without antibiotics. After 5-6 hours,
cells had attached to the Petri dish and the medium was replaced with fresh cell culture
medium containing Zeocin (250 µg/mL). Medium (with Zeocin) was replaced on day 4
after transfection. At day 7 after transfection the first single clones are observed and a
medium exchange is performed. At day 10 after transfection, a medium exchange was
also performed, and at day 11 after transfection, isolated cell colonies are picked. A
concentration of 250 µg/mL of Zeocin in the medium yielded single colonies.
Zeocin™’s method of killing the cells is different from other eukaryotic antibiotics in-
cluding hygromycin, G418 and blasticidin. Zeocin sensitive cells do not de-attach from
the cell surface. Instead, cells increase in size and show an abnormal cell shape (Flp-
In™system user manual, Version E, 9 November 2010, 25-0306, Invitrogen). Single
colonies of Zeocin resistance clones were identified (Figure 3.3) and labelled with a pen
from the outside of the Petri dish. Then, a cell scraper was used to de-attach the labelled
colonies from the plate by carefully scrapping only the cells inside of the colony (Zeocin
sensitive cells colonies were big enough and had a different opacity in the Petri dish,
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that could be seen with the naked eye). The de-attached cells were collected from the
Petri dish by pipetting up and down with a pipette containing 10 µL fresh medium. The
Zeocin resistant cells were further propagated in a 12-well plate with medium containing












Figure 3.3: Selection of MDCK II cells transfected with the pFRT/LacZeo plasmid.
MDCK II cells were transfected with the pFRT/LacZeo plasmid and selected in medium
containing 250 µg/mL of Zeocin. Cells which are resistant to Zeocin have the normal
cell shape of the original MDCK II cells, whereas Zeocin sensitive cells have an elongated
phenotype, and appear to be bigger.
3.9.4 TEER (transepithelial electrical resistance) measurements
MDCK II cells form tight junctions and allow the study of drug transport through
polarized cell monolayers. In order to assess whether the cells have formed a monolayer,
the transepithelial electrical resistance (TEER) can be measured by placing an electrode
on the basolateral side of the monolayer and an electrode on the apical side of the
monolayer.
For this purpose, cells were seeded at a density of 100.000 cells/well on a single well of a
Transwellr 12-well plate (1 mL of medium on the bottom well and 0.6 mL of medium
on the top well). The resistance between the two sides of the monolayer was measured
with an EVOMr Volt/Ohmmeter coupled with a STX2 electrode (Table 2.7, Section
2.5).
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3.9.5 β-Galactosidase assay
The β-Galactosidase assay assesses the activity of the pFRT/LacZeo plasmid when trans-
fected into mammalian cells. The assay is based on the hydrolysis of o-Nitrophenyl-β-
D-galactopyranosid (ONPG), a synthetic substrate of the enzyme β-galactosidase. The
β-gal assay kit ( Life Technologies ) was used according to the manufacturers instruc-
tions with slight modifications. Briefly, MDCK II cells growing on a 10 cm Petri dish
were collected with a cell scraper and diluted in 1 mL PBS. The cells were centrifuged
for 5 min at 250 ×g and the supernatant was removed. The cell pellet was re-suspended
in 100 µL of 1X lysis buffer and samples were snap-frozen on liquid nitrogen, and then
thawed at 37°C. This was repeated twice. The insoluble cell material was pelleted by cen-
trifugation at maximum speed for 5 min on a bench-top centrifuge. From each sample,
1, 5 and 10 µL of the supernatant (containing the soluble cell lysate) were transferred
into a new 1,5 µL tube, and diluted to 30 µL with deionized water. To each tube, 70
µL of ONPG and 200 µL of 1X cleavage buffer were added. The tubes were mixed by
gently flicking the bottom of the tube and short centrifugation. After incubation for 30
min at 37°C, the reaction was stopped by adding 500 µL of stop buffer and absorbance
was read at 405 nm. As a control, a sample of non-transfected MDCK II cells was also
assayed. The β-Galactosidase activity was normalized to the total protein amount as
determined by the BCA assay. Specific activity was calculated based on the following
equations:
Specific activity = nmoles of ONPGhydrolysed /t /mg protein (3.3)
• t is the time of incubation at 37°C
• mg protein is the protein amount determined by the BCA assay
nmoles of ONPGhydrolysed =
OD405 × V olume(nL)
extinction coefficient × 1 cm
(3.4)
• OD405 is the absorption at 405 nm
• V olume is the total volume of the assay 8 × 105nL (800 µL total volume)
• The extinction coefficient of the hydrolysed ONPG is 4500nl/nmoles− cm
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3.10 Data analysis
3.10.1 Enzyme kinetics
The membrane transporter dependent uptake was calculated by subtracting the uptake
in cells transfected with the empty vector (uptakeemptyvector) from the uptake in cells
expressing a membrane transporter (uptaketransporter):
Transporter dependent uptake = uptaketransporter − uptakeemptyvector (3.5)
The Michaelis-Menten constants, VMax and KM , and the half-maximal inhibition con-
stants, IC50, were calculated using non-linear regressions with Sigma Plot 12 (Systat
Software Inc., Erkrath, Germany).
VMax and KM were determined according to the Michaelis-Menten equation, where [S]
represents the substrate concentration:









The half-maximal inhibition constants, IC50 were determined by measuring the uptake
at a single concentration of the substrate, with different concentrations of the inhibitor
drug, and fitting the data into the equation:




• Y is the percent of uptake at different concentrations of the inhibitor
• S is the concentration of the inhibitor
• Ymax is the Y value at the top plateau of the curve (maximum uptake value)
• Ymin is the Y value at the bottom plateau of the curve (minimum uptake value)
• IC50 is the concentration of the drug between the top and bottom plateaus
• H is the Hill slope, which describes the steepness of the inhibition curve
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3.10.2 Estimation of maximal drug concentration in the portal vein
The plasma concentration of drugs which are metabolised in the liver, may be higher in
the portal vein than in the rest of the body. This is due to the fact that drugs reach
the liver directly after being absorbed in the intestine and have not yet suffered any
kind of liver metabolism. The theoretical maximal plasma unboud drug concentration
in the portal vein, CMAXPort,Unb., was calculated with the following equation, derived
from Ahlin et al. (2011) and Ito et al. (1998).
CMAXPort,Unb. = fu × (CMax +
ka ×D × Fa
Qh
) (3.9)
• fu is the fraction of unbound drug in the plasma
• CMax is the maximal plasma concentration
• ka is the absorption rate constant (set to 0,1 min−1)
• D is the dose in nmol
• Fa is the fraction from the drug which is absorbed into the portal vein (set to 0,99)
• Qh is the hepatic blood flow (set to 1610 mL/min)
3.10.3 Prediction of drug chemical properties
The LogD7.4 and pKa values of the drugs analyzed were estimated based on their chemi-
cal structures using ADMET Predictor 5.5 (Simulations Plus, Lancaster, CA, USA). Us-
ing the estimated pKa, the percentage of drug which is protonated at pH 7,4 (%[BH+])
was calculated according to the Henderson-Haselbach equation, as follows:
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3.10.4 Statistics
The Student’s t-test was used for two independent group comparisons. ANOVA was
used for multiple group comparisons followed by post-hoc pair-wise comparisons using
Tukey’s HSD test. Spearman’s correlation was used to analyze the correlation between
the estimated LogD7.4 and the measured membrane permeability (Pe) values. The statis-




4.1 Membrane permeability of psychotropic drugs
Systematic screens were performed in order to identify psychotropic drugs with low
membrane permeability by passive diffusion. These drugs may benefit from carrier-
mediated transport to penetrate the cell membrane. First the membrane permeability
of psychotropic drugs was estimated by calculating their physicochemical properties,
and secondly, experimentally determined by means of a PAMPA assay (parallel artificial
membrane permeability assay).
4.1.1 Computer based prediction of the physicochemical properties of
drugs
The membrane permeability of drugs was first assessed by in silico prediction of their
physicochemical properties. Table 4.1 shows the LogD at pH 7.4, LogP and pKa of
several psychiatric drugs obtained by simulation with the Software ADMET Predictor
5.5. The fraction of the drug protonated at pH 7.4 was obtained with the Henderson-
Hasselbach equation. Out of the 31 drugs tested, 22 were estimated to be above 90%
positively charged at pH 7.4 (Table 4.1). However, only 6 out of the 31 drugs tested
were estimated to have low logD7.4 values, lower than 0: tranylcypromine, sulpiride,
clozapine, amisulpride, tiapride and milnacipram. A low logD7.4 means that a drug
is more hydrophilic, and a high logD7.4 means that a drug is more hydrophobic. The
most hydrophilic drug was tranylcypromine (LogD = −0.53), and the least hydrophilic
drug, clomipramine (LogD = −3.93). Drugs with low logD7.4 are expected to have
low membrane permeability and to profit from carrier mediated transport to penetrate
cellular membranes.
44
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Table 4.1: Physicochemical properties of psychotropic drugs at pH 7.4. The logD7.4,
LogP and pKa values were obtained by simulation with the Software ADMET Predictor
5.5. The fraction of the drug protonated at pH 7.4 was calculated with the Henderson-
Hasselbach equation.
Drug logD7,4 LogP pkA Fraction protonated
at pH 7,4 (%)
Tranylcypromine -0.53 1.72 9.65 99.4
Sulpiride -0.51 0.91 8.80 96.2
Clozapine -0.38 2.65 10.43 99.9
Amisulpride -0.29 1.32 9.00 97.5
Tiapride -0.23 2.37 8.83 96.4
Milnacipram -0.07 2.09 9.56 99.3
Sultopride 0.09 1.70 8.95 97.3
Methylphenidate 0.82 2.19 8.75 95.7
Paliperidone 1.2 1.83 7.92 76.8
Melperon 1.43 3.49 9.46 99.1
Citalopram 1.82 3.57 9.14 98.2
Paroxetine 1.83 3.77 9.34 98.9
Desipramine 1.85 4.32 9.87 99.7
Nortriptyline 1.96 4.57 10.01 99.8
Lamotrigine 1.99 1.99 3.41 0.0
Risperidone 2.16 2.83 7.97 78.8
Duloxetine 2.26 4.51 9.65 99.4
Fluoxetine 2.37 4.73 9.76 99.6
Olanzapine 2.43 3.00 7.84 73.4
Quetiapin 2.47 2.81 7.48 54.6
Mirtazapine 2.49 2.71 7.23 40.3
Doxepine 2.65 4.35 9.09 98.0
Haloperidol 2.83 3.93 8.46 92.0
Perazine 3.18 4.28 8.46 92.0
Imipramine 3.25 4.81 8.95 97.3
Amitriptyline 3.25 4.99 9.13 98.2
Perphenazine 3.32 4.02 8.00 79.9
Promethazin 3.37 4.44 8.43 91.5
Fluphenazine 3.47 4.18 8.02 80.7
Flupentixol 3.91 4.74 8.16 85.2
Clomipramin 3.93 5.40 8.86 96.6
Chapter 4. Results 46
4.1.2 Transporter independent membrane permeability
The PAMPA (parallel artificial membrane permeability assay) assay is an experimental
method of determining the membrane permeability of a drug. The PAMPA membranes
are composed of a mixture of artificial phospholipids, which represent a cellular mem-
brane better than the partition coefficient LogP , and allow for an estimation of the
permeability coefficient (Pe) of a drug.
The psychotropic drugs listed on Table 4.1 were ranked by their permeability coefficient
on the PAMPA assay in Figure 4.1.
Amisulpride and sulpiride were the least permeable drugs, within the drugs tested.
Amisulpride had a Pe of 0.36 × 10−6cm/s and sulpiride had a Pe of 1.19 × 10−6cm/s.
The most permeable drug was doxepine, with a Pe of 24.9 × 10−6cm/s. Interestingly,
the drug with the lowest predicted logD, tranylcypromine, had a Pe of 9.5 × 10−6cm/s.
Figure 4.1: Comparison of the carrier-independent membrane permeabilities of com-
monly used psychotropic drugs. Shown are means and standard error of the means of
at least two independent PAMPA experiments.
Drugs which have a lower logD7.4 value, should be less membrane permeable and have a
lower Pe value. However, only 26% of the variability in the drug membrane permeabilities
could be explained by the variations in the logD7.4 values (r
2 = 0.26, Figure 4.2 A). The
variation in the logP explained 36% of the variability in drug membrane permeability
(Figure 4.2 B).
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Sulpiride, amisulpride, tiapride and sultopride are weak bases, which are more than 96%
protonated at the physiological pH of 7.4 (Table 4.1). Their low membrane permeabil-
ity (Figure 4.1) and their weak basic properties suggest that these drugs may benefit
from carrier-mediated influx transport by organic cation transporters to penetrate cell
membranes. This will be further explored in this work.
Figure 4.2: Correlation between experimentally determined Pe and the predicted
logD7.4 (A) and logP (B) of psychotropic drugs
4.2 Gene expression analysis of membrane drug
transporters
The expression of membrane drug transporters was analysed in tissues relevant for the
distribution and elimination of psychotropic drugs . The aim was to identify the trans-
porters which support the penetration of the psychotropic drugs, identified in the previ-
ous section (Section 4.1.2), through cellular barriers, especially through the blood-brain
barrier. Custom designed Taqmanr microfluidic cards were used to study the expres-
sion of 85 potentially relevant membrane transporter genes in tissues important for the
distribution and elimination of psychotropic drugs, such as the liver, kidney, intestine
and brain.
The expression of membrane transporter genes was also studied in primary cells isolated
from human brain tissue. In addition, the expression of membrane transporter genes
was studied in HEK293 cell lines stably expressing the gene of the organic cation trans-
porter OCT1(SLC22A1 ) and the empty vector and in the immortalised human brain
endothelial cell line, hCMEC/D3.
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4.2.1 Validation of the TaqManr low density array microfluidic cards
To validate the cDNA synthesis method used in this work, as well as the TaqManr
microfluidic cards, replicates of the cDNA synthesis were performed and run on different
arrays (Figure 4.3 A). Furthermore, one of the cDNA samples was analysed in two
independent cards, in order to evaluate inter-array variability (Figure 4.3). There was a
good correlation (r > 0.96) between the replicates of both the cDNA synthesis (Figure
4.3 A), as well as between different arrays (Figure 4.3 B). In addition, some of the
transporter genes which were included in the TaqManr microfluidic cards were also
analysed with the gold standard TaqManr single gene expression assay. The correlation
between the Ct values of both these assays was very good (r = 0.93, Figure 4.4).
Figure 4.3: Validation of the cDNA synthesis and TaqManr microfluidic cards. A)
Variation between different cDNA synthesis reactions of the same RNA sample. B)
Same cDNA run on two different TaqManr microfluidics cards. Show are the Ct values
for each of the 90 transporters tested. The data used for this correlation is shown in
tables C.3, C.4 and C.5 in Appendix C.
Figure 4.4: Comparison of the Ct values obtained with TaqManr single assays and
TaqManr microfluidic cards. Shown is the correlation of the Ct values for the trans-
porters OCT1 (SLC22A1 ), OCT2 (SLC22A2 ) and OCTN2 (SLC22A5 ), as well as
housekeeping gene TBP in the samples HBMEC1 and HBMEC2 (Tables C.3, C.4).
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4.2.2 Gene expression analysis in organs relevant for drug pharma-
cokinetics
The expression of membrane transporter genes was studied in RNA samples obtained
from liver, kidney, intestine and brain tissue, the organs which are most important for
drug absorption, distribution and elimination.
The major organs where drug eliminations occurs are the liver and the kidney. The
organic cation transporter 1, OCT1 (SLC22A1 ), was the transporter which showed the
highest expression in the liver sample. The expression of OCT1 was 2.9-fold higher
than the expression of GLUT-2 (SLC2A2 ), the major glucose transporter in the liver,
and 1.7-fold higher than OATP1B1 (SLCO1B1 ), the major anion transporter in the
liver (Figure 4.5 A). The second and third organic cation transporters with the highest
expression in the liver were OCT3 (SLC22A3 ) and MATE1 (SLC47A1 ), respectively.
In contrast to the liver, where the major organic cation transporter is OCT1, the kidney
has several OCTs which were expressed at high levels. The most expressed organic
cation transporters in the kidney were OCTN2 (SLC22A5 ) and OCT2 (SLC22A2 ),
followed by MATE-1 (SLC47A1 ) and MATE-2 (SLC47A2 ) respectively. The organic
anion transporters OAT1 (SLC22A6 ) and OAT3 (SLC22A8 ) were also expressed at high
levels in the kidney (Figure 4.5 B).
The expression of organic cation transporters in the intestine was lower compared to
the liver and kidney. OCTN2 was the most expressed organic cation transporter in the
intestine, followed by OCT3 and MATE-1. High expression of PEPT-1 (SLC15A1 ),
a peptide transporter which is also able to transport drugs, was detected. The efflux
transporters MDR-1 and BCRP were also among the most expressed transporters in the
intestine. By far the transporter with the highest gene expression was the glucose-sodium
co-transporter SGLT-1 (SLC5A1 )(Figure 4.6 A).
The expression of organic cation transporters in the brain was lower than in the liver,
kidney and intestine. However, OCTN2 mRNA was clearly detected in the brain. In
addition, MATE-1 and OCT3 were also detected in the brain, although at low levels
(Figure 4.6 B).
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(a) Expression of membrane transporters in the
liver
(b) Expression of membrane transporters in the
kidney
Figure 4.5: Gene expression analysis of membrane transporters in liver and kidney
tissue using TaqManr Low density Array microfluidic cards. The expression is nor-
malised to the arithmetic mean of the expression of 6 housekeeping genes (GADPH,
ACTB, HPRT1, MVP, TBP, UBC). The data represented in this figure is shown in
tables C.1 and C.2 in Appendix C.
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(a) Expression of membrane transporters in the
intestine
(b) Expression of membrane transporters in the
brain
Figure 4.6: Gene expression analysis of membrane transporters in intestine and brain
tissue using TaqManr Low density Array microfluidic cards. The expression is nor-
malised to the arithmetic mean of the expression of 6 housekeeping genes (GADPH,
ACTB, HPRT1, MVP, TBP, UBC). The data represented in this figure is shown in
tables C.1 and C.2 in Appendix C.
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4.2.3 Gene expression analysis in primary human brain cells
The brain is a complex organ composed of several cell types. Here, the RNA expression
of drug transporters was studied in different types of primary human brain cells in order
to dissect which drug transporters may facilitate the entry of psychotropic drugs into
the brain.
The endothelial cells which form the blood vessels in the brain and the cells which form
the choroid plexus epithelium are the first barriers which drugs have to face before they
reach the brain. Primary microvascular endothelial cells from the brain were studied in
order to identify transporters relevant for penetrating the blood-brain barrier (BBB),
and choroid plexus epithelial cells for penetrating the blood-CSF barrier (BCSFB). As-
trocytes are one of the most abundant cell types in the brain, and were also studied for
membrane transporter expression.
Within the three cell types analysed, transporter expression was the highest in brain
microvascular endothelial cells (HBMECs). As shown in Figure 4.7, the number of
transporters with high gene expression is higher in human brain microvascular than in
astrocytes and choroid plexus epithelial cells.
The expression of drug membrane transporters in primary astrocytes was low, with
OCTN2 being the most expressed organic cation transporter. MATE-1 was also detected
at very low amounts (Figure 4.8 A).
In choroid plexus epithelial cells, the expression of drug membrane transporters was
higher than in astrocytes, but lower than in microvascular endothelial cells. OCTN2
was, like in astrocytes, the most expressed cation transporter in choroid plexus epithelial
cells (Figure 4.8 A).
OCTN2 was the most expressed organic cation transporter in human brain microvascular
endothelial cells (HBMECs) (Figure 4.9). OCT3, OCT1, OCTN1 and MATE-1 were also
detectable, at low levels (Appendix C, tables C.1 and C.2). Their expression levels were
comparable with the expression of ENT2 (SLC29A2 ), a nucleotide transporter known
to be expressed at the blood-brain barrier (Young et al. (2013)).
Worth mentioning, was the high expression of the breast cancer resistance protein
(BCRP) in HBMECs (ABCG2 ) (Figure 4.9). The efflux transporter BCRP was highly
expressed in primary microvascular endothelial cells and intestine (Figures 4.6 and 4.9),
two of the major drug barriers in the human body. In contrast, MDR-1 (ABCB1 ) an
important efflux transporter, is detectable in most of the tissues studied (Figures 4.5,
4.6, 4.8 and 4.9). LAT-1, an amino-acid transporter that is known for its high expression
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at the blood-brain barrier (Boado et al. (1999)) also showed a high expression in our
sample (Figure 4.9).
Figure 4.7: Distribution of the expression of membrane transporters in primary cells
from the human brain. Only the transporters with relative gene expression higher than
0 were used for this analysis. The analysis was performed with SPSS version 21.0 using
data from tables C.1 and C.2 from Appendix C.
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(a) Expression of membrane transporters in pri-
mary human Astrocytes.
(b) Expression of membrane transporters in pri-
mary human choroid plexus epithelial cells.
Figure 4.8: Gene expression analysis of membrane transporters using TaqManr Low
density Array microfluidic cards. Gene expression analysis of membrane transporters in
Intestine and brain tissue using TaqManr Low density Array microfluidic cards. The
expression is normalised to the arithmetic mean of the expression of 6 housekeeping
genes (GADPH, ACTB, HPRT1, MVP, TBP, UBC). The data represented in this
figure is shown in tables C.1 and C.2 in Appendix C.
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Figure 4.9: Gene expression analysis of membrane transporters in primary human
brain microvascular endothelial cells (HBMECs) using TaqManr low density array mi-
crofluidic cards. The expression is normalised to the arithmetic mean of the expression
of 6 housekeeping genes (GADPH, ACTB, HPRT1, MVP, TBP, UBC).. The data
represented in this figure is shown in tables C.1 and C.2 in Appendix C.
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4.2.4 Donor to donor variation in the expression of drug transporters
in primary human brain microvascular endothelial cells
The commercially obtained mRNA used in this study was isolated from primary human
brain microvascular endothelial cells (HBMECs) which were isolated from three unre-
lated donors. The results of the gene expression analysis for the three different donors
are shown for all the analyzed genes in tables C.3, C.4 and C.5 in Appendix C. At the
low expression levels observed for organic cation transporters, there was inter-individual
variability in the expression of OCT1 and OCT3 and less inter-individual variability in
the expression of OCTN1, OCTN2 and MATE-1 (Figure 4.10).
Figure 4.10: mRNA expression of the organic cation transporters of the SLC22 fam-
ily and MATE-1(SLC47A1 ) in human brain microvascular endothelial cells (HBMECs).
Shown are the mean RNA expression levels in HBMECs obtained from three 3 indepen-
dent donors. At least two independent measurements were performed for each sample.
The expression is normalised to the arithmetic mean of the expression of 6 housekeeping
genes (GADPH, ACTB, HPRT1, MVP, TBP, UBC).
The large neutral amino-acid transporter (LAT-1, sub unit SLC7A5 ) is one of the
most expressed membrane transporter genes in human brain microvascular endothe-
lial cells (Figure 4.9). This amino-acid transporter has been recently shown to be able
to transport psychotropic drugs (Geier et al. (2013b)). The efflux transporters MDR-1
(ABCB1 ) and BCRP (ABCG2 ) are also major drug transporters at the blood-brain
barrier. The variability on the expression of LAT-1, MDR-1 and BCRP is shown on
Figure 4.11 for the 3 samples analysed in this study. LAT-1 (SLC7A5 ) showed substan-
tially higher expression in donor number 2 in comparison to donors number 1 and 3. The
LAT-1 sub unit SLC3A2, which acts as a chaperone and does not have substrate binding
properties, did not show inter-donor variability. The expression of MDR-1 and BCRP
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also varied in the samples obtained from different donors. Donor number 2 showed very
low expression of the efflux transporters MDR-1 (ABCB1 ) and BCRP (ABCG2 ).
Figure 4.11: mRNA expression of the LAT-1 subunits(SLC3A2 and SLC7A5 ), MDR-
1(ABCB1 ) and BCRP (ABCG2 ) in human brain microvascular endothelial cells (HB-
MECs). Shown are the mean RNA expression levels in HBMECs obtained from 3 inde-
pendent donors. At least two independent measurements were performed for each sam-
ple. The expression is normalised to the expression of 6 housekeeping genes (GADPH,
ACTB, HPRT1, MVP, TBP, UBC).
The correlation between the transport gene expression in HBMECs for the mRNA ob-
tained from different donors was analysed for all the transporter genes studied. A good
correlation for transporter gene expression between donor 1 and donor 3 was observed
(r=0.95). The correlation between donors 1 and 2, and 2 and 3 was lower (r=0.52 and
r=0.57, respectively). This shows the big similarities in transporter gene expression in
the RNAs obtained from Donors 1 and 3, in contrast to donor 2 (Figure 4.12).
Figure 4.12: Comparison of the gene expression analysis in primary HBMECs (human
brain microvascular endothelial cells) RNA obtained from different donors. The data
represented in this figure is shown in tables C.1 and C.2 in Appendix C.
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4.2.5 Gene expression analysis in the HEK293-pcDNA5, HEK-OCT1
and hCMEC/D3 cell lines
Here it was evaluated wether the over-expression of one membrane transporter affects the
expression of other transporters in the in vitro model used in this study. The expression
of drug transporters in the HEK293 cell line over expressing OCT1 was compared to
the expression in the control cell line containing only the empty vector pcDNA5. This
analysis showed that over-expressing the OCT1 gene does not alter the expression of
other membrane transporter genes (Figure 4.13).
The expression of membrane transporters was also analysed in the human brain mi-
crovascular endothelial cell line hCMEC/D3. The expression of drug transporters in
the hCMEC/D3 cell line is similar to primary HBMECs, with some notable exceptions
(Figure 4.14). In hCMEC/D3 cells, the expression of LAT-1 (SLC7A5 ), and BCRP
(ABCG2 ) were reduced by 3.8 and 4.6 -fold, respectively, in comparison to primary
HBMECs. On the other hand, the expression of MDR1 (ABCB1 ), was 2-fold higher in
the hCMEC/D3 cell line. The expression of the glucose transporter GLUT1 (SLC2A1 )
was also higher in hCMEC/D3 cells, as expected in an immortalised cell line.
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Figure 4.13: Gene expression analysis of membrane transporters in the HEK-pcDNA5
and HEK-OCT1 cell lines using TaqManr Low density Array microfluidic cards. The
data represented in this figure provides from table C.7 in Appendix C.
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Figure 4.14: Gene expression analysis of membrane transporters in the hCMEC/D3
cell line using TaqManr Low density Array microfluidic cards. The data represented
in this figure is shown in tables C.1, C.2 and C.6 in Appendix C.
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4.3 Immunohistochemistry of brain tissue
An experiment was performed to stain human membrane transporters in paraffin fixed
brain tissue slides. The goal was to validate the expression and analyse the localisation
of transporters, which were suggested to be expressed in brain microvascular endothelial
cell lines at the mRNA level. BCRP (ABCG2 ) and MDR-1 (ABCB1 ) were highly
expressed at the blood-brain barrier (Figure 4.9). The immunostaining of BCRP showed
to be very specific for blood vessels in the brain (Figure 4.15), which is not surprising
as this transporter has a very specific expression in brain microvascular endothelial cells
(Figure 4.9 vs 4.8 and Geier et al. (2013a)). The staining of MDR-1 was not as strong
as the staining of BCRP, but its expression on the microvascular blood vessels in the
brain was still detected (Figure 4.16).
OCT1 (SLC22A1 ) and OCTN2 (SLC22A2 ) have been previously suggested to be ex-
pressed at the human blood-brain barrier by immonostaining (Lin et al. (2010) and Kido
et al. (2001)). However, in the samples analysed in this study, OCTN2 was the only
transporter which was detected at average levels at the mRNA level. The mRNA levels
of OCT1 in human brain microvascular endothelial cells, were comparatively low(Figure
4.9). By means of immunostaining, it was not possible to detect either the presence of
OCT1 nor of OCTN2 in the brain (Figure 4.17).
A) B) 
C) D) 
Figure 4.15: Immunostaining of BCRP in parrafin-fixed brain tissue slides. A) and
B) show two regions of the same brain tissue slide at a magnification of 100×. C) and
D) show two regions of the same brain tissue slide at a magnification of 200×.
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A) B) 
Figure 4.16: Immunostaining of MDR-1 in parrafin-fixed brain tissue slides. The
magnification used was 100×(A) and 200×(B).
A) B) 
C) D) 
Figure 4.17: Lack of Immunostaining of OCTN2 (A and B) and OCT1 (C and D) in
brain blood vessels. The magnification used was 100×for A) and C) and 400×for B)
and D).
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4.4 Validation of the HEK293 cell lines expressing OCT1,
OCT2, OCT3, OCTN1 and OCTN2 with typical sub-
strates
In this work, HEK293 cell lines over expressing the organic cation transporters of the
SLC22 family, OCT1, OCT2, OCT3, OCTN1 and OCTN2, were used to study drug
uptake. In order to validate these cell lines, they were incubated with the typical sub-
strates for organic cation transporters, TEA+ (OCT1, OCT2, OCTN1 and OCTN2)
and MPP+ (OCT1 and OCT3)(Koepsell (2013)). As expected, OCT1 and OCT3 trans-
ported MPP+, and OCT1, OCT2, OCTN1 and OCTN2 transported TEA+ (Figures
4.18 and 4.19). The KM and VMax were determined as explained on section 3.10.1.
Differences in comparison to the literature were observed in the KM values determined,
which may be due to methodological differences in the determination of the kinetic
parameters (Table 4.2).
The KM for the uptake of MPP
+ by OCT1 was 12-fold higher than reported in the
literature. The differences could derive from the fact that Zhang et al. (1997) used
oocytes as a transport system, and performed the uptake for 90 min, resulting in very
different experimental conditions. The KM for the OCT3 mediated MPP
+ uptake was
similar to what is reported in the literature.
The KM for the uptake of TEA
+ by OCT1 was on the same order of magnitude (2-fold
higher) than what was previously reported in the literature and the KM for the uptake of
TEA+ by OCT2 was 4-fold higher than previously reported. In both cases, an indirect
method for determining KM was used, which may have resulted in these differences
(Bednarczyk et al. (2003) and Suhre et al. (2005)). No kinetic parameters are known
for the uptake of TEA+ by OCTN1 and OCTN2, but the uptake was comparable to
what is described in the literature (Kawasaki et al. (2004) and Ohashi et al. (2002)).
Table 4.2: Kinetics of the uptake of TEA+ and MPP+ by organic cation transporters
of the SLC22 family
VMax KM KM Literature
pmol min−1 mgprotein−1 µM µM
MPP+
OCT1 1591.0 ±361.9 183.7 ±42.7 15 (Zhang et al. (1997))
OCT3 1236.0 ±118.6 29.3 ±7.5 47 (Wu et al. (2000))
TEA+
OCT1 2521.0 ±535.9 341.7 ±46.2 168 (Bednarczyk et al. (2003))
OCT2 7685.7 ±382.3 183.0 ±5.7 46 (Suhre et al. (2005))
OCTN1 435.0 ±66.0 570.0 ±115.8 No Indication of KM
OCTN2 533.0 ±154.7 535.3 ±140.5 No Indication of KM
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Figure 4.18: Validation of the HEK-OCT1(A) and HEK-OCT3 (B) cell lines with the
substrate MPP+. The concentration dependent uptake was measured in comparison to
the control cell line expressing the empty vector.
Figure 4.19: Validation of the HEK-OCT1, HEK-OCT2, HEK-OCTN1 and HEK-
OCTN2 cell lines with the substrate TEA+. The concentration dependent uptake was
measured for 2 min in cell lines over expressing OCT1(A) and OCT2(B), OCTN1(C)
and OCTN2(D) in comparison to the control cell line expressing the empty vector.
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4.5 Transport of the poorly membrane permeable antipsy-
chotics amisulpride, sulpiride, sultopride and tiapride
by organic cation transporters
As shown on section 4.1.2, the drugs amisulpride, sulpiride, sultopride and tiapride are
very hydrophilic and have low membrane permeability. Furthermore, they are weak
bases and are more than 96% positively charged at the physiological pH of 7.4 (Table
4.1), making them good candidates to be substrates of organic cation transporters. In
this section, the ability of organic cation transporters to mediate the cellular uptake of
amisulpride, sulpiride, sultopride and tiapride, was studied.
4.5.1 Uptake of amisulpride by the organic cation transporters of the
SLC22 family
Amisulpride is a weak base, with a pKa of 9.0 (Figure 4.20). The ability of the organic
cation transporters of the SLC22 family to mediate the cellular uptake of amisulpride
was studied. Amisulpride was incubated at concentration of 5 µM with HEK293 cells
overexpressing the transporters OCT1(SLC22A1 ), OCT2(SLC22A2 ), OCT3(SLC22A3 ),
OCTN1(SLC22A4 ) and OCTN2(SLC22A5 )(Figure 4.21). The experiment was also per-
formed in the presence of known OCT inhibitors. Tetrabutylamonium (TBA+) was used
to inhibit the uptake by OCT1 and OCT2 (Nies et al. (2011)), irinotecan was used to
inhibit the uptake by OCT3 (Shnitsar et al. (2009)) and L-carnitine was used to inhibit
the uptake by OCTN1 and OCTN2(Stocker et al. (2013b)).
Figure 4.20: Chemical structures of amisulpride and sulpiride. The pKa values were
obtained using ADMET Predictor 5.5 (Table 4.1)






Figure 4.21: Cellular uptake of amisulpride at concentration of 5 µM in cells overex-
pressing OCT1, OCT2, OCT3, OCTN1, OCTN2, and the control cell line (transfected
with the empty expression vector). The uptake was inhibited either by 1 mM TBA+
(OCT1 and OCT2), 250 µM irinotecan (OCT3), or 500 µM L-carnitine (OCTN1 and
OCTN2). Shown are the means and standard error of the means of three independent
experiments(∗p < 0, 05 and ∗ ∗ p < 0, 01, Student’s t-test).
Amisulpride was transported by all the organic cation transporters from the SLC22
family studied (Figure 4.21). Cells over-expressing OCT1 and OCTN2 have shown the
strongest transport (7.1-fold and 5.9-fold increase, respectively, compared to cells trans-
fected with the empty vector, pcDNA5). The increase was 3.2-fold, 2.9-fold and 2.2-fold,
in cells expressing OCTN1, OCT3 and OCT2, respectively. The uptake of amisulpride
by OCT1 and OCT2 was completely inhibited by TBA+ (p < 0, 01, Student’s t-test) and
the transport of amisulpride by OCT3 was completely inhibited by irinotecan (p < 0.05,
Student’s t-test). The uptake of amisulpride by OCTN1 and OCTN2 was significantly
inhibited by L-carnitine(p < 0.05, Student’s t-test)(Figure 4.21).
The concentration dependance of the amisulpride uptake by OCT1, OCT2, OCT3,
OCTN1 and OCTN2, was investigated using concentrations ranging from 5 to 200 µM .
All cell lines expressing a drug transporter showed higher uptake of amisulpride than
the control cell lines(Figure 4.22 A and B). In order to measure only the transporter-
mediated amisulpride uptake, the uptake in the control cells was subtracted from the
uptake in the cells over expressing a membrane transporter. The transporter-mediated
uptake of amisulpride followed Michaelis-Menten kinetics (Figure 4.22 C and D). All the
membrane transporters studied, showed moderate affinities for the uptake of amisul-
pride (KM > 150µM), with the exception of OCT1, which showed the highest affinity
for amisulpride (KM = 31.3 ± 5.4µM)(Table 4.3). With an intrinsic clearance of 1.9
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mL min−1 mgprotein−1, OCT1 was the best transporter for amisulpride, within the
cation transporters of the SLC22 family (Table 4.3).
Figure 4.22: Concentration dependence of amisulpride uptake by OCT1, OCT2, and
OCT3 (A) and by OCTN1 and OCTN2 (B). Transporter mediated uptake of amisul-
pride by OCT1, OCT2, OCT3 (C) and by OCTN1 and OCTN2 (D). The transporter
mediated uptake was calculated by subtracting the uptake in the cell lines expressing
the empty vector (control), from the transporter over-expressing cell lines) Show and
the means and standard error of the means of three independent experiments.
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4.5.2 Uptake of sulpiride by the organic cation transporters of the
SLC22 family
Sulpiride is a weak base, with a pKa of 8.8 (Figure 4.20). The uptake of sulpiride by
the organic cation transporters of the SLC22 family was investigated. Sulpiride uptake
was increased 2.5-fold in cells overexpressing OCT1 and 1.8-fold in cells over expressing
OCT2, compared to the cells transfected with the empty vector. Co-incubation with
the OCT1 and OCT2 inhibitor TBA+ completely inhibited the uptake of sulpiride by
these transporters(p < 0, 01, Student’s t-test)(Figure 4.23). In contrary to amisulpride,
no uptake was observed in cells over expressing OCT3, OCTN1 and OCTN2.
Figure 4.23: Cellular uptake of sulpiride at a concentration of 5 µM in cells overex-
pressing OCT1, OCT2, OCT3, OCTN1, OCTN2, and in the control cell line (trans-
fected with the empty expression vector). The uptake was inhibited either by 1 mM
TBA+ (OCT1 and OCT2), 250 µM irinotecan (OCT3), or 500 µM L-carnitine (OCTN1
and OCTN2). Shown are the means and standard error of the means of three indepen-
dent experiments(∗ ∗ p < 0, 01, Student’s t-test).
A concentration dependent uptake of sulpiride was also observed in the OCT1 and OCT2
over-expressing cell lines which followed Michaelis-Menten kinetics (Figure 4.24 A and
B). Both OCT1 and OCT2 showed low affinity for the transport of sulpiride. Similar to
amisulpride, OCT1 was also the best transporter for sulpiride, among the transporters
of the SLC22 family, with an intrinsic clearance of 4,3 mLmin−1 mgprotein−1 (Table
4.3).
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Figure 4.24: Concentration dependence of sulpiride uptake by OCT1, OCT2, and
OCT3 (A) and by OCTN1 and OCTN2 (B). Transporter mediated uptake of sulpiride
by OCT1, OCT2, OCT3 (C), OCTN1 and OCTN2 (D). The transporter mediated
uptake was calculated by subtracting the uptake in the cell lines expressing the empty
vector (Control), from the transporter over-expressing cell lines). Shown are the means
and standard error of the means of three independent experiments.
Table 4.3: Kinetics of amisulpride and sulpiride transport by organic cation trans-
porters of the SLC22 family
KM VMax CLint (VMax/KM )
µM pmol min−1 mgprotein−1 mLmin−1 mgprotein−1
Amisulpride
OCT1 31.3 ±5.4 59.6 ±6,.4 1.9
OCT2 167.9 ±32.1 99.2 ±18.8 0.6
OCT3 191.9 ±6.1 162.4 ±28.6 0.8
OCTN1 179.9 ±20.1 78.8 ±13.6 0.4
OCTN2 185.3 ±68.0 168.8 ±34.8 0.9
Sulpiride
OCT1 259.7 ±5.4 1081.4 ±188 4.2
OCT2 187.2 ±21.6 439 ±4.7 2.3
4.5.3 Uptake of sultopride and tiapride by the organic cation trans-
porters of the SLC22 family
Sultopride and tiapride are two psychotropic drugs which are structurally similar to
amisulpride and sulpiride and also showed low membrane permeability on the PAMPA
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assays (Pe < 2, 5 × 10−6, Figure 4.1). Although they are not as broadly used as
amisulpride in the clinics, the ability of the organic cation transporters of SLC22 family
to transport sultopride and tiapride was also studied. In contrast to amisulpride and
sulpiride, the uptake of sultopride and tiapride was not increased in any of the cell
lines over-expressing the organic cation transporters of the SLC22 family. In addition,
the uptake did not decrease in the presence of specific OCT inhibitors. Therefore,
it is concluded that tiapride and sultopride are not substrates of the organic cation
transporters of the SLC22 family.
Figure 4.25: Lack of transport of sultopride and tiapride by the organic cation trans-
porters of the SLC22 family. The uptake of 5 µM of sultopride (A) and tiapride (B) was
measured in HEK293 cell lines over-expressing the transporters OCT1, OCT2, OCT3,
OCTN1, OCNT2 and the empty vector (control). The uptake was inhibited by either
1 mM TBA+(OCT1 and OCT2), 250 µM or 500 µM of L-carnitine. Shown are the
means and standard error of the means of 3 independent experiments.
OCT1 can mediate the uptake of amisulpride and sulpiride and was the most efficient
transporter for these two drugs (Figures 4.21 and 4.22). It is therefore surprising that
OCT1 cannot mediate the uptake of sultopride or tiapride. In order to assess the ability
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of these drugs to bind to the OCT1 transporter, an experiment was performed where
amisulpride, sulpiride, sultopride and tiapride were used to inhibit MPP+, a typical
OCT1 substrate. The results are presented on Figure 4.26 and Table 4.4.
As expected, amisulpride, the best OCT1 substrate within all the drugs tested (Table
4.3), was also the drug with the highest affinity to OCT1 (IC50 = 104µM). Sultopride,
tiapride and sulpiride had low affinity for the OCT1 transporter (IC50 = 697µM , IC50
>1000 µM and IC50 >1000 µM , respectively)(Table 4.4).
Figure 4.26: Inhibition of the OCT1 mediated MPP+ uptake by amisulpride,
sulpiride, sultopride and tiapride. The uptake was measured for 2 min with 5nM
of MPP+ co incubated with drug concentrations ranging from 1 to 1000 µM . Shown
are the means and standard error of the means of 3 independent experiments.
Table 4.4: Inhibition of the OCT1-mediated MPP+ uptake by amisulpride, sulpiride,
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4.5.4 Effect of polymorphisms on the OCT1 (SLC22A1 ) gene on the
uptake of amisulpride by OCT1
The OCT1 gene (SLC22A1 ) is highly genetically polymorphic. Because OCT1 is the
transporter with the highest intrinsic clearance for amisulpride and sulpiride, it is im-
portant to study how genetic variants in OCT1 may affect the uptake of amisulpride
and sulpiride(Table 4.3). The uptake of amisulpride and sulpiride was measured in cells
over-expressing the wild-type OCT1* allele and the OCT*2 to *6 variant alleles, which
are the most common OCT1 variants in the Caucasian population. The uptake of both
amisulpride and sulpiride was reduced in cells over-expressing the genetic variants, in
comparison to the wild-type OCT1*1 variant (post hoc Turkey-HSD text p < 0, 001;
Figure 4.27). These results indicate that individuals which carry the loss of function
OCT1 variants may have a reduced uptake of amisulpride and sulpiride in organs where
OCT1 is expressed and plays a role in drug transport across the cell membrane.
Figure 4.27: Uptake of 5µM of amisulpride (A) and sulpiride (B) by HEK293 cells
expressing the wild-type OCT1*1 variant (green bars), the loss of function variants
OCT1*2 to *6(red bars), and the empty vector(white bar). Show are the means and
standard error o the means of three independent experiments. ∗ ∗ ∗p < 0, 001 for
comparing the OCT1*2 to *6 alleles with the OCT1*1 allele (post-hoc Tukey-HSD
after significant ANOVA test for differences among the groups).
4.5.5 Uptake of amisulpride by the MATE1 and MATE2-K trans-
porters
A special focus was put on amisulpride, the most important neuroleptic of the benzamide
class (Pani & Gessa (2002)) which has a high renal clearance (330 mL/min)(Rosenzweig
et al. (2002)). The MATE1 and MATE2-K transporters (SLC47A1 and SLC47A2, re-
spectively) are expressed on the luminal membrane of the renal epithelium (Nies et al.
Chapter 4. Results 73
(2011)), and may be relevant for the elimination of amisulpride into the urine. There-
fore, the ability of MATE1 and MATE2-K to transport amisulpride was evaluated.
Both MATE1 (SLC47A1 ) and MATE2-K (SLC47A2 ) showed concentration depen-
dent uptake of amisulpride (Figure 4.28). The transport-dependent uptake of amisul-
pride by MATE1 and MATE2-K was also calculated (Figure 4.28 B and C), and the
Michaelis-Menten constants (KM and VMax) as well as the transporter intrinsic clear-
ance (CLint (VMax/KM )) were determined (Table 4.5). MATE1 showed the highest
affinity for amisulpride (KM = 12.0) which was higher than the affinity of MATE2-K
(KM = 36.7).
Figure 4.28: Uptake of amisulpride in cell lines expressing MATE-1 and MATE2-K
in comparison to the control cell line expressing the empty vector (A). The transporter
dependent uptake of amisulpride by MATE-1 (B) and MATE2-K (C) was calculated
by subtracting the uptake in the cells expressing the empty vector from the uptake in
the cell lines expressing the transporter. Shown are the means and standard error o
the means of three independent experiments.
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Table 4.5: Kinetics of amisulpride and sulpiride transport by the MATE-1 and
MATE2-K transporters
KM VMax CLint (VMax/KM )
µM pmol min−1 mgprotein−1 mLmin−1 mgprotein−1
MATE-1 12.0 ±1.5 704.3 ±178.9 58.6
MATE2-K 36.7 ±6.6 2247.3 ±130.3 62.4
4.6 Uptake of amisulpride and sulpiride in the human brain
endothelial cell line hCMEC/D3
The uptake of amisulpride and sulpiride was studied in human brain microvascular
endothelial cells. The hCMEC/D3 cell line was used as a model, as it is a well char-
acterised human brain microvascular endothelial cell line (Weksler et al. (2005)). The
uptake of amisulpride and sulpiride was studied at the concentrations of 1, 5 and 25
µM at 37°C and 4°C. Both concentration dependent uptake and temperature dependent
uptake was observed for amisulpride and sulpiride. This indicates the presence of a
a carrier-mediated transport mechanism in the hCMEC/D3 cell line, which is able to
transport these two drugs.
Figure 4.29: Concentration and temperature dependant uptake of amisulpride and
sulpiride in the human brain microvascular endothelial cell line hCMEC/D3. The
figures show the uptake of 1, 5 and 25 µM of amisulpride (A) and sulpiride (B) at
37°C (closed circles) and 4°C (open circles) for 2 min.
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The uptake of amisulpride and sulpiride in the hCMEC/D3 cell line was inhibitable by
MPP+(Figure 4.30), a model organic cation and known inhibitor of OCT1, OCT2 and
OCT3 (Nies et al. (2011)). MPP+ inhibited 45% of the temperature dependent fraction
of the amisulpride uptake (difference between uptake at 37°C and uptake at 4°C), and
71% of the temperature dependent fraction of the sulpiride uptake.
In addition, 1 mM of non-radiolabeled MPP+ also inhibited the uptake of radiolabeled
3H-MPP+ itself, showing that a mechanism for the uptake of organic cation transporters
is present in this cell line (Figure 4.31).
Verapamil and L-carnitine inhibited the uptake of sulpiride (Figure 4.30 A), but not
amisulpride (Figure 4.30 B). Verapamil and L-carnitine are inhibitors of OCTN2 (Stocker
et al. (2013b)), which is expressed in this cell line (Figure 4.14). Therefore, the opposite
result was expected, because amisulpride, and not sulpiride, is an OCTN2 substrate
(Figure 4.21). This could indicate the presence of an unknown transport mechanism
and will be discussed in section 5.4.
Figure 4.30: Inhibition of the uptake of amisulpride and sulpiride in the human brain
microvascular endothelial cell line hCMEC/D3. The uptake of 5 µM of amisulpride (A)
and sulpiride (B) was inhibited with medium at 4°C, with 1mM of MPP+, verapamil
or L-carnitine. Shown are the means and standard error of the means of two or more
independent experiments. ∗p < 0, 05 and ∗ ∗ ∗p < 0, 001 for comparison with the
uptake without inhibitors at 37°C (post hoc Turkey-HSD after significant ANOVA test
for differences among the groups).
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Figure 4.31: Inhibition of the uptake of 3H-MPP+ on the hCMEC/D3 cell line by
1 mM of non-labeled MPP+. The uptake of 10 nM of 3H-MPP+ was performed for
2 min in the absence (Control) and in the presence of 1 mM of non-labeled MPP+.
Shown are the means and standard error of the means of two or more independent
experiments (∗ ∗ p < 0, 01, Student’s t-test).
4.7 Interaction between psychotropic drugs with high mem-
brane permeability and OCT1
It has been shown that several psychotropic drugs, including antidepressants, can strongly
inhibit the organic cation transporter OCT1 (Zhang et al. (1998), Ahlin et al. (2008),
Nies et al. (2011) and Haenisch et al. (2012)). These include clozapine, citalopram
and amitriptyline. It was then speculated that these drugs may also be substrates for
OCT1 and may depend on OCT1 to enter the liver and be further metabolized. In this
work, clozapine, citalopram and amitriptyline were studied as possible OCT1 substrates.
Lamotrigine and amantadine, two psychotropic drugs which are proposed in the litera-
ture as OCT1 substrates, were additionally studied (Dickens et al. (2012), Lozano et al.
(2013) and Becker et al. (2011)).
4.7.1 Lack of uptake of clozapine, lamotrige, amantadine and citalo-
pram by OCT1
Clozapine, citalopram, lamotrigine and amantadine are psychotropic drugs prescribed
for several different indications and are known to interact with OCT1 (Table 4.6).
Clozapine and citalopram are known to inhibit OCT1 (Nies et al. (2011) and Haenisch
et al. (2012)) but it is not known whether they also are OCT1 substrates.
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Lamotrigine has been suggested to be OCT1 substrate (Dickens et al. (2012)), although
the evidence is very weak, as the experiments were performed in KCL22 cells, a leukaemia
cell line. This approach to measure OCT1-mediated uptake has been heavily criticised
in recent literature (Burger et al. (2013)).
Amantadine has also been proposed in the literature to be a substrate of the human
OCT1, although without evidence (Lozano et al. (2013)) and Becker et al. (2011)).
The only evidence for the uptake of amantadine by the organic cation transporter 1 is a
publication which shows that amantadine is a substrate of the rat Oct1 (Goralski et al.
(2002)).
In this work, the ability of OCT1 to mediate the uptake of clozapine, lamotrigine,
amantadine and citalopram was investigated in a well validated HEK293 cell line over-
expressing the human OCT1 (Saadatmand et al. (2012)). No increase in the uptake of
these drugs was observed in HEK293 cell over-expressing the human OCT1 in relation
to the control cells (Figure 4.32).
Table 4.6: Previous evidence for the interaction of the psychotropic drugs analyzed
in this study, with OCT1
Drug Indication Literature IC50µM
Citalopram Depression OCT1 inhibitor 3,1; 19 (Nies et al. (2011))
Clozapine Schizophrenia OCT1 inhibitor 6.65 (Haenisch et al. (2012))
Lamotrigine Epilepsy OCT1 substrate (Dickens et al. (2012)) -
Amantadine Parkinson OCT1 substrate (Lozano et al. (2013)) 18 (Nies et al. (2011))
Figure 4.32: Lack of uptake of clozapine, citalopram, lamotrigine and amantadine
by the human OCT1. The uptake was measured for 2 min. Drug concentrations used
were 13nM for clozapine, 12 nM for citalopram, 200nM for lamotrigine and 2.2µM for
amantadine. Show are the means and standard error of the means of 2-4 independent
experiments.
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4.7.2 Charachterization of the interactions between amitriptyline and
OCT1
Amitriptyline is a tricyclic antidepressant, which is known to inhibit OCT1 (Ahlin et al.
(2008)) and has very high membrane permeability (Figure 4.1 and Table 4.1). Amitripty-
line is an organic cation, protonated at pH 7,4, and is eliminated by metabolism in
the liver. The pharmacokinetics of amitriptyline have been investigated in relation to
polymorphisms in liver metabolising enzymes of the CYP450 family (Kirchheiner et al.
(2004)). OCT1 is the major liver transporter for organic cations (Figure 4.5 and Koepsell
(2013)) and an additional study is being currently conducted, at the Institute for Clini-
cal Pharmacology in Göttingen, to study the influence of polymorphisms on the OCT1
gene on the pharmacokinetics of amitriptyline in healthy human volunteers. This section
studies how amitriptyline interacts with the organic cation transporter 1, and whether
amitriptyline is a substrate for this transporter.
First, the interaction of amitriptyline with OCT1 was confirmed by showing that amitripty-
line inhibits the uptake of the typical OCT1 substrate MPP+ (Figure 4.33). Amitripty-
line showed a high affinity to OCT1 (IC50 = 4.3 ±1.3 µM).
After showing that amitriptyline binds to OCT1 with high affinity, the uptake of amitripty-
line was studied with different incubation times at the concentration of 15 nM . The
uptake of amitriptyline was in average higher on cells over-expressing OCT1, as in the
control cells (Figure 4.34). However, the absolute uptake on both the OCT1 over-
expressing cell line and the control cell line was very variable in the three independent
experiments performed (Figure 4.34 A). When comparing the uptake in the OCT1 over-
expressing cells to the uptake in the control cell lines for each individual experiment,
the uptake was significantly increased (p < 0.05) and was between 18% and 31% higher
in cells over-expressing OCT1 for the incubation times between 10 s and 2 min (Figure
(4.34 B). For the incubation time of 2 s no uptake was observed, and for an incubation
time of 5 s, the uptake of amitriptyline was 54% higher when comparing each individual
experiment.
Amitriptyline has a high protein binding (Brunton & Knollman (2011)). Addition of
serum may substantially decrease the fraction of drug which is unbound, and therefore,
the amount of free drug which is available for the membrane transporter. Furthermore,
it is not known whether the presence of serum proteins (or other substances present in
serum) directly affects the activity of the membrane transporter. In vivo, when drugs are
in the blood stream, they are bound to serum proteins. Therefore, the effect of serum on
the uptake of amitriptyline was also experimentally studied. The average uptake on the
cell lines expressing OCT1 was higher than in the control cells. However, the absolute
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values were also very variable, probably due to the high passive diffusion component of
the uptake (Figure 4.35). The net cellular uptake in both OCT and control cells in the
presence of serum was lower.
Finally, the inhibition of amitriptyline uptake by specific OCT1 inhibitors was analysed.
If a substance is substrate for a membrane transporter, its uptake should be reduced in
the presence of specific inhibitors. The presence of MPP+ had no effect on the uptake
of amitriptyline both on OCT1 over expressing and in the control cells. In contrast, the
presence of desipramine reduced the uptake of amitriptyline in OCT1 over expressing
cells by 66% (Figure 4.36 A). However, a similar reduction of the uptake of amitriptyline
(60%), in the presence of desipramine, was also observed in the control cell line, which
does not express OCT1 (Figure 4.36 B). Therefore, it could not be shown whether there
is specific uptake of amitriptyline by OCT1.
Weak bases which are very lipophilic (like amitriptyline) can accumulate in a cell by a
process called lysosomal trapping (Funk & Krise (2012), citeKazmi2013, and Logan et al.
(2014)). Desipramine is known to reduce lysosomal trapping (Daniel et al. (1995)).
High concentrations of NH4Cl in the medium are also known to have the same effect. In
order to confirm that the reduced reduced uptake in the presence of desipramine is due
to lysosomal trapping and not due to the inhibition of an unknown transporter present
in HEK293 cells, the uptake was also measured in the presence of NH4Cl. Co-incubation
with NH4Cl also reduced the uptake of amitriptyline in both the cells over expressing
OCT1 and in the control cells carrying the empty vector (Figure 4.36).
Figure 4.33: Inhibition of the OCT1 mediated MPP+ uptake by amitriptyline.
OCT1-overexpressing cells were incubated for 2 min with 5 nM 3H-MPP+ in the
presence of increasing concentrations of amitriptyline. Shown are the means and the
standard error of the means of three independent experiments.
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Figure 4.34: Time dependent uptake of amitriptyline by OCT1. The time dependance
of the uptake of amitriptyline by OCT1 was studied by incubating 15 nM of 3H-labeled
amitriptyline with HEK cells over expressing OCT1 and the control cells expressing the
empty vector, with the uptake time varying between 2 and 120 s. (A) represents the
absolute uptake in pmol mg−1mgprotein−1 in three independent experiments and (B)
the relative uptake of amitriptyline by OCT1, calculated for each individual experiment
by diving the uptake in cells over-expressing OCT1 by the uptake in cells expressing
the empty vector. Shown are the means and the standard error of the means of three
independent experiments. (∗p < 0, 05, ∗ ∗ p < 0, 01, ∗ ∗ ∗p < 0, 001 Student’s t-test).
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Figure 4.35: The role of human serum on the uptake of amitriptyline by OCT1. The
uptake of 0.1 and 1 µM of amitriptyline was measured for 2 min in cell lines over-
expressing OCT1 or the empty vector. The uptake was measured using as transport
medium, HBSS, or serum obtained from the blood of 2 unrelated individuals. Shown
are the means and the standard error of the means of two independent experiments.
p > 0.2 for all the results shown (Student’s t-test).
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Figure 4.36: Inhibition of amitriptyline uptake by MPP+, desipramine and NH4Cl.
The uptake of 2 nM of amitriptyline was measured for 2 min in cell lines over-expressing
OCT1 or the empty vector. The uptake was inhibited with either 1 mM of MPP+, 200
µM of desipramine or 20 µM of NH4Cl. Shown are the means and the standard error
of the means of three independent experiments.
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4.7.3 Drug-drug interactions involving psychiatric drugs which affect
the OCT1-mediated uptake of morphine
Morphine was recently described as a substrate of the organic cation transporter 1,
OCT1. Morphine is mainly eliminated in the liver, where OCT1 plays a major role
in its uptake (Tzvetkov et al. (2013)). Therefore, drugs which inhibit OCT1 may
inhibit the uptake of morphine in the liver therefore affecting the elimination of morphine
and leading to higher blood concentrations. Indeed, some antidepressants are used as
adjuvants in pain treatment in order to potentiate the effects of morphine. Typically used
antidepressants are amitriptyline, fluoxetine, imipramine and clomipramine. Also anti-
emetics, like topisetron and ondansetron, are prescribed together with morphine during
cancer treatment or during or following surgical interventions. The chemotherapeutic
agent irinotecan, may also be given together with morphine during cancer treatment, as
well as the calcium channel blocker verapamil, which is known to potentiate the effects
of morphine. These drugs were studied for drug-drug interactions with OCT1 (Vaupel
et al. (1993)).
All the analysed drugs inhibited the uptake of morphine by OCT1. The strongest
inhibitor was ondansetron (IC50= 1.2 ±0.2 µM), and the weakest inhibitor was codeine
(IC50= 10.9 ±0.8 µM). All the drugs tested had an IC50 value lower than MPP+, a
typical OCT1 substrate and inhibitor (Figures 4.37 and 4.38). It is interesting to observe
that codeine, the pro-drug of morphine, also had a low IC50.
When a drug is taken orally, its concentration in the portal vein is higher than in the
peripheral circulation, because drugs have not yet suffered the first past effect in the
liver. The maximal unbound drug concentration in the portal vein (CMax,Port,Unb.) and
the maximal unbound plasma drug concentration CMax,Unb. can be calculated from the
maximal plasma concentration (CMax) as explained on section 3.10.2. This is specially
important for drugs which are mainly liver metabolised and suffer from a very strong
first pass effect (Table 4.7, CMax,Unb. vs CMax,Port,Unb.). The IC50 values for the inhi-
bition of morphine uptake by several drugs were compared with the estimated unbound
maximal portal vein concentrations for each inhibitor (Table 4.7). At clinically relevant
concentrations of the drugs in the portal vein, irinotecan, veparamil and ondansetron
are able to inhibit more than 50% of the OCT1 mediated mophine uptake. On the other
hand, only ondansetron and irinotecan had a CMax,Unb./IC50 ratio equal or higher than
0,1.
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Figure 4.37: Inhibition of the OCT1 mediated morphine uptake by commonly co-
administrated drugs: Codeine, amitriptyline, verapamil, irinotecan, fluoxetine. OCT1-
overexpressing cells were incubated for 2 min with 5 nM 3H-morphine in the presence
of increasing concentrations of the inhibitor. The white circles show the uptake in the
non-inhibited control cells transfected with the empty vector.
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Figure 4.38: Inhibition of the OCT1 mediated morphine uptake by commonly co-
administrated drugs: Ondasetron, clomipramine, imipramine, tropisetron. OCT1-
overexpressing cells were incubated for 2 min with 5 nM 3H-morphine in the presence
of increasing concentrations of the inhibitor. The white circles show the uptake in the
non-inhibited control cells transfected with the empty vector.
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Table 4.7: Inhibition of OCT1-mediated morphine uptake by drugs commonly co-
administered with morphine.
IC50 Dose CMax,Unb. CMax,Unb./IC50 CMax,Port,Unb. Inhibition of OCT1 mediated
µM µM µM morphine uptake
at CMaxPort,Unb.
Irinotecan (i.v.) 1.5 ±0.3 240 mg/m2 3.89 2.6 3.9 76%
Verapamil 1.6 ±0.3 120 mg 0.06 0.04 1.7 54%
Ondansetron (oral) 1.2 ±0.2 24 mg 0.12 0.1 1.2 52%
Ondansetron (i.v.) 1.2 ±0.2 0.15 mg/kg 0.08 0.06 0.08 3%
Imipramine 6.2 ±1.4 200 mg 0.07 0.01 4.5 34%
Codeine 10.9 ±0.8 30 mg 0.11 0.01 4.3 24%
Amitriptyline 4.4 ±1.6 100 mg 0.01 0.002 1 19%
Tropisetron 3.3 ±0.6 5 mg 0.04 0.01 0.3 17%
Fluoxetine 6.0 ±0.3 60 mg 0.01 0.002 0.7 6%
Clomipramine 4.6 ±0.6 50 mg 0.005 0.001 0.4 3%
CMAX,Port,Unb. represents the maximal unbound plasma concentration in the portal vein and is cal-
culated with equation 3.9 described on section 3.10.2. The maximal plasma concentrations CMax,Unb.
and the fraction of unbound drug in plasma (fu), which are required for the calculations, were obtained
from Goodman and Gilman’s The Pharmacological Basis of Therapeutics (Brunton & Knollman (2011))
except for the CMaxof ondansetron (Zofran
r, information for prescribers), tropisetron (Kutz (1993)) ,
codeine(Tzvetkov et al. (2013)), fluoxetine (Moraes et al. (1999)) and clomipramine (Herrera et al.
(2000)) and and the fu of tropisetron (Navoban
r, information for prescribers) and clomipramine (Kelly
& Myers (1990)). In the case of i.v. administration, the CMAX,Port,Unb. was assumed equal to CMax,Unb.
4.8 The cellular uptake of tyramine is affected by genetic
polymorphisms in OCT1
OCT1 is a highly polymorphic gene, whose polymorphisms show different patterns of dis-
tribution worldwide (Stalmann et al. (2014)). OCT1 is an important transporter which
may help to detoxify exogenous substances in the liver. The reasons for the occurrence
of common polymorphisms in the OCT1 gene are unknown and one may speculate that
diet is one of the responsible factors. Tyramine is a biogenic amine present in food, and
it is been proposed to be a substrate for the human OCT1 (Schömig et al. (2006)).
However, detailed characterisation of the uptake of tyramine by OCT1 is lacking. The
interactions of tyramine with OCT1 and the effects of OCT1 polymorphisms on tyramine
uptake were analysed in details in this work.
First, the ability of tyramine to inhibit the typical OCT1 substrate MPP+ was inves-
tigated (Figure 4.39). Tyramine showed only a moderate affinity for OCT1 (IC50 =
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76.5 ± 12.9). Secondly, the uptake of tyramine by OCT1 has KM = 94.7 ± 28.2 and
VMax = 380.9 ± 19.6 (Figure 4.40), corresponding to a CLInt 4mL/min mgprotein−1.
The influence of genetic polymorphisms in OCT1 on tyramine uptake was investigated
(Figure 4.41). All the OCT1 genetic variants abolished the uptake of tyramine (p <
0, 001), with the exceptions of alleles *8 *10 and *13. Alelle *8 showed an uptake
similar to the wild-type variant *1. Alleles *10 (p < 0, 01) and *13 (p < 0, 001) showed
a decrease in uptake of 30% and 44% compared to the *1 allele, respectively.
Figure 4.39: Inhibition of the OCT1 mediated MPP+ uptake by tyramine. OCT1-
overexpressing cells were incubated for 2 min with 5 nM 3H-MPP+ in the presence of
increasing concentrations of tyramine.Shown are the means and the standard error of
the means of three independent experiments.
Figure 4.40: Kinetics of the OCT1 mediated tyramine uptake. Uptake of tyramine
in HEK-293 cells expressing OCT1 in comparison to the control cell line expressing the
empty vector (A). The transporter dependent uptake of tyramine by OCT1 (B) was
calculated by subtracting the uptake in the cells expressing the empty vector from the
uptake in the cell lines expressing the transporter. Shown are the means and standard
error o the means of three independent experiments.
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Figure 4.41: Uptake of 10 µM of tyramine by HEK293 cells expressing the wild-type
OCT1*1 variant (green bars), the loss of function variants OCT1*2 to *14(red bars),
and the empty vector(white bar). Show are the means and standard error o the means
of three independent experiments. ∗ ∗ ∗p < 0, 001 and ∗ ∗ ∗p < 0, 01 for comparing the
OCT1*2 to *14 alleles with the OCT1*1 allele (post-hoc Tukey-HSD after significant
ANOVA test for differences among the groups).
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4.9 Establishment of a MDCK II cell line for targeted
chromosomal gene integration
In this work, influx transport was measured in HEK293 cell lines which were established
through targeted chromosomal integration (Saadatmand et al. (2012)). This is specially
advantageous when studying genetic variants in proteins (for example, genetic variants
in the OCT1 gene), as all the genes will be expressed at the same level and the different
genetic variants cloned in different cell lines can be easily compared.
At the blood-brain barrier, efflux transport may play a more important role than influx
transport. Whereas influx transport can be studied by measuring drug accumulation
in normal cell cultures (for example, with HEK293 cells), in order to study membrane
transport by efflux transporters, a cell line capable of forming a tight monolayer is
needed. The substrate is placed on the bottom well of a Transwellr plate, and the
permeability through the monolayer can be measured (similar to what is depicted on
figure 1.6 B of the introduction). MDCK II cells can form tight polarised cell monolayers
and allow for these types of measurements (Dukes et al. (2011)). When an efflux
transporter is cloned into MDCK II cells, a difference in the membrane permeability of
a drug can be measured if the drug is a substrate for the transporter.
Whereas HEK293 cell lines for targeted chromosomal integration, like the ones used in
this study, are available commercially (Life Technologies), this is not the case for MDCK
cells. The only MDCK cell line for target chromosomal integration which is described in
the literature is a MDCK type I strain (Fröhlich et al. (2004)), which is known to have
an unstable phenotype (Dukes et al. (2011)). Therefore, an MDCK II cell line which
allows for targeted chromosomal gene integration was established. In this section three
clones of a MDCK II cell line transfected with the pFRT/LacZeo plasmid were isolated
and analysed.
In order to study wether the cloning procedure had an effect on the formation of polarised
cell monolayers, the TEER (transepithelial electrical resistance) in the cell line stably
expressing the plasmid was compared to the control, non-transfected, MDCK II cell
line. There were no significant differences between the TEER on the MDCK II clones
generated and the original cell line (Figure 4.42). The only exception was the higher
TEER of Clone 2 at passage +4, on day 3, which was higher than the other cell lines.
This may have due with differences on cell seeding. On day 4 the differences were not
present any more.
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In order to confirm the stable integration of this plasmid (which includes a gene for
the β-Galactosidase enzyme), an ONPG hydrolysis assay was performed at two differ-
ent passages (ONPG, o-Nitrophenyl-β-D-galactopyranosid, a synthetic substrate of the
enzyme β-Galactosidase, section 3.9.5). All the clones showed β-Galactosidase activity,
whereas the original MDCK II cell line did not show any activity (Figure 4.43). On both
passages, +4 and +5, Clone 3 showed the highest amount of β-Galactosidase activity,
followed by Clone 1 and Clone 2, respectively.
Figure 4.42: Characterization of the MDCK II cell lines cloned with the
pFRT/LacZeo plasmid at two different passages. Measurements of the transepithe-
lial electrical resistance (TEER) in transwellr plates. Panels A and B show the same
analysis, performed in different clones at passage +4 and +5, respectively, compared
to the untransfected control MDCK II cell line. Show and the means and standard
deviations of two replicates for each data point.
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Figure 4.43: Characterization of the MDCKII cell lines cloned with the pFRT/LacZeo
plasmid at two different passages. Activity of the enzyme β-Galactosidase, measured by
hydrolysis of ONPG, which indicates expression of the pFRT/LacZeo plasmid. Panels
A and B show the same analysis, performed in different clones at passage +4 and +5,
respectively, compared to the untransfected control MDCK II cell line. Shown are the
means and standard deviations of two replicates for each data point.
5
Discussion
5.1 Membrane permeability of psychotropic drugs
This work showed the potential of the PAMPA assay to identify substrates which may
depend on membrane transport to penetrate cell membranes, within a pool of sub-
stances. Amisulpride, sulpiride, tiapride and sultopride were identified in the PAMPA
assay as substances with low membrane permeability which may depend on membrane
transporters to enter the cells. These are weak bases, more than 96% protonated at
pH 7.4 (Table 4.1). Amisulpride and sulpiride were later identified as substrates of the
organic cation transporters of the SLC22 family, and amisulpride as a substrate for the
MATE1 and MATE2-K transporters.
Most of the psychiatric drugs studied in this work were weak bases and protonated at
psysiological pH (7,4) (Table 4.1). The most hydrophilic drugs, with the lowest LogD7.4,
were tranylcypromine, sulpiride, clozapine and amisulpride.
Substantial discrepancies were observed between the in silico predicted permeability,
and the permeability measured experimentally with the PAMPA assay. Drugs which are
more hydrophilic, should have lower membrane permeability. However, tranylcypromine,
the drug with the lowest LogD7.4 at pH 7.4 (LogD7.4 = −0.53, Table 4.1), showed a
high membrane permeability on the PAMPA assay (Pe = 9.5 × 10−6cm/s, Figure 4.1).
Tranylcypromine has a highly exposed amine group (Figure 5.1), which explains the
high pKa and low logD (Table 4.1), but the rest of the molecule is very hydrophobic,
explaining the high LogP (Table 4.1) and high permeability in the PAMPA assay (Figure
4.1).
The correlation of the LogP with the membrane permeability was better than the corre-
lation of the LogD value (Figure 4.2). This may indicate that the permeability through
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the PAMPA membrane depends more on the lipophilicity (measured by the LogP ) than
on the pKa of the substance (which influences the LogD value).
Figure 5.1: Tranylcypromine - a drug with low LogD and high permeability in the
PAMPA assay
Here, the PAMPA assay was successfully used to screen for drugs which are substrates
of membrane transporters. This was possible due to the use of UV as a detection
method which allowed the comparison of the membrane permeabilities of many different
compounds in a short time frame. The development of a HPLC based method for each
substance to be tested would be a work-intensive procedure.
The PAMPA assay also used for the early identification of other weak basic substances,
like atropine and sumatriptan, which have limited drug permeability and benefit from
carrier-mediated transport to enter the liver (not part of this dissertation). These drugs
were later shown, in the working group, to be substrates of OCT1 and the pharma-
cokinetics of sumatriptan were in addition shown to be dependent on OCT1 genetic
polymorphisms in healthy volunteers.
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5.2 Amisulpride and sulpiride are substrates of the organic
cation transporters of the SLC22 family and MATEs
This work identified amisulpride and sulpiride as substrates of the organic cation trans-
porters of the SLC22 family. Amisulpride and sulpiride are pyschotropic drugs in the
class of the substituted benzamides, and are used to treat schizophrenia (Rao et al.
(1981), Pani & Gessa (2002) and Komossa et al. (2010)). The chemical structures
of amisulpride and sulpiride are very similar (Figure 4.20), however, small structural
differences seem to account for different substrate specificities.
It was shown that amisulpride is a substrate for the transporters OCT1, OCT2, OCT3,
OCTN1 and OCTN2 and that sulpiride is a substrate for the transporters OCT1 and
OCT2 (Figures 4.21 and 4.23). This was the first time that an interaction between
amisulpride and the organic cation transporters of the SLC22 family was reported.
The finding that sulpiride is a substrate of OCT1 and OCT2 (Figures 4.23 and 4.24)
is in line with the previously reported ability of sulpiride to inhibit OCT2 (Kido et al.
(2011)), and the suggested involvement of OCTs in the uptake of sulpiride in Caco-2
cells (Watanabe et al. (2002)).
This study shown that OCTN1 and OCTN2 do not transport sulpiride (Figure 4.23),
in contrast to what was suggested by Watanabe et al. (2002). Watanabe et al. showed
that 20% of the uptake of sulpiride in Caco-2 cells was inhibited by adding 3 mM
L-Carnitine and suggested that OCTN1 and OCTN2 may transport sulpiride in Caco-
2 cells. However, the authors also acknowledged that there may be another not-yet
identified transporter transporting sulpiride from the apical side in Caco-2 cells. The
present study showed that OCTN1 and OCTN2 do not transport sulpiride, supporting
the hypothesis for the involvement of another apical transporter for sulpiride in Caco-2
cells. The involvement of another transporter is in line with the observed inhibition of
the uptake of sulpiride by L-carnitine in hCMEC/D3 cells (Figure 4.30 B), which will
be discussed in section 5.4.
The MATE1 and MATE2-K transporters, which are expressed in the liver (MATE1)
and kidney (MATE1, MATE2-K) may be important for the elimination of amisulpride,
which has been shown to be a substrate for both these transporters (Figure 4.28). The
role of MATE1 and MATE2-K on the uptake of sulpiride is not known and it was not
studied in this work, as sulpiride is not clinically as relevant as amisulpride.
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5.3 The role of carrier-mediated transport of amisulpride
and sulpiride at the blood-brain barrier
Amisulpride and sulpiride have a low membrane permeabity and it is not known how
they cross the blood-brain barrier. Both drugs are dopamine receptor D2 blockers and
need to pass the blood-brain barrier in order to reach their site of action. Transporters
from the SLC22 family have been suggested to be expressed at the blood-brain barrier
(Dickens et al. (2012), Lin et al. (2010) and Geier et al. (2013a)). Furthermore, OCT1
and OCT2 have been shown to mediate the uptake of MPTP, and MPP+ in brain
microvascular endothelial cells (Lin et al. (2010)). Taken together with the ability of
OCT1 and OCT2 to transport amisulpride and sulpiride, it can be suggested that OCT1,
OCT2 and other OCTs from the same family may mediate the uptake of amisulpride and
sulpiride at the blood-brain barrier. Additionally, MATE1 has been recently proposed
to be expressed in microvascular endothelial cells which form the blood-brain barrier
and may be relevant for the uptake of amisulpride into the brain (Geier et al. (2013a)).
Sulpiride has been previously indicated as a substrate of PEPT-1 (Watanabe et al.
(2002)) which is, however, not expressed at the blood-brain barrier (Figure 4.9 and
Geier et al. (2013a)).
The brain-to-blood ratios (
concentrationunboud,brain
concentrationunboud,plasma
) of amisulpride and sulpiride in rats,
are lower than one (Dufour & De Santi (1988) and Culot et al. (2013)). When the
ratio is lower than one, it may mean that drug uptake is a combination of the processes
of passive diffusion, influx transport and efflux transport, and that efflux processes are
the major part of the equation. However, this does not rule out that a small change
in the influx transport alters the concentration of the drug at the site of action. On
the other hand, the above mentioned studies were performed in rats, and the pattern of
transporter expression in the brain may be different between rodents and humans. In
contrast, Okura et al. (2014a) have shown in rats that tramadol has a brain-to-blood
ratio greater than one, indicating the presence of a mechanism for the influx transport
of cationic drugs at the blood-brain barrier in rats.
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5.4 Transport of amisulpride and sulpiride in hCMEC/D3
cells
The hCMEC/D3 cell line is a well characterized immortalised brain microvascular en-
dothelial cell line, used as a model of the blood-brain barrier (Weksler et al. (2005)).
Several studies have already been performed where the expression of membrane trans-
porters and their functionality were analysed in this cell line (Dauchy et al. (2009),
Dickens et al. (2012), Ohtsuki et al. (2013) and Okura et al. (2014a)).
A carrier-mediated influx uptake mechanism for amisulpride and sulpiride was identified
in the hCMEC/D3 cell line. Both concentration- and temperature dependent uptake
were observed for amisulpride and sulpiride, which suggests carrier-mediated transport
(Figure 4.29). Furthermore, the uptake of amisulpride and sulpiride was inhibited by
MPP+ (Figure 4.30), a typical substrate and inhibitor of organic cation transporters
(Nies et al. (2011)).
OCT1 and OCT2 can transporter amisulpride and sulpiride, as it was shown in this study
(Figures 4.21 and 4.23). However, their expression in hCMEC/D3 cells is either low, or
non-existent, as shown in this study, and by others (Figure 4.14 and C.6, Ohtsuki et al.
(2013) and Okura et al. (2014a)). Dickens et al. (2012) have reported functionality of
OCT1 in hCMEC/D3 cells, however, the mRNA levels of OCT1 in the hCMEC/D3 cells
reported in their study were similar to the OCT1 expression in the kidney, which shows
that OCT1 is not highly expressed in the hCMEC/D3 cells. The presence of OCNT2
on the other hand, was detected in this study, and corresponds to what is described in
the literature (Ohtsuki et al. (2013)).
Regarding the evidence for the low expression of organic cation transporters in hCMEC/D3
cells (this work, Ohtsuki et al. (2013) and Okura et al. (2014a)), it is plausible to assume
that, not OCTs, but another transport mechanism, which has not been yet identified, is
present in hCMEC/D3 cells and can transport amisulpride and sulpiride. This transport
mechanism seems to transport organic cations, and be inhibitable by ”organic cation”-
like substances. The existence of an unknown transport mechanism in hCMEC/D3 was
suggested by publications of other authors which have shown that ”organic cation”-
like substances, as tramadol and apomorphine (Kitamura et al. (2014), Okura et al.
(2014b) and Shimomura et al. (2013)), are transported into hCMEC/D3 cells by a not
yet identified carrier-mediated transport mechanism. Tramadol and morphine (similar
to apomorphine) have been both shown to be a substrate for OCT1 in humans (Tzvetkov
et al. (2011) and Tzvetkov et al. (2013)).
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Another piece of evidence supporting the existence and involvement of another organic
cation transporter in the amisulpride and sulpiride uptake in hCMEC/D3 cells is the
inhibition of sulpiride uptake by L-carnitine (Figure 4.30 B). L-carnitine is an inhibitor
of OCTN2 (Stocker et al. (2013b)) and it was shown that sulpiride is not a substrate
for OCTN2 (Figure 4.23). Therefore, the inhibition of sulpiride uptake in hCMEC/D3
cells cannot be due to inhibition of OCTN2. Watanabe et al. (2002) have also reported
the inhibition of the uptake of sulpiride in Caco-2 cells by L-carnitine. This suggests
that sulpiride may be taken up in Caco-2 and hCMEC/D3 cells, not by OCTN2, but
by another kind of transport mechanism, which is inhibitable by L-carnitine. Watanabe
et al. (2002) also proposed the existence of this mechanism in Caco-2 cells.
The influx of amisulpride may also be mediated by and unknown transport mecha-
nism. In contrast to sulpiride, L-carnitine does not inhibit the uptake of amisulpride
in hCMEC/D3 cells, although amisulpride is transported by OCTN2 (Figures 4.21 and
4.22). OCTN2 can transport in both directions (influx and efflux, Koepsell (2013)).
This means that the influx of amisulpride may be mediated by the already mentioned
unknown transport mechanism and the efflux may be mediated by OCTN2. In this
scenario, when both the influx and efflux are inhibited, the net uptake will be equal to
the non-inhibited control (Figure 4.30 A).
A possible interaction between influx transport and efflux transport in the uptake of
amisulpride was identified in hCMEC/D3 cells. Verapamil did not change the rate of
amisulpride uptake into the hCMEC/D3 cell line (Figure 4.30). Verapamil is known
to inhibit both organic cation transporters and MDR1 (Nies et al. (2011) and Pauli-
Magnus et al. (2000)). MDR1 is know to transport amisulpride (Schmitt et al. (2006))
and is expressed and functional in the hCMEC/D3 cell line (Figure 4.14, Poller et al.
(2008),Dauchy et al. (2009) and Ohtsuki et al. (2013)). Therefore, the net uptake equal
to the control may be the result of simultaneous inhibition of OCT-mediated influx and
MDR1-mediated efflux of amisulpride by verapamil (Figure 4.30 A). On the other hand,
sulpiride is not a substrate for MDR1 (Feng et al. (2008)), and therefore, verapamil
only inhibits the influx transport, resulting in an uptake lower than the uptake in the
non-inhibited control (Figure 4.30 B).
Currently, there have been 1022 transporter genes identified in the human genome (sec-
tion 1.3.2, Introduction) from which 395 are solute carriers (SLC family, Hediger et al.
(2013)). Therefore, the analysis of amisulpride and sulpiride uptake by the organic
cation transporters of the SLC22 family may have just scratched the surface of the pos-
sible number of transporters which are relevant for the blood-brain barrier uptake of
amisulpride and sulpiride and other drugs.
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5.5 Organic cation transporters may influence the phar-
macokinetics of amisulpride and sulpiride
Besides the penetration of the blood-brain barrier, carrier-mediated transport of amisul-
pride and sulpiride may allow these drugs to cross several cellular barriers important for
drug absorption and elimination (Figure 5.2).
The transporters relevant for the pharmacokinetics of sulpiride are the same as for
amisulpride, with the exception of OCTN2, OCTN1 (Figure 4.23) and MDR1. Amisul-
pride is a substrate for MDR1(Schmitt et al. (2006)), whereas sulpiride is not (Feng
et al. (2008)). A summary of the membrane transporters important for the absorption,
metabolism, distribution and elimination of amisulpride is depicted on figure 5.2.
The renal clearances of amisulpride and sulpiride are 330 and 223 ml/min, respectively,
(Rosenzweig et al. (2002) and Wiesel et al. (1980)), indicating that tubular secretion
plays a substantial role in drug elimination (Introduction, section 1.2.3). For amisul-
pride, fu ×GFR = 104mLmin−1, which means that more than two thirds of the renal
clearance of amisulpride are due to tubular secretion. It is likely that OCT2 is the
basolateral (blood) transporter responsible for the high renal secretion of both drugs.
On the other hand, MATE1 and MATE2-K are known to be expressed on the luminal
membrane (urine) of kidney proximal tubule cells and may be mediate the secretion of
amisulpride into the urine. MATE1 and MATE2-K have a higher intrinsic clearance for
transporting amisulpride, and higher affinity for amisulpride, than OCT2 (Tables 4.3
and 4.5). This could mean that the basolateral (blood) uptake of amisulpride in the
kidney is the rate-limiting step for its elimination in the kidney. However, the analysis
of drug-drug interactions, has to be done on a case-to-case basis, taking into account
the affinity of the inhibiting drug for OCT2 and MATE1 and MATE2-K. Ito et al.
(2012) have elegantly shown that inhibition of the MATE transporters on the luminal
membrane, and not of the OCT2 transporters on the basolateral membrane of kidney
proximal tubules is the mechanisms responsible for the inhibition of the renal clearance
of organic cations by cimetidine.
A drug-drug interaction study of amisulpride with cimetidine has never been performed.
Interestingly, the prescribing information of both amisulpride and sulpiride cites several
known drug-drug interactions which drugs which are also known to inhibit organic cation
transporters like quinidine, verapamil and imipramine (Nies et al. (2011)).
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Figure 5.2: Localization of the membrane transporters which may play a role on
the pharmacokinetics of amisulpride. The difference between this figure and figure 1.9
from the introduction is inclusion of only the organic cation transporters which may
be relevant for the pharmacokinetics of amisulpride (blue), as well as the inclusion of
transporters where their localisation and role is still debatable (orange). These include
the presence of OCT1 in the apical membrane in the intestine (Han et al. (2013)) and
a transporter responsible for the basolateral intestinal transport of amisulpride into the
blood. The role of OCT1 and OCT2 at the blood-brain barrier is still debatable, as
discussed on section 5.8 (Lin et al. (2010)). OCTN2 has been proposed to be localised
on the basolateral in bovine BMECs (Miecz et al. (2008)) and is expressed at the human
blood-brain barrier (Figure 4.9). As discussed in section 5.4, another transporter may
be involved on the transport of amisulpride at the blood-brain barrier.
Amisulpride and sulpiride are not metabolized in the liver, but biliary excretion may
account for up to 20% of their total clearance (Rosenzweig et al. (2002) and Wiesel
et al. (1980)). OCT1 is a transporter of both amisulpride and sulpiride and it is
likely that it plays a role on the hepatic uptake and further billiary clearance of these
two drugs. As shown on figure 5.2, OCT1 is the sinusoidal (blood) uptake transporter
for amisulpride in the liver, and MDR1 and MATE-1 are the canicular (bile) efflux
transporters for amisulpride. MATE-1 has a higher affinity (lower KM , and a higher
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CLint for amisulpride than OCT1 (Tables 4.3 and 4.5). This may mean that MATE1,
together with MDR1 clear amisulpride from the hepatocytes, at a rate which is higher
than its OCT1 mediated uptake. This suggests that OCT1 mediated uptake is the
limiting step on the billiary clearance of amisulpride.
PEPT-1 is highly expressed in the intestine and is likely to be responsible for the absorp-
tion of sulpiride (Figure 1.9 and Figure 4.6). In addition, OCT1 has also been identified
in the intestinal epithelium (Han et al. (2013)) and may play a role on the absorption
of amisulpride and sulpiride.
5.6 Role of polymorphisms in organic cation transporters
on the pharmacokinetics of amisulpride and sulpiride
In this study it was shown that the uptake of amisulpride and sulpiride is affected by
genetic variants in OCT1. OCT1 is highly polymorphic, and five of the common OCT1
alleles are known to lead to reduced OCT1 activity in 9% of the caucasian population
(Brockmöller & Tzvetkov (2013)). This adds amisulpride and sulpiride to the limited
list of clinically relevant drugs which were shown to be dependent on OCT1 to cross
cellular barriers (Table 5.1). As stated previously, 20% of the amisulpride present in the
blood stream is eliminated through the bile and OCT1 is likely the limiting step in the
billiary elimination of amisulpride. The role of OCT1 on the distribution of amisulpride
and sulpiride to the brain still needs confirmation in vivo, before concluding about the
possible role of OCT1 polymorphisms on the therapy with these two drugs. Likewise,
the role of OCT1 in intestinal absorption also needs further investigations (Han et al.
(2013)). In addition to OCT1, genetic polymorphisms in OCT2, MATE1 and MATE2
are also known and should be considered for further studies (Tzvetkov et al. (2009) and
Stocker et al. (2013a)).
Table 5.1: Clinically relevant drugs shown to be OCT1 substrates
Drug Reference Drug Reference
Metformin Shu et al. (2007) Lamivudine Jung et al. (2008)
Morphine Tzvetkov et al. (2013) Zalcitabine Jung et al. (2008)
Tramadol Tzvetkov et al. (2011) Amisulpride This work
Tropisetron Tzvetkov et al. (2012) Sulpiride This work
Sorafenib Swift et al. (2013)
Chapter 5. Discussion 101
5.7 Sultopride and Tiapride are not substrates of the or-
ganic cation transporters of the SLC22 family
Although organic cation transporters of the SLC22 family can transport amisulpride and
sulpiride, they cannot transport sultopride and tiapride, two drugs which are structurally
very similar (Figure 4.25). These results suggest that structural differences between
these drugs account for substrate specificity. One of such differences may be the amine
moiety, near the aromatic ring, which is present in amisulpride and sulpiride, but missing
in sultopride and tiapride (Figure 5.3).
Figure 5.3: Comparison of the chemical structures of sulpiride, amisulpride, sultopride
and tiapride. Shown in grey is the amine group which is present in amisulpride and
sulpiride but not in sultopride and tiapride.
The amine group in amisulpride and sultopride could form hydrogen bonds with the
OCT1 transporter. Amine groups which are connected to a benzene ring (like amisul-
pride, Figure 5.3) may also form hydrogen bonds (Szaty lowicz (2008)). It has been
suggested by Moaddel et al. (2005) that an electron donor pair is important for binding
to OCT1 (Figure 1.10). An interesting experiment to confirm this hypothesis, would
be testing whether amisulpride and sulpiride are still substrates of organic cation trans-
porters after substituting the amino group in amisulpride and sulpiride by a methyl
group (-CH3).
Altough sultopride and tiapride are not transported by OCT1, they also inhibited the
OCT1-mediated uptake of MPP+ with different affinities. Amisulpride showed the high-
est affinity for OCT1, whereas sultopride, tiapride and sulpiride showed lower affinity
(Figure 4.26 and Table 4.4). Because sultopride and tiapride showed low affinity to
OCT1, it is not surprising that they are not substrates of this transporter (Figure 4.25).
On the other hand, sulpiride, which was shown to be an OCT1 substrate (Table 4.3 and
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Figures 4.23 and 4.24), had the lowest affinity from all the drugs tested (>1000 µM ,
Figure 4.26). The fact that the KM of sulpiride (259.7 µM , Table 4.3) is lower than its
IC50 for inhibiting MPP
+ may reflect the polispecificty of the OCT1 transporter. The
binding sites for MPP+ may be different than the binding sites for sulpiride, therefore
sulpiride may not be efficient in inhibiting the transport of MPP+.
5.8 Gene expression analysis of drug membrane transpor-
ters in tissues relevant for drug distribution and pri-
mary brain cells
The gene expression of membrane transporters was studied at the mRNA level on liver,
kidney, intestine and brain tissues. The major transporters which are known to be
expressed in these organs, were also found in the samples analysed in this study (Fig-
ures 4.5, 4.6, 4.8 and 4.9, Section 4.2). In the liver, the uptake transporters OCT1
(SLC22A1) and OATP1B1 (SLCO1B1) were found to be highly expressed. Within all
the transporters analysed, OCT1 was the major membrane transporter in the liver,
which reenforces the likely important role that it plays in the removal of xenobiotics
from the blood flow. In the kidney, the transporters OCT2 (SLC22A2 ) and OAT1
(SLC22A6 ) and OAT3 (SLC22A8 ) were highly expressed. In the intestine, high ex-
pression of the efflux transporter MDR1 (ABC1B1 ) could be shown, as well as of the
PEPT1 transporters (SLC15A1 ). In the brain, high expression of MDR1 (ABCB1 ) was
detected.
Within the primary cells from the brain which were analysed, the transporter expression
was the highest in HBMECs (human brain microvascular endothelial cells)(Figure 4.7).
This was expected, as these cells form the major barrier between the blood and the brain,
and are also important for the transport of for example nutrients from the blood into
the brain.The transporter expression was also analysed in mRNA from primary human
choroid plexus epithelial cells and astrocytes. The expression of membrane transporters
was the lowest in astrocytes, reflecting the non-barrier properties of these cells. On the
other hand, astrocytes which are close to blood vessels in the brain may have different
transporter-expressing patterns, however this was not studied in this work (Figures 4.7,
4.8 and 4.9).
A principle component analysis of the gene expression of membrane transporters in the
several different tissues analysed, grouped the HBMECs close to the choroid plexus
epithelial cells. This shows that the pattern of transporter expression is similar in
these two cell types which have barrier functions (Figure 5.4). Nonetheless, the relative
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gene expression of membrane transporters is higher in HBMECs than in choroid plexus































HBMECs Ch. Plexus  
epithelial cells 
Figure 5.4: Principal component analysis of gene expression in tissues and primary
cells. The analysis was performed on SPSS 21.0, by extracting two factors, which are
shown on the figure. Note: The KMO test of sample adequacy = 0.718 and Bartlett’s
test of sphericity (significance < 0.05) show that the analysis can be performed (SPSS
user manual).
The mRNA expression analyses showed that OCTN2 (SLC22A5 ), OCT1(SLC22A1 ),
OCT3(SLC22A3 ) and OCTN1(SLC22A4 ) are expressed in human brain microvascular
endothelial cells and may play a role in drug uptake at the blood-brain barrier (Figure
4.10). These findings are consistent with previous studies reporting mRNA (Lin et al.
(2010), Dickens et al. (2012), Kido et al. (2001) and Geier et al. (2013a)) and protein
expression (Lin et al. (2010) and Geier et al. (2013a)) of these transporters at blood-
brain barrier.
It is debatable whether OCT1 is really expressed at the blood-brain barrier. This work
(Figure 4.9 and Figure 4.10) and others (Shawahna et al. (2011) and Geier et al.
(2013a)) show that the expression of OCT1 in the brain is very low, in contrast to
Dickens et al. (2012) and Lin et al. (2010), who proposed that OCT1 is functional and
highly expressed at the blood-brain barrier. The presence of OCT1 in the brain could
not be confirmed in this study by immunostaining (Figure 4.17).
OCTN2, on the other hand, has been shown to be present at the blood-brain barrier
(Kido et al. (2001)) and its gene expression was also detectable both in this work, as in
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the rest of the literature (Figure 4.9 and Geier et al. (2013a)). Like OCT1, the presence
of OCTN2 at the blood-brain barrier could not be confirmed by immunostaining (Figure
4.17). Other antibodies and staining procedures may help to detect OCT1 and OCTN2
at the blood-brain barrier.
The previously suggested expression of OCT2 (Lin et al. (2010)) in human brain en-
dothelial cells was not confirmed by this work (Figures 4.9 and table C.2). Lin et al.
(2010) have obtained the primary human brain endothelial cells (HBMECs) from the
same provider where the RNA for this work was obtained (ScienCell, Table 2.2). How-
ever, whereas this work studied RNA expression in HBMECs, Lin et al. have only
studied protein expression, using antibodies. The antibodies used by Lin et al. have yet
to be validated. Antibodies can be non-specific and also stain other proteins which are
not OCT2. Furthermore, Lin et al. have shown reduced uptake of MPP+ in BMECs
after transfection with an siRNA against OCT2. Again, no validation of the siRNAs is
shown on the work of Lin et al., and siRNAs may also have off-target effects. On the
other hand, Lin et al. have cultured the HBMECs ex vivo and in cannot be excluded
that the cell culture conditions may affect the gene expression of membrane transporters.
The already known presence of MDR1 (ABCB1 ) and BCRP (ABCG2 ) at the blood-
brain barrier was confirmed in this study both at the RNA expression level (Figure
4.9) as well as at the protein level (Figures 4.15 and 4.16). It was shown that this
staining procedure can be used to detect membrane transporters in brain microvascular
endothelial cells. Furthermore, the expression of BCRP at the blood-brain barrier was
stronger than the expression of MDR1. This may suggest that BCRP is the main efflux
transporter at the blood-brain barrier, and it requires further investigation in order to
identify the role that BCRP plays on preventing the entrance of drugs into the brain,
also in relation to its genetics polymorphisms (Ieiri et al. (2009)).
Figure 5.5: Comparison of the gene expression analysis in primary HBMECs (human
brain microvascular endothelial cells) with the study of Geier et al. (2013a). The
correlated data was obtained from tables C.1 and C.2.
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The expression of drug transporters in HBMECs determined in this study correlated
poorly with recently published data by Geier et al. (2013a) (r=0.17, Figure 5.5). Geier
et al. detected, for example, high expression of OCT3 and MATE1 and the blood-brain
barrier, which could not be confirmed in this study. The correlation between donor 2
alone and the data from Geier et al. was better than the correlation for the average
of donors 1 and 3 , but still low (r=0.33, Figure 5.6). The correlation was better for
comparing the mRNA samples from the three donors used in this study (Figure 4.12,
results).
Figure 5.6: Comparison of the gene expression analysis in primary HBMECs (human
brain microvascular endothelial cells) with the study of Geier et al. (2013a) - Part 2.
The average of transporter gene expression in mRNA from donors 1 and 3 (A) and
transporter gene expression in mRNA from donor 2 were compared with the study of
Geier et al.. The correlated data was obtained from tables C.3, C.4 and C.5.
The discrepancies between this study and the study from Geier et al. may be due to
variations in the procedure used to obtain the RNA. The RNA used by Geier et al.
was obtained directly from freshly isolated HBMECs, whereas the samples analyzed
in this study were obtained from HBMECs cultured ex vivo. Both approaches have
advantages and disadvantages. Using freshly isolated HBMECs has the advantage of
avoiding the changes in transporter gene expression which may occur by culturing the
cells ex vivo. It has been reported that the expression of transporter genes in primary
hepatocytes decreases with culture time (Tchaparian et al. (2011)). On the other hand,
the direct analysis of the mRNA after cell isolation increases the risk of contamination
with other cell types (for example, astrocytes). The ex vivo approach, as used in this
work, guarantees a more homogeneous endothelial cell culture, as the cells are grown for
one passage on specific endothelial cell medium, before the isolation of the mRNA.
Differences in the procedure used to analyse gene expression may also lead to the dis-
crepant results between this study and the study from Geier et al. (2013a). In this work
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TaqManr qPCR assays for gene expression analysis were used, whereas Geier et al.
(2013a) used an OpenArrayr system, which in their hands, showed a poor correlation
with the TaqManr assay (Geier et al. (2013a), Supplementary figure S2). In contrast,
the TaqManr low density arrays used in this study use the same principle of detection
as the gold standard TaqManr single assay. As expected, the Ct values obtained in
the microfluidic cards correlated very well to the Ct values obtained with single gene
expression assays, for the genes analysed (Figure 4.4).
In the study of Geier et al. (2013a) no reproducibility studies for validating the cDNA
synthesis or inter-array variability were performed. In contrast, the cDNA synthesis and
the TaqManr arrays used in this study proved to be very robust (Figure 4.3).
Inter-donor variability in transporter expression in HBMECs was observed in this study.
The correlation between the gene expression in donors 1 and 3 is 95%, whereas the
correlation between donors 1 and 2 and 2 and 3 were 52% and 57%, respectively (Figure
4.12). Regarding the expression of organic cation transporters, strong inter-individual
variability in the expression of OCT1 and OCT3 was observed (Figure 4.10). Strong
variations in OCT transporters in other organs are well known. More than 100-fold
variation has been observed in the expression of OCT1 in the liver (Nies et al. (2009)
and O’Brien et al. (2013)). One explanation of this may be differences in methylation
status (Schaeffeler et al. (2011)). Also the LAT-1 transporter (subunit SLC7A5), a well
defined hallmark transporter in HBMECs showed, showed much higher expression in
donor number 2 as in donors number 1 and 3. The same donor number 2, showed very
low expression of MDR1 and ABCG2 (Figure 4.11). Differences in the expression of
MDR1 have been attributed to genetic polymorphisms (Johne et al. (2002)), however,
the three donors of the mRNA analysed in this work, were not genotyped.
5.9 Interaction between psychotropic drugs with high mem-
brane permeability and OCT1
Neither citalopram, clozapine, amantadine nor lamotrigine benefited from the over ex-
pression of OCT1 to cross the cell membrane. All these drugs showed the same uptake
in cells over-expressing OCT1 compared to control cells (Figure 4.32).
Citalopram and clozapine can inhibit OCT1 (Table 4.6). However they have high mem-
brane permeability (Figure 4.1) and may simply diffuse through the cell membrane,
making its interaction with OCT irrelevant for their in vitro uptake.
Although amantadine is a substrate of the rat Oct1(Goralski et al. (2002)), this study
shows that it is not a substrate of the human OCT1, as it has been stated by (Lozano
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et al. (2013) and Becker et al. (2011)). These authors incorrectly cite a paper from
Jonker & Schinkel (2004), where it is stated that amantadine is a substrate for the rat
Oct1. Jonker & Schinkel (2004) correctly cite the paper of Goralski et al. (2002) were it
is shown that amantadine is transported by the rat Oct1. It is known for other substrates
that the mouse, rat and human OCT1 differ in their substrate specificity (Dresser et al.
(2000)).
This study suggests also that lamotrigine does not depend on OCT1 to penetrate cell
membranes. Lamotrigine (Dickens et al. (2012)) has been proposed to be a substrate for
OCT1 in KCL22 cells. Measurements of OCT1-mediated drug uptake in this cells has
been heavily criticised. KCL22 cells have been used to show in vitro uptake of imatinib
by OCT1, which has been refuted by recent publications (Burger et al. (2013) and Nies
et al. (2014)).
In this work it is shown that there is no increase in the uptake of lamotrigine in OCT1
over expressing HEK293 cells in comparison to the control cells. The HEK293 cell lines
used in the present study have been established by targeted chromosomal gene integra-
tion and extensively validated (Saadatmand et al. (2012)), and present a much better
model to study the uptake of lamotrigine by OCT1. Further evidence which supports
the finding that lamotrigine is not a substrate for OCT1 is the fact that lamotrigine is
very lipophilic and not protonated at the physiological pH of 7.4 (pKa = 3.41, LogD7.4
= 1.99 and 0% protonated at pH 7.4, Table 4.1).
5.9.1 The interaction of amitriptyline with OCT1
Amitriptyline is an interesting drug to be analyzed from the point of view of personalized
medicine guided by pharmacogenenomics, as it is extensively metabolized in the liver.
The influence of polymorphisms on liver metabolising enzymes on amitriptyline phar-
macokinetics has already been studied in detail (Kirchheiner et al. (2004) and Steimer
et al. (2004)), however, nothing is known about drug influx transporters. OCT1 is
the major organic cation transporter in the liver, and amitriptyline has been already
shown to interact with OCT1 by inhibiting the uptake of the OCT1 model substrate
ASP+ (Ahlin et al. (2008)). This finding was confirmed in this study by showing that
amitriptyline inhibits the OCT1-mediated uptake of MPP+ and morphine (Figures 4.33
and 4.37).
The measurements of amitriptyline uptake in OCT1 over-expressing cells in comparison
to the control cells showed a big variation, as seen on figure 4.34 A. Despite the big
variation, the average uptake in OCT1 over-expressing cells was higher than in the
control cells. However, the standard error of the mean in the control cells was higher
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than the increase in the uptake observed in the OCT1 over-expressing cells. This may
be related to the fact that amitriptyline is a very lipophilic drug with high membrane
permeability (Figure 4.1 and Table 4.1). However, when analysing each independent
experiment, the uptake of amitriptyline was between 18% and 31% higher in the cells
over-expressing OCT1 in comparison the control cells (Figure (4.34 B).
The presence of serum did not affect the uptake of amitriptyline by OCT1. As expected,
the net cellular uptake in the presence of serum was lower, as serum reduces the amount
of drug which free to cross the cell membrane (Figure 4.35). In vivo, the fraction of
amitriptyline which is bound to serum is 92.7% (Brunton & Knollman (2011)). However,
as observed on figure 4.35, the reduction in the uptake of amitriptyline in the presence
of serum was only between 40%-74%. In the in vitro system used in this work, other
factors like drug binding to the plastic in the cell culture plates may contribute to the
final amitriptyline amounts determined after cell lysis and could explain why in the
presence of serum the reduction was not equal to the fraction bound to plasma proteins.
The inhibition of amitriptyline uptake in OCT1-overexpressing cells and control cells in
the presence of inhibitors could not shown that amitriptyline is a substrate for OCT1.
The typical OCT1 inhibitor MPP+ did not reduced the uptake of amitriptyline in cells
over-expressing OCT1 and in the control cell lines. Incubation with desipramine reduced
the uptake of amitriptyline in cells over-expressing OCT1, but also in the control cells
(Figure 4.36), showing that this reduction of the uptake does not depend on OCT1.
The inhibition of amitriptyline uptake by desipramine in the control cell lines, as well
as in the OCT1-overexpressing cells, can also be due a phenomena called ”lysossomal
trapping” (Ohkuma & Poole (1978),de Duve et al. (1974), Daniel et al. (2001) and
Kazmi et al. (2013)). Lysossomal trapping is typical for lipophilic drugs (LogP >1)
with a pKa above 6. This is the case for both amitriptyline and desipramine (Table 4.1).
Such drugs can easily diffuse through the cell membrane, and when they diffuses into the
lysossomes, they become protonated (lysossomes have a pH of 4-5) and do not diffuse
back into the cell, resulting in an accumulation of drug in the lysossome (Kazmi et al.
(2013)). The accumulation ratio in lysosomes for mono- and dibasic drugs are about 3
and 1000 times the total volume of the cell (Kazmi et al. (2013)). Lysosomal trapping
is a saturable process (Daniel et al. (2001)) and one hypothesis is that desipramine
may compete for the lysossomal trapping of amitriptyline and therefore, reduce the
drug uptake. The hypothesis of lysossomal trapping was confirmed, because NH4Cl also
inhibited the uptake of amitriptyline in both cell lines. NH4Cl is a competitor for the
lysossomal trapping of drugs (Kazmi et al. (2013)). Lysosommal trapping does not
depend on the expression of membrane transporters and therefore, it is observed in both
the OCT1 over-expressing cells and in the control cells.
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Although OCT1 mediated amitriptyline uptake could not be shown in the in vivo model
used in this study, it cannot be ruled out that OCT1 has a role in amitryiptyline phar-
macokinetics as amitriptyline has a big affinity for OCT1 (Ahlin et al. (2008) and
Figures 4.37 and 4.33). OCT1 polymorphisms have been shown in humans to be impor-
tant in the pharamacokinetics (ondansetron) and pharmacodynamics (ondansetron and
imatinib) of drugs, which could not be shown in vitro to be OCT1 substrates (Tzvetkov
et al. (2012), White et al. (2007), White et al. (2010) and Burger et al. (2013) and
Nies et al. (2014)). Studies in patients and healthy volunteers may be required in order
to fully understand whether OCT1 has a role on the pharmacokinetics of amitriptyline.
5.9.2 Inhibition of OCT1-mediated morphine uptake by antidepres-
sants and other drugs
Although the antidepressants analysed in this study did not benefit from OCT1 to pen-
etrate cell membranes, they can still interact with OCT1. Here it was shown that an-
tidepressants (amitriptyline, clomipramine, fluoxetine and imipramine), and other drugs
can inhibit the OCT1-mediated uptake of morphine (Figures 4.37 and 4.38). Morphine
is eliminated through gluconoridation in the liver, and has been identified as a substrate
for OCT1. Furthermore, the pharmacokinetics of morphine have been shown to depend
on OCT1-mediated liver uptake Tzvetkov et al. (2013).
Co-medication with irinotecan, a cancer drug which may be administrated together with
morphine, may result in higher morphine plasma concentrations. At clinically relevant
concentrations, irinotecan inhibited 76% of the OCT1-mediated morphine uptake (Table
4.7).
The concentration of drugs on the portal vein is transiently higher than on the periph-
eral circulation because drugs have not yet been subjected to first pass metabolism in
the liver. When considering the maximal unbound concentration in the portal vein,
irinotecan, ondansetron and verapamil are able to inhibit more than 50% of the OCT1-
mediated morphine uptake (Table 4.7).
New molecular entities may be tested for OCT1 inhibition during drug development
if they are expected to be given together with morphine. In addition, other opioids
should also be tested for these interactions. The International transporter consortium
recommends that a clinical drug-drug interaction study is performed in case a relevant
drug-drug interaction is identified. When the ratio CMax,Unb/IC50 is equal or greater
than 0.1 a relevant drug-drug interaction may occur (Giacomini et al. (2010)). This was
the case for irinotecan (i.v) and ondansetron (oral) (Table 4.7). The pharmacokinetics
of ondansetron, may depend on the CYP2D6 genotype (Kaiser et al. (2002)), making
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its plasma concentrations, and OCT1 inhibition potential, genotype-dependent. This is
an example of a possibly complex drug-gene-drug interaction.
The OCT1 variants *2 and *3 have a residual morphine transport activity, meaning that
they are still able to transport small amounts of morphine.(Tzvetkov et al. (2013)). It
is known that different OCT1 variants react differently to OCT1 inhibitors (Ahlin et al.
(2011)). The study of the inhibition of morphine-mediated OCT1 uptake in OCT1
variants *2 and *3 also needs to be considered.
5.10 Genetic variants in OCT1 affect the uptake of the
biogenic amine tyramine
Polymorphisms in the OCT1 gene reduced tyramine uptake (Figure 4.41). Tyramine is
a biogenic amine that is produced as a by-product of bacterial fermentation. It is pro-
duced by bacteria like Carnobacterium sp. and Lactobacillus sp. (Masson et al. (1996)).
As a product of bacterial fermentation, tyramine is present in food products like smoked
meat, cheese and wine (Pechanek et al. (1983)). High amounts of tyramine in the blood
may lead to high blood pressure, migraine and nausea. Tyramine is metabolised by
mono-amine oxidases (MAO), which are present in the liver (Grimsby et al. (1990)).
The ability of tyramine to interact with OCT1, and the kinetic parameters of tyramine
uptake by OCT1 were analysed in this study (Section 4.8). The intrinsic clearance of
tyramine by OCT1 was in the same order of magnitude as previously reported (Schömig
et al. (2006)). Tyramine represents therefore a good example of how genetics may be
related to food and natural compounds. It is ,however, unlikely that tyramine repre-
sented a selection process for the loss of OCT1 activity, as nausea, migraine and high
blood pressure are not directly life-threatening conditions. Still, according to the in
vitro evidence presented in this study, carriers of decreased function OCT1 alleles may
experience increases blood pressure and unpleasant feelings when eating food containing
tyramine. This hypothesis needs confirmation in vivo.
5.11 Establishment of a MDCK II cell line for targeted
chromosomal integration
One of the aims of this work was to develop models to study drug transport at the
blood-brain barrier. One approach was to use the hCMEC/D3 cell line to study influx
transport of psychotropic drugs. The other approach was to develop a cell line which
may be used in the future to study the transport of drugs by efflux transporters .
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In this work, a MDCK II cell line, including a site for target chromosomal integration
in its genome, was established. To achieve this goal, the pFRT/LacZeo plasmid was
transfected into the cell line, and after successfully picking of the clones, the cell line
demonstrated TEER measurements between 150-200 Ohm ∗ cm2 (Figure 4.42), which
were similar to the untransfected control cell line, and in accordance with values re-
ported in the literature for the MDCK II cell line (Soldner et al. (2000)). The suc-
cessful integration of the plasmid was confirmed by measuring the functionally of the
β-Galactosidase marker gene by means of an ONPG hydrolysis assay (Figure 4.43). This
does not, however, show how many copies of the plasmid are integrated in the genome
of the MDCKII-pFRT/LacZeo cell lines. Quantitative real-time PCR may be used to
quantify the number of copies of the plasmid which were integrated in the genome of
the parental MDCK II cell line (Abad et al. (2010) and Huang et al. (2013)).
The MDCK II cell line is a strain isolated from the parental MDCK cell line, and is the
most commonly used MDCK strain (Dukes et al. (2011)). The parental MDCK cell line
and the MDCK I strain, have unstable phenotypes (Dukes et al. (2011)), and therefore
may not be as suitable as the MDCK II cell line for the establishment of transporter
models. The MDCK II cell line has been widely used to study vectorial transport with
efflux transporters by research groups which are well established in the field (example:
Jonker et al. (2000) and Poller et al. (2011)).
This MDCK II cell line can in the future be used as a model to study efflux transport,
by allowing the stable expression of transporter genes. In particular, the targeted chro-
mosomal integration approach is interesting for studying transporter pharmacogenetics.
This approach guarantees that after stable integration of the genes, the membrane trans-
porters carrying different genetic variants, will be express at the same level, allowing the
comparison between different genetic variants.
6
Conclusion
This study has shown that most psychiatric drugs have high membrane permeability,
and may not required carrier-mediated efflux transport to enter cells. The potential of
the PAMPA assay (Paralell Aritifical Membrane Permeability Assay) to quickly screen
drugs with high and low membrane permeability was also shown. Using the PAMPA
assay, the psychotropic drugs amisulpride and sulpiride were identified as drugs with
limited membrane permeability which benefit from carrier-mediated transport to cross
cellular barriers.
Amisulpride is a substrate for all the organic cation transporters of the SLC22 family,
OCT1, OCT2, OCT3, OCTN1 and OCTN2. On the other hand, sulpiride is only a
substrate for OCT1 and OCT2. The OCTs of the SLC22 family may contribute to the
penetration of amisulpride and sulpiride through the blood-brain barrier, but further
work is required in order to clarify the clinical implications of these findings, with re-
spect to therapy efficacy, genetic variation in drug transporters and potential drug-drug
interactions. Although amisulpride and sulpiride are not metabolized in the liver, OCT1
may still be relevant for their billiary clearance, which accounts for ca. 20% of the total
clearance of amisulpride and sulpiride. Amisulpride and sulpiride are slowly absorbed,
and it remains unknown whether OCT1 plays a role on the enterohepatic circulation of
amisulpride and sulpiride, and whether it contributes to a longer permanence of these
drugs in the body. On the other hand, amisulpride and sulpiride are predominantly
eliminated in the kidney and have a high renal clearance, suggesting a secretion mech-
anism in the kidney proximal tubules. In this context, OCT2 was identified as the
transporter which is likely responsible for the removal of amisulpride and sulpiride from
the blood on the renal proximal tubule. Furthermore, amisulpride, the most important
psychotropic drug within the benzodiazepine class, was also identified as a substrate for
MATE1 and MATE2-K transporters, which may also contribute to its renal secretion
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and blood-brain barrier transport (in case of MATE1). However, OCT2, and not the
MATEs, is likely the limiting step in the secretion of amisulpride in the kidney.
Extensive gene expression analysis were carried out in primary cells from the brain and in
tissues relevant for drug distribution. It was shown that the expression of organic cation
transporter in brain tissues is much lower compared to the expression in, for example,
liver or kidney. According to this study, the organic cation transporters OCT1, OCT3,
OCTN1, OCTN2 and MATE1 are expressed at the blood-brain barrier. However, OCT1,
OCT3, OCTN1 and MATE1 are expressed at low levels. In contrast, the expression of
efflux transporters like MDR1 and BCRP was, as expected, very high at the blood-brain
barrier. Considering the evidence presented in this study, and available the literature,
leads to the conclusion that the study of the expression of membrane transporters at the
blood-brain barrier is not a simple question. The presence of organic cation transporters
in brain microvascular endothelial cells is still in debate, with different authors, reporting
contradictory results. This also reflects the difficulties in studying the brain, and in
obtaining brain material from humans. Still, it becomes clear that even if organic cation
transporters are expressed in the blood-brain barrier, they are not expressed at high
levels. Likely, there is a not yet identified transporter which can transport organic
cations through the blood-brain barrier. On the other hand, some drugs may also take
advantage of nutrient transporters which are highly expressed at the blood-brain barrier,
like LAT-1 (amino-acid transporter) in order to penetrate the brain.
It was shown that some psychotropic drugs with high membrane permeability interact
strongly with OCT1, and are capable of inhibiting the OCT1 mediated uptake of drugs
which depend on OCT1 to be metabolized in the liver, as morphine. Potentially rele-
vant drug-drug interactions involving morphine and OCT1 were identified. Irinotecan,
ondansetron and verapamil are able to inhibit the OCT1 mediated uptake of morphine
by more than 50% at concentrations which are clinically relevant.
Several drugs which are known to interact with OCT1, such as amitriptyline, citalo-
pramin, clozapine, lamotrigine and amantadine were tested as OCT1 substrates. It is
concluded that OCT1 does not mediate the in vitro uptake of any of these drugs in
the models used. However, other examples, like imatinib and ondansetron, exist, where
OCT1 polymorphisms were suggested to affect the pharmacokinetics and efficacy in hu-
mans, although the affected drugs were not shown to be OCT1 substrates in the in vitro
models used. Therefore, studies in patient cohorts or healthy volunteers are required in
order to conclude on the influence of OCT1 polymorphisms on the pharmacokinetics of
psychotropic drugs with high membrane permeability, like amitriptyline.
Tyramine, previously suggested as a substrate of OCT1, was identified in this work in
relation to polymorphisms in the OCT1 gene. It was shown that tyramine uptake is lower
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in cells over-expressing OCT1 genetic variants in comparison to cells over-expressing the
wild type OCT1. Tyramine was studied in the context of finding naturally occurring
substances (not synthetic drugs) which may depend on OCT1 to be eliminated in the
liver, in order to find substances that may have been responsible during evolution for
the appearance of very common genetic mutations in OCT1. Although it is likely that
tyramine is not the substance responsible for establishing the selection pressure leading
to OCT1 deficiency, it is a good example of how genetic variation may interact with
food and nutrition.
In the context of establishing a model of the blood-brain barrier, the hCMEC/D3 cell line
was used at the Institute of Clinical Pharmacology to show carrier-mediated transport of
amisulpride and sulpiride in a relevant blood-brain barrier model. This work also showed
that the hCMEC/D3 cell line does not express either OCT1 or OCT2. Comparing
this work, and work from other authors, it can be concluded that there is a not yet
identified carrier-mediated transport mechanism in the hCMEC/D3 cell line which has
some substrate overlap with OCT1 (amisulpride, sulpiride, tramadol). The identification
of this transporter could in the future be achieved through methods like high-throughput
RNA-sequencing and searching for gene homology, as well as by studying the uptake of
these drugs in the presence of different inhibitors. Identifying this influx transport
mechanism would bring the field of membrane transport at the blood-brain barrier a
step further. As efflux transport may play a bigger role than influx transport at the
blood-brain barrier, an MDCK II cell line ready for targeted chromosomal integration
of transporter genes was successfully established and may be used in further studies
analysing membrane drug permeability in cellular monolayers expressing several different
efflux transporters and their genetic variants.
Ultimately, the identification of drugs which require membrane transport to cross cel-
lular barriers, and the corresponding membrane transporters, is an important step in
understanding the complexity of drug pharmacokinetics and variability in drug response.
This may be especially true for psychotropic drugs acting in the central nervous system,
which need to penetrate the blood-brain barrier to reach their site of action. This work
can serve as basis for further, more complex and detailed studies analysing not only drug
transport at the blood-brain barrier using the established models, but also to dissect the
factors which may affect the pharmacokinetics of drugs like amisulpride and sulpiride,
for which the relevant cation transporters are now known.
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Table A.1: Reference numbers of the assays used on the custom made TaqManr low
density arrays. The assays signed with a * were also used as TaqManr single assays
for validating the low density arrays.
Gene Assay Number Gene Assay number
ABCA1 Hs01059118 m1 SLC22A4 Hs00268200 m1
ABCA2 Hs00242232 m1 SLC22A5* Hs00929869 m1
ABCA3 Hs00975530 m1 SLC22A6 Hs00537914 m1
ABCB1 Hs00184500 m1 SLC22A7 Hs00198527 m1
ABCB11 Hs00184824 m1 SLC22A8 Hs01056647 m1
ABCB4 Hs00240956 m1 SLC22A9 Hs00971064 m1
ABCB5 Hs00698751 m1 SLC25A13 Hs00185185 m1
ABCB6 Hs01039213 m1 SLC25A27 Hs00188687 m1
ABCB7 Hs00188776 m1 SLC28A1 Hs00984403 m1
ABCC1 Hs00219905 m1 SLC28A2 Hs00188407 m1
ABCC10 Hs00375701 m1 SLC28A3 Hs00910439 m1
ABCC11 Hs01090768 m1 SLC29A1 Hs01085706 m1
ABCC12 Hs00264354 m1 SLC29A2 Hs00155426 m1
ABCC2 Hs00166123 m1 SLC29A3 Hs00983219 m1
ABCC3 Hs00358656 m1 SLC2A1 Hs00892681 m1
ABCC4 Hs00988734 m1 SLC2A2 Hs01096904 m1
ABCC5 Hs00981087 m1 SLC2A3 Hs00359840 m1
ABCC6 Hs01081201 m1 SLC31A1 Hs00977268 g1
ABCC8 Hs01093761 m1 SLC38A2 Hs01089954 m1
ABCC9 Hs00245832 m1 SLC38A5 Hs01012028 m1
ABCD1 Hs00163610 m1 SLC3A1 Hs00165789 m1
ABCD3 Hs00161065 m1 SLC3A2 Hs00374243 m1
ABCG2 Hs01053790 m1 SLC47A1 Hs00217320 m1
ABCG8 Hs00223690 m1 SLC47A2 Hs00398719 m1
ACTB Hs99999903 m1 SLC5A1 Hs01573790 m1
ATP7A Hs00163707 m1 SLC5A4 Hs00429526 m1
ATP7B Hs00163739 m1 SLC6A2 Hs01567442 m1
GAPDH Hs99999905 m1 SLC6A3 Hs00997364 m1
HPRT1 Hs99999909 m1 SLC6A4 Hs00984355 g1
MVP Hs00245438 m1 SLC6A6 Hs00161778 m1
SLC10A1 Hs00161820 m1 SLC7A11 Hs00204928 m1
SLC10A2 Hs01001557 m1 SLC7A5 Hs00185826 m1
SLC13A1 Hs00223704 m1 SLC7A6 Hs00938056 m1
SLC15A1 Hs00953898 m1 SLC7A7 Hs00909952 m1
SLC15A2 Hs00221539 m1 SLC7A8 Hs00794796 m1
SLC16A1 Hs00161826 m1 SLC7A9 Hs00943195 m1
SLC16A10 Hs01039921 m1 SLCO1A2 Hs00366488 m1
SLC16A2 Hs00185140 m1 SLCO1B1 Hs00272374 m1
SLC16A3 Hs00358829 m1 SLCO1B3 Hs00251986 m1
SLC19A1 Hs00953342 m1 SLCO2A1 Hs00194554 m1
SLC19A2 Hs00949693 m1 SLCO2B1 Hs00200670 m1
SLC19A3 Hs00228858 m1 SLCO3A1 Hs00203184 m1
SLC22A1* Hs00427552 m1 SLCO4A1 Hs00249583 m1
SLC22A11 Hs00218486 m1 SLCO4C1 Hs00698884 m1
SLC22A12 Hs00375985 m1 SLCO5A1 Hs00229597 m1
SLC22A14 Hs00899722 m1 SLCO6A1 Hs00542846 m1
SLC22A2* Hs01010723 m1 TBP* Hs99999910 m1
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Protocol for the DAB-Immunostaining of paraffin-embedded sections on glass:
• Deparaffinization
– 2 ×5 min Xylene
• Hydration
– 10 min 100% Ethanol
– 5 min 95% Ethanol
– 5 min 70% Ethanol
– 1 min ddH2O
• Peroxidase block
– 30 min 0,01 M PBS + 2 mL 30% H2O2
– 1 min ddH2O
• Antigen retrieval
– 10 mM citrate buffer
– 10 min microwave: 800 W until boiling, then 80 W
– 15 min cool down
• Washing
– 1 min ddH2O
– 15 min 0,01 M PBS + 0,1% Triton (permeabilisation of membranes)
– 5 min 0,01 M PBS
• Unspecific block
– 1h: 0,01 M PBS + 10% FCS + 4% milk powder
– incubate by circle sections with a lipid pen
• Incubation with the primary antibody
– Dilute primary antibody at specific concentration in 0,01 M PBS + 10% FCS
– Overnight incubation
• Washing
– 3x5 min 0,01 M PBS + 0,1% Triton
– 1 min 0,01 M PBS
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• Incubation with the secondary antibody
– Dilute antibody (1:200) in 0,01 M PBS + 10% FCS
– Incubate 1h at 37°C and during the waiting time prepare the ABC solution
• Washing
– 3x5 min 0,01 M PBS
• ABC incubation (VECTASTAINr Elite ABC system - Avidin/Biotin Complex)
– 0,01 M PBS + 10% FCS + solution A 1:100 + solution B:100 (prepared at
least 30 min before use and stored at 4°C)
– Incubate 1,5h at 37°C
• Washing
– 3x5 min 0,01 M PBS
• DAB staining
– 5 mL 50mM Tris/HCl pH 7,5 + 100 µL DAB stock solution (Toxic) + 2,5
µL 30% H2O2 (added just before use)
– DAB stock solution: 25 mg/mL in 50 mM Tris/HCl pH 7,5
• Washing
– 3x5 min 0,01 M PBS
• Counterstaining
– 40 s filtered hematoxylin
– dip in ddH2O
– 5 min under running tap water
• Dehydration
– 1 min 70% Ethanol
– 5 min 95% Ethanol
– 10 min 100% Ethanol
– 2x5 min Xylene
• Embedding
– Eukitt Quick hardening mounting medium
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Table C.1: Gene expression analysis in tissues and primary cells - Part 1. Liver and
kidney show the average of one sample measured two independent times. Intestine,
Brain, Astrocytes and CP. Epi. Cells ( choroid plexus epithelial cells ) were determined
one time. HBMECs (human brain microvascular endothelial cells) represent the average
of three samples obtained from three different donors, measured more than 2 times each
(the results for each donor are shown on tables C.3, C.4 and C.5).
Gene Liver Kidney Intestine Brain Astrocytes CP. Epi. Cells HBMECs
ABCA1 1.080 0.071 0.195 0.058 0.039 0.063 0.171
ABCA2 0.022 0.073 0.065 1.175 0.062 0.031 0.019
ABCA3 0.016 0.079 0.021 0.445 0.003 0.027 0.165
ABCB1 0.336 0.474 1.050 0.085 0.008 0.012 0.092
ABCB11 0.026 0.000 0.000 0.000 0.001 0.000 0.000
ABCB4 0.998 0.011 0.004 0.003 0.007 0.005 0.015
ABCB5 0.000 0.000 0.000 0.000 0.000 0.000 0.000
ABCB6 0.034 0.050 0.031 0.045 0.023 0.026 0.030
ABCB7 0.188 0.308 0.307 0.179 0.142 0.126 0.106
ABCC1 0.012 0.021 0.028 0.011 0.043 0.055 0.088
ABCC10 0.045 0.042 0.094 0.079 0.064 0.047 0.076
ABCC11 0.013 0.001 0.000 0.002 0.000 0.000 0.000
ABCC12 0.000 0.000 0.000 0.000 0.000 0.000 0.000
ABCC2 0.047 0.158 0.167 0.001 0.001 0.000 0.001
ABCC3 0.200 0.087 0.128 0.001 0.051 0.013 0.000
ABCC4 0.019 0.240 0.050 0.023 0.024 0.096 0.034
ABCC5 0.035 0.148 0.100 0.393 0.066 0.054 0.049
ABCC6 0.031 0.023 0.021 0.000 0.000 0.000 0.000
ABCC8 0.000 0.001 0.002 0.126 0.000 0.000 0.000
ABCC9 0.016 0.014 0.020 0.010 0.000 0.001 0.000
ABCD1 0.003 0.002 0.014 0.000 0.004 0.002 0.002
ABCD3 0.108 0.178 0.103 0.059 0.036 0.044 0.027
ABCG2 0.063 0.020 0.604 0.094 0.000 0.001 0.341
ABCG8 0.152 0.000 0.409 0.003 0.000 0.000 0.000
ATP7A 0.000 0.000 0.000 0.000 0.000 0.000 0.000
ATP7B 0.067 0.044 0.117 0.042 0.019 0.025 0.033
SLC10A1 0.048 0.000 0.000 0.000 0.000 0.000 0.000
SLC10A2 0.000 0.082 0.314 0.000 0.000 0.000 0.000
SLC13A1 0.000 1.382 0.067 0.000 0.000 0.000 0.000
SLC15A1 0.016 0.281 2.046 0.000 0.001 0.002 0.000
SLC15A2 0.002 0.078 0.007 0.079 0.001 0.001 0.000
SLC16A1 0.227 0.188 0.131 0.111 0.164 0.275 0.205
SLC16A10 0.169 0.067 0.074 0.042 0.000 0.011 0.000
SLC16A2 0.022 0.022 0.002 0.022 0.010 0.032 0.005
SLC16A3 0.021 0.054 0.035 0.015 0.084 0.144 0.377
SLC19A1 0.025 0.012 0.081 0.023 0.025 0.049 0.039
SLC19A2 0.064 0.132 0.081 0.101 0.037 0.139 0.031
SLC19A3 0.432 0.032 0.090 0.015 0.001 0.001 0.001
SLC22A1 1.697 0.003 0.001 0.001 0.001 0.001 0.001
SLC22A11 0.002 0.399 0.000 0.000 0.000 0.000 0.000
SLC22A12 0.000 0.534 0.000 0.000 0.000 0.000 0.000
SLC22A14 0.000 0.002 0.001 0.003 0.001 0.001 0.000
SLC22A2 0.000 0.870 0.001 0.002 0.000 0.000 0.000
SLC22A3 0.144 0.061 0.054 0.013 0.001 0.000 0.002
SLC22A4 0.001 0.007 0.006 0.001 0.000 0.001 0.001
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Table C.2: Gene expression analysis in tissues and primary cells - Part 1. Liver and
kidney show the average of one sample measured two independent times. Intestine,
Brain, Astrocytes and CP. Epi. Cells ( choroid plexus epithelial cells ) were determined
one time. HBMECs (human brain microvascular endothelial cells) represent the average
of three samples obtained from three different donors, measured more than 2 times each
(the results for each donor are shown on tables C.3, C.4 and C.5).
Gene Liver Kidney Intestine Brain Astrocytes CP. Epi. Cells HBMECs
SLC22A5 0.064 1.092 0.247 0.098 0.031 0.036 0.017
SLC22A6 0.000 1.299 0.000 0.006 0.000 0.000 0.000
SLC22A7 0.068 0.049 0.000 0.000 0.000 0.000 0.000
SLC22A8 0.000 0.879 0.000 0.003 0.000 0.000 0.000
SLC22A9 0.022 0.000 0.000 0.001 0.000 0.000 0.000
SLC25A13 0.242 0.137 0.083 0.028 0.044 0.094 0.084
SLC25A27 0.009 0.070 0.045 0.570 0.006 0.010 0.003
SLC28A1 0.093 0.084 0.114 0.000 0.000 0.000 0.000
SLC28A2 0.000 0.000 0.086 0.000 0.000 0.000 0.000
SLC28A3 0.002 0.000 0.017 0.001 0.000 0.002 0.001
SLC29A1 0.402 0.268 0.224 0.228 0.057 0.233 0.753
SLC29A2 0.002 0.015 0.010 0.024 0.004 0.009 0.003
SLC29A3 0.098 0.058 0.015 0.040 0.009 0.033 0.034
SLC2A1 0.009 0.116 0.075 0.432 0.790 0.325 0.340
SLC2A2 0.587 0.488 0.471 0.000 0.000 0.000 0.000
SLC2A3 0.063 0.043 0.130 0.403 0.065 0.062 0.138
SLC31A1 1.071 0.634 0.625 0.152 0.164 0.235 0.200
SLC38A2 0.484 0.145 0.119 0.178 0.222 0.142 0.247
SLC38A5 0.001 0.002 0.011 0.009 0.026 0.007 0.013
SLC3A1 0.001 2.274 0.342 0.007 0.000 0.000 0.000
SLC3A2 0.426 0.700 0.263 0.310 0.257 0.511 0.643
SLC47A1 0.090 0.398 0.013 0.016 0.015 0.000 0.000
SLC47A2 0.000 0.206 0.001 0.000 0.001 0.000 0.000
SLC5A1 0.003 0.011 3.739 0.000 0.000 0.000 0.000
SLC5A4 0.002 0.003 0.377 0.007 0.000 0.000 0.004
SLC6A2 0.001 0.002 0.001 0.000 0.000 0.000 0.000
SLC6A3 0.000 0.000 0.000 0.001 0.000 0.000 0.000
SLC6A4 0.000 0.001 0.192 0.000 0.000 0.000 0.000
SLC6A6 0.030 0.214 0.299 0.072 0.021 0.073 0.041
SLC7A11 0.003 0.002 0.009 0.130 0.024 0.054 0.242
SLC7A5 0.013 0.027 0.017 0.087 0.028 0.215 0.186
SLC7A6 0.065 0.051 0.057 0.087 0.046 0.159 0.115
SLC7A7 0.008 0.111 0.119 0.001 0.001 0.001 0.006
SLC7A8 0.044 0.897 0.238 0.142 0.005 0.090 0.002
SLC7A9 0.029 0.255 0.655 0.003 0.001 0.000 0.000
SLCO1A2 0.001 0.001 0.000 0.266 0.000 0.000 0.000
SLCO1B1 0.972 0.000 0.000 0.000 0.000 0.000 0.000
SLCO1B3 0.034 0.005 0.000 0.000 0.000 0.000 0.000
SLCO2A1 0.009 0.174 0.067 0.007 0.002 0.013 0.081
SLCO2B1 0.004 0.001 0.002 0.000 0.000 0.000 0.002
SLCO3A1 0.014 0.028 0.011 0.070 0.008 0.018 0.002
SLCO4A1 0.027 0.081 0.019 0.055 0.000 0.005 0.005
SLCO4C1 0.015 0.530 0.021 0.011 0.002 0.008 0.001
SLCO5A1 0.001 0.009 0.025 0.014 0.056 0.006 0.000
SLCO6A1 0.000 0.000 0.000 0.000 0.000 0.000 0.000
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Table C.3: Gene expression analysis in human brain microvascular endothelial cells -
Donor 1. Samples 1 and 2 represent the same cDNA run on two different microfluidic
cards. Samples 3 and 4 represent independent measurements (RNA synthesis and real-
time qPCR) of this sample. Figure 4.3 A shows the graphical representation of the
correlation between samples 2 and 3 (independent cDNA synthesis) and Figure 4.3 B
shows the graphical representation of the correlation between samples 1 and 2 (same
cDNA synthesis, independent microfluidic cards.
Drug membrane transporter expression in HBMECs - Donor 1
Detector Measurement Detector Measurement
1 2 3 4 Average 1 2 3 4 Average
ABCA1 0.206 0.237 0.228 0.338 0.252 SLC22A5 0.020 0.023 0.017 0.044 0.026
ABCA2 0.017 0.022 0.012 0.039 0.022 SLC22A6 0.000 0.000 0.000 0.000 0.000
ABCA3 0.299 0.308 0.275 0.424 0.327 SLC22A7 0.000 0.000 0.000 0.000 0.000
ABCB1 0.169 0.223 0.156 0.278 0.207 SLC22A8 0.000 0.000 0.000 0.000 0.000
ABCB11 0.000 0.000 0.000 0.000 0.000 SLC22A9 0.000 0.000 0.000 0.000 0.000
ABCB4 0.021 0.029 0.029 0.044 0.031 SLC25A13 0.104 0.125 0.090 0.195 0.128
ABCB5 0.000 0.000 0.000 0.000 0.000 SLC25A27 0.004 0.006 0.004 0.011 0.007
ABCB6 0.032 0.024 0.024 0.071 0.038 SLC28A1 0.000 0.000 0.000 0.000 0.000
ABCB7 0.089 0.100 0.095 0.247 0.133 SLC28A2 0.000 0.000 0.000 0.000 0.000
ABCC1 0.098 0.100 0.096 0.296 0.147 SLC28A3 0.001 0.000 0.000 0.000 0.000
ABCC10 0.090 0.079 0.096 0.154 0.105 SLC29A1 0.765 0.939 0.792 2.599 1.274
ABCC11 0.000 0.000 0.000 0.000 0.000 SLC29A2 0.004 0.002 0.003 0.008 0.004
ABCC12 0.000 0.000 0.000 0.000 0.000 SLC29A3 0.027 0.049 0.025 0.099 0.050
ABCC2 0.001 0.003 0.001 0.002 0.002 SLC2A1 0.406 0.339 0.450 0.680 0.468
ABCC3 0.000 0.000 0.000 0.000 0.000 SLC2A2 0.000 0.000 0.000 0.000 0.000
ABCC4 0.025 0.018 0.018 0.046 0.027 SLC2A3 0.068 0.052 0.061 0.096 0.069
ABCC5 0.052 0.034 0.041 0.096 0.056 SLC31A1 0.152 0.221 0.130 0.437 0.235
ABCC6 0.000 0.000 0.000 0.000 0.000 SLC38A2 0.197 0.258 0.169 0.306 0.233
ABCC8 0.000 0.000 0.000 0.000 0.000 SLC38A5 0.015 0.013 0.010 0.049 0.022
ABCC9 0.000 0.000 0.000 0.000 0.000 SLC3A1 0.000 0.000 0.000 0.000 0.000
ABCD1 0.003 0.002 0.003 0.002 0.003 SLC3A2 0.675 0.429 0.699 0.930 0.683
ABCD3 0.036 0.031 0.027 0.042 0.034 SLC47A1 0.000 0.000 0.000 0.000 0.000
ABCG2 0.520 0.539 0.538 1.136 0.683 SLC47A2 0.000 0.000 0.000 0.000 0.000
ABCG8 0.000 0.000 0.000 0.000 0.000 SLC5A1 0.000 0.000 0.001 0.000 0.000
ATP7A 0.000 0.000 0.000 0.000 0.000 SLC5A4 0.009 0.011 0.008 0.013 0.010
ATP7B 0.043 0.056 0.047 0.070 0.054 SLC6A2 0.000 0.000 0.000 0.000 0.000
SLC10A1 0.000 0.000 0.000 0.000 0.000 SLC6A3 0.000 0.000 0.000 0.000 0.000
SLC10A2 0.000 0.000 0.000 0.000 0.000 SLC6A4 0.000 0.000 0.000 0.000 0.000
SLC13A1 0.000 0.000 0.000 0.000 0.000 SLC6A6 0.052 0.061 0.065 0.109 0.072
SLC15A1 0.000 0.000 0.000 0.000 0.000 SLC7A11 0.374 0.427 0.375 0.555 0.433
SLC15A2 0.000 0.000 0.000 0.000 0.000 SLC7A5 0.077 0.079 0.064 0.074 0.073
SLC16A1 0.147 0.200 0.150 0.435 0.233 SLC7A6 0.161 0.149 0.142 0.270 0.180
SLC16A10 0.000 0.000 0.002 0.001 0.001 SLC7A7 0.010 0.010 0.008 0.011 0.010
SLC16A2 0.004 0.006 0.005 0.010 0.006 SLC7A8 0.001 0.002 0.003 0.006 0.003
SLC16A3 0.369 0.238 0.403 0.474 0.371 SLC7A9 0.000 0.000 0.001 0.000 0.000
SLC19A1 0.034 0.038 0.043 0.056 0.043 SLCO1A2 0.000 0.000 0.000 0.000 0.000
SLC19A2 0.022 0.032 0.028 0.034 0.029 SLCO1B1 0.000 0.000 0.000 0.000 0.000
SLC19A3 0.001 0.002 0.000 0.001 0.001 SLCO1B3 0.000 0.000 0.000 0.000 0.000
SLC22A1 0.000 0.005 0.001 0.001 0.002 SLCO2A1 0.053 0.040 0.044 0.148 0.071
SLC22A11 0.000 0.000 0.000 0.000 0.000 SLCO2B1 0.010 0.002 0.001 0.011 0.006
SLC22A12 0.000 0.000 0.000 0.000 0.000 SLCO3A1 0.002 0.002 0.002 0.003 0.002
SLC22A14 0.000 0.000 0.000 0.000 0.000 SLCO4A1 0.010 0.008 0.007 0.022 0.012
SLC22A2 0.000 0.000 0.000 0.000 0.000 SLCO4C1 0.003 0.005 0.002 0.004 0.003
SLC22A3 0.000 0.000 0.000 0.001 0.000 SLCO5A1 0.000 0.000 0.000 0.001 0.000
SLC22A4 0.003 0.002 0.001 0.001 0.002 SLCO6A1 0.000 0.000 0.000 0.000 0.000
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Table C.4: Gene expression analysis in human brain microvascular endothelial cells -
Donor 2. Samples 1 and 2 represent independent measurements (RNA synthesis and
real-time qPCR) of this sample. Figure 4.3 A shows the graphical representation of the
correlation between samples 1 and 2.
Drug membrane transporter expression in HBMECs - Donor 2
Gene Measurement Gene Measurement
1 2 Average 1 1 Average
ABCA1 0.192 0.149 0.170 SLC22A5 0.011 0.014 0.013
ABCA2 0.030 0.022 0.026 SLC22A6 0.000 0.000 0.000
ABCA3 0.009 0.010 0.009 SLC22A7 0.000 0.000 0.000
ABCB1 0.005 0.004 0.004 SLC22A8 0.000 0.000 0.000
ABCB11 0.000 0.000 0.000 SLC22A9 0.000 0.000 0.000
ABCB4 0.007 0.004 0.005 SLC25A13 0.035 0.033 0.034
ABCB5 0.000 0.000 0.000 SLC25A27 0.002 0.002 0.002
ABCB6 0.016 0.016 0.016 SLC28A1 0.000 0.000 0.000
ABCB7 0.055 0.076 0.066 SLC28A2 0.000 0.000 0.000
ABCC1 0.046 0.068 0.057 SLC28A3 0.001 0.002 0.001
ABCC10 0.054 0.066 0.060 SLC29A1 0.057 0.110 0.083
ABCC11 0.000 0.000 0.000 SLC29A2 0.004 0.002 0.003
ABCC12 0.000 0.000 0.000 SLC29A3 0.015 0.031 0.023
ABCC2 0.001 0.001 0.001 SLC2A1 0.192 0.205 0.199
ABCC3 0.000 0.000 0.000 SLC2A2 0.000 0.000 0.000
ABCC4 0.026 0.034 0.030 SLC2A3 0.236 0.239 0.237
ABCC5 0.044 0.051 0.048 SLC31A1 0.168 0.290 0.229
ABCC6 0.000 0.000 0.000 SLC38A2 0.403 0.331 0.367
ABCC8 0.000 0.000 0.000 SLC38A5 0.006 0.006 0.006
ABCC9 0.001 0.001 0.001 SLC3A1 0.000 0.000 0.000
ABCD1 0.001 0.001 0.001 SLC3A2 0.946 0.590 0.768
ABCD3 0.024 0.019 0.022 SLC47A1 0.001 0.000 0.000
ABCG2 0.012 0.010 0.011 SLC47A2 0.000 0.000 0.000
ABCG8 0.000 0.000 0.000 SLC5A1 0.000 0.000 0.000
ATP7A 0.000 0.000 0.000 SLC5A4 0.000 0.001 0.001
ATP7B 0.017 0.028 0.022 SLC6A2 0.000 0.000 0.000
SLC10A1 0.000 0.000 0.000 SLC6A3 0.000 0.000 0.000
SLC10A2 0.000 0.000 0.000 SLC6A4 0.000 0.000 0.000
SLC13A1 0.000 0.000 0.000 SLC6A6 0.017 0.014 0.016
SLC15A1 0.000 0.000 0.000 SLC7A11 0.161 0.156 0.158
SLC15A2 0.000 0.000 0.000 SLC7A5 0.410 0.355 0.382
SLC16A1 0.115 0.202 0.158 SLC7A6 0.074 0.063 0.068
SLC16A10 0.000 0.000 0.000 SLC7A7 0.001 0.000 0.001
SLC16A2 0.005 0.007 0.006 SLC7A8 0.001 0.002 0.001
SLC16A3 0.368 0.357 0.362 SLC7A9 0.000 0.000 0.000
SLC19A1 0.020 0.017 0.019 SLCO1A2 0.000 0.000 0.000
SLC19A2 0.031 0.039 0.035 SLCO1B1 0.000 0.000 0.000
SLC19A3 0.001 0.002 0.001 SLCO1B3 0.000 0.000 0.000
SLC22A1 0.000 0.001 0.001 SLCO2A1 0.003 0.003 0.003
SLC22A11 0.000 0.000 0.000 SLCO2B1 0.000 0.000 0.000
SLC22A12 0.000 0.000 0.000 SLCO3A1 0.001 0.000 0.001
SLC22A14 0.000 0.000 0.000 SLCO4A1 0.000 0.000 0.000
SLC22A2 0.000 0.000 0.000 SLCO4C1 0.000 0.001 0.000
SLC22A3 0.003 0.004 0.003 SLCO5A1 0.000 0.001 0.000
SLC22A4 0.001 0.000 0.001 SLCO6A1 0.000 0.000 0.000
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Table C.5: Gene expression analysis in human brain microvascular endothelial cells
(HBMECs) - Donor 3. Samples 1 and 2 represent independent measurements (RNA
synthesis and real-time qPCR) of this sample. Figure 4.3 A shows the graphical repre-
sentation of the correlation between samples 1 and 2.
Drug membrane transporter expression in HBMECs - Donor 3
Gene Measurement Gene Measurement
1 2 Average 1 2 Average
ABCA1 0.090 0.092 0.091 SLC22A5 0.011 0.013 0.012
ABCA2 0.009 0.009 0.009 SLC22A6 0.000 0.000 0.000
ABCA3 0.162 0.156 0.159 SLC22A7 0.000 0.000 0.000
ABCB1 0.070 0.063 0.066 SLC22A8 0.000 0.000 0.000
ABCB11 0.000 0.000 0.000 SLC22A9 0.000 0.000 0.000
ABCB4 0.007 0.009 0.008 SLC25A13 0.098 0.083 0.090
ABCB5 0.000 0.000 0.000 SLC25A27 0.001 0.001 0.001
ABCB6 0.030 0.044 0.037 SLC28A1 0.000 0.000 0.000
ABCB7 0.128 0.113 0.121 SLC28A2 0.000 0.000 0.000
ABCC1 0.063 0.054 0.058 SLC28A3 0.001 0.001 0.001
ABCC10 0.056 0.068 0.062 SLC29A1 0.831 0.970 0.901
ABCC11 0.000 0.000 0.000 SLC29A2 0.002 0.001 0.002
ABCC12 0.000 0.000 0.000 SLC29A3 0.028 0.029 0.028
ABCC2 0.001 0.000 0.000 SLC2A1 0.360 0.345 0.353
ABCC3 0.000 0.000 0.000 SLC2A2 0.000 0.000 0.000
ABCC4 0.037 0.051 0.044 SLC2A3 0.109 0.109 0.109
ABCC5 0.045 0.042 0.043 SLC31A1 0.147 0.128 0.137
ABCC6 0.000 0.000 0.000 SLC38A2 0.165 0.118 0.142
ABCC8 0.000 0.000 0.000 SLC38A5 0.014 0.007 0.010
ABCC9 0.000 0.000 0.000 SLC3A1 0.000 0.000 0.000
ABCD1 0.001 0.001 0.001 SLC3A2 0.478 0.481 0.479
ABCD3 0.028 0.021 0.025 SLC47A1 0.000 0.000 0.000
ABCG2 0.389 0.266 0.327 SLC47A2 0.000 0.000 0.000
ABCG8 0.000 0.000 0.000 SLC5A1 0.000 0.000 0.000
ATP7A 0.000 0.000 0.000 SLC5A4 0.002 0.003 0.003
ATP7B 0.024 0.024 0.024 SLC6A2 0.000 0.000 0.000
SLC10A1 0.000 0.000 0.000 SLC6A3 0.000 0.000 0.000
SLC10A2 0.000 0.000 0.000 SLC6A4 0.000 0.000 0.000
SLC13A1 0.000 0.000 0.000 SLC6A6 0.037 0.034 0.035
SLC15A1 0.000 0.000 0.000 SLC7A11 0.137 0.136 0.136
SLC15A2 0.001 0.000 0.000 SLC7A5 0.116 0.086 0.101
SLC16A1 0.227 0.222 0.225 SLC7A6 0.107 0.085 0.096
SLC16A10 0.000 0.000 0.000 SLC7A7 0.006 0.006 0.006
SLC16A2 0.002 0.002 0.002 SLC7A8 0.001 0.000 0.001
SLC16A3 0.379 0.419 0.399 SLC7A9 0.001 0.000 0.000
SLC19A1 0.064 0.050 0.057 SLCO1A2 0.000 0.000 0.000
SLC19A2 0.030 0.030 0.030 SLCO1B1 0.000 0.000 0.000
SLC19A3 0.001 0.001 0.001 SLCO1B3 0.000 0.000 0.000
SLC22A1 0.000 0.000 0.000 SLCO2A1 0.185 0.156 0.171
SLC22A11 0.000 0.000 0.000 SLCO2B1 0.002 0.000 0.001
SLC22A12 0.000 0.000 0.000 SLCO3A1 0.002 0.002 0.002
SLC22A14 0.000 0.000 0.000 SLCO4A1 0.003 0.006 0.004
SLC22A2 0.000 0.000 0.000 SLCO4C1 0.000 0.000 0.000
SLC22A3 0.002 0.001 0.002 SLCO5A1 0.000 0.002 0.001
SLC22A4 0.001 0.001 0.001 SLCO6A1 0.000 0.000 0.000
Appendix C. Gene expression of membrane transporters - Tables 126
Table C.6: Gene expression analysis in the hCMEC/D3 cell line. Figure 4.14 shows
the graphical representation of the data contained in this table.
Drug membrane transporter expression in the hCMEC/D3 cell line
Gene Gene
ABCA1 0.019 SLC22A5 0.014
ABCA2 0.009 SLC22A6 0.000
ABCA3 0.164 SLC22A7 0.000
ABCB1 0.185 SLC22A8 0.000
ABCB11 0.000 SLC22A9 0.000
ABCB4 0.000 SLC25A13 0.080
ABCB5 0.000 SLC25A27 0.000
ABCB6 0.018 SLC28A1 0.000
ABCB7 0.090 SLC28A2 0.000
ABCC1 0.029 SLC28A3 0.000
ABCC10 0.038 SLC29A1 0.870
ABCC11 0.000 SLC29A2 0.001
ABCC12 0.000 SLC29A3 0.011
ABCC2 0.001 SLC2A1 0.884
ABCC3 0.031 SLC2A2 0.000
ABCC4 0.050 SLC2A3 0.041
ABCC5 0.022 SLC31A1 0.147
ABCC6 0.000 SLC38A2 0.110
ABCC8 0.000 SLC38A5 0.016
ABCC9 0.000 SLC3A1 0.000
ABCD1 0.000 SLC3A2 0.487
ABCD3 0.029 SLC47A1 0.000
ABCG2 0.074 SLC47A2 0.000
ABCG8 0.000 SLC5A1 0.000
ATP7A 0.000 SLC5A4 0.002
ATP7B 0.004 SLC6A2 0.000
SLC10A1 0.000 SLC6A3 0.000
SLC10A2 0.000 SLC6A4 0.000
SLC13A1 0.000 SLC6A6 0.013
SLC15A1 0.000 SLC7A11 0.199
SLC15A2 0.001 SLC7A5 0.049
SLC16A1 0.260 SLC7A6 0.113
SLC16A10 0.000 SLC7A7 0.000
SLC16A2 0.000 SLC7A8 0.001
SLC16A3 0.408 SLC7A9 0.000
SLC19A1 0.026 SLCO1A2 0.000
SLC19A2 0.026 SLCO1B1 0.000
SLC19A3 0.000 SLCO1B3 0.000
SLC22A1 0.000 SLCO2A1 0.068
SLC22A11 0.000 SLCO2B1 0.000
SLC22A12 0.000 SLCO3A1 0.000
SLC22A14 0.000 SLCO4A1 0.024
SLC22A2 0.000 SLCO4C1 0.000
SLC22A3 0.000 SLCO5A1 0.000
SLC22A4 0.001 SLCO6A1 0.000
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Table C.7: Gene expression analysis in the HEK-OCT1 and HEK-pcDNA5 cell lines.
Figure 4.13 shows the graphical representation of the data contained in this table.
Drug membrane transporter expression in the HEK-OCT1 and HEK-pcDNA5 cell lines
Gene Sample Gene Sample
HEK-OCT1 HEK-pcDNA5 HEK-OCT1 HEK-pcDNA5
ABCA1 0.000 0.000 SLC22A5 0.112 0.110
ABCA2 0.042 0.044 SLC22A6 0.000 0.000
ABCA3 0.152 0.157 SLC22A7 0.000 0.000
ABCB1 0.136 0.157 SLC22A8 0.000 0.000
ABCB11 0.000 0.000 SLC22A9 0.000 0.000
ABCB4 0.003 0.009 SLC25A13 0.321 0.499
ABCB5 0.000 0.000 SLC25A27 0.028 0.039
ABCB6 0.031 0.041 SLC28A1 0.000 0.000
ABCB7 0.434 0.434 SLC28A2 0.000 0.000
ABCC1 0.065 0.055 SLC28A3 0.000 0.000
ABCC10 0.080 0.111 SLC29A1 1.011 0.922
ABCC11 0.000 0.000 SLC29A2 0.037 0.036
ABCC12 0.000 0.000 SLC29A3 0.044 0.044
ABCC2 0.001 0.001 SLC2A1 0.584 0.662
ABCC3 0.000 0.000 SLC2A2 0.000 0.000
ABCC4 0.240 0.211 SLC2A3 0.013 0.037
ABCC5 0.108 0.112 SLC31A1 0.303 0.342
ABCC6 0.000 0.000 SLC38A2 0.175 0.161
ABCC8 0.001 0.000 SLC38A5 0.000 0.000
ABCC9 0.000 0.000 SLC3A1 0.000 0.000
ABCD1 0.000 0.001 SLC3A2 0.688 0.710
ABCD3 0.167 0.166 SLC47A1 0.038 0.033
ABCG2 0.014 0.014 SLC47A2 0.000 0.000
ABCG8 0.000 0.000 SLC5A1 0.000 0.000
ATP7A 0.000 0.000 SLC5A4 0.000 0.000
ATP7B 0.167 0.146 SLC6A2 0.000 0.000
SLC10A1 0.000 0.000 SLC6A3 0.000 0.000
SLC10A2 0.000 0.000 SLC6A4 0.000 0.000
SLC13A1 0.000 0.000 SLC6A6 0.075 0.083
SLC15A1 0.005 0.001 SLC7A11 0.054 0.052
SLC15A2 0.001 0.001 SLC7A5 0.155 0.153
SLC16A1 0.802 0.810 SLC7A6 0.175 0.233
SLC16A10 0.187 0.201 SLC7A7 0.000 0.000
SLC16A2 0.032 0.023 SLC7A8 0.078 0.066
SLC16A3 0.000 0.001 SLC7A9 0.001 0.001
SLC19A1 0.363 0.351 SLCO1A2 0.000 0.000
SLC19A2 0.131 0.159 SLCO1B1 0.000 0.000
SLC19A3 0.012 0.010 SLCO1B3 0.000 0.000
SLC22A1 16.163 0.002 SLCO2A1 0.001 0.002
SLC22A11 0.000 0.000 SLCO2B1 0.000 0.000
SLC22A12 0.000 0.000 SLCO3A1 0.018 0.010
SLC22A14 0.000 0.000 SLCO4A1 0.076 0.076
SLC22A2 0.000 0.000 SLCO4C1 0.017 0.009
SLC22A3 0.000 0.000 SLCO5A1 0.049 0.047
SLC22A4 0.000 0.000 SLCO6A1 0.000 0.000
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naes, Hans, & Senner, Frank. 2010. Coexistence of passive and carrier-mediated
processes in drug transport. Nature reviews. Drug discovery, 9(8), 597–614.
Suhre, Wendy M., Ekins, Sean, Chang, Cheng, Swaan, Peter W., & Wright, Stephen H.
2005. Molecular determinants of substrate/inhibitor binding to the human and rab-
bit renal organic cation transporters hOCT2 and rbOCT2. Molecular pharmacology,
67(4), 1067–1077.
Swift, Brandon, Nebot, Noelia, Lee, Jin Kyung, Han, Tianxiang, Proctor, William R.,
Thakker, Dhiren R., Lang, Dieter, Radtke, Martin, Gnoth, Mark J., & Brouwer, Kim
L. R. 2013. Sorafenib hepatobiliary disposition: mechanisms of hepatic uptake and
disposition of generated metabolites. Drug metabolism and disposition: the biological
fate of chemicals, 41(6), 1179–1186.
Szaty lowicz, Halina. 2008. Structural aspects of the intermolecular hydrogen bond
strength: H-bonded complexes of aniline, phenol and pyridine derivatives. Journal
of Physical Organic Chemistry, 21(10), 897–914.
Tarling, Elizabeth J., de Aguiar Vallim, Thomas Q., & Edwards, Peter A. 2013. Role of
ABC transporters in lipid transport and human disease. Trends in endocrinology and
metabolism: TEM, 24(7), 342–350.
Tchaparian, Eskouhie H., Houghton, Jessica S., Uyeda, Craig, Grillo, Mark P., & Jin,
Lixia. 2011. Effect of culture time on the basal expression levels of drug transporters
in sandwich-cultured primary rat hepatocytes. Drug metabolism and disposition: the
biological fate of chemicals, 39(12), 2387–2394.
Tzvetkov, M. V., Vormfelde, S. V., Balen, D., Meineke, I., Schmidt, T., Sehrt, D.,
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